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CHAPTER I  
INTRODUCTION 
Epidemiology of Triple-Negative Breast Cancer 
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype which is 
characterized by minimal or no expression of estrogen receptors (ER) and progesterone receptors 
(PR), and the absence of overexpression of human epidermal growth factor 2 (HER2). In the 
United States, TNBC makes up 15-20% of breast cancers.
1-3
 These tumors tend to occur more in 
women who are young and/or African-American.
4
 Additionally, they are typically diagnosed at 
later stages than other breast cancer subtypes and are associated with poorer prognosis.
5
 Due to 
its aggressive nature, rates of recurrence and mortality are higher in TNBC compared with other 
breast cancer subtypes and prognosis by breast cancer subtype varies by time since diagnosis.
6,7
  
Current Treatment for TNBC 
The primary treatment for TNBC consists of combination chemotherapy. Despite that 
studies have found that TNBC tumors are more sensitive to chemotherapy than hormone receptor 
positive cancers,
3,4,8-12
 a pathologic complete response (pCR) only occurs in ~30% of TNBC 
cases.
13
 One study showed that there was no difference in 3-yr survival between TNBC and non-
TNBC patients when a pCR was achieved, but survival was significantly lower for TNBC 
patients as compared to non-TNBC patients who did not achieve pCR (68% vs 88%, p=0.001).
10
 
Residual disease is common following treatment and accounts for worse outcomes and an 
increased risk of metastatic recurrence;
9,13
 therefore, differences in survival between TNBC and 
2 
 
non-TNBC patients may be due to the presence of residual disease, as well as the aggressiveness 
of this tumor subtype.
14
  
Although chemotherapy is the standard treatment, currently TNBC does not have a 
standard treatment plan for chemotherapy type/combination and/or dosage. TNBC tumors treated 
with neoadjuvant anthracycline- or anthracycline plus taxane-based chemotherapy regimens have 
been shown to respond well and have higher rates of pCR compared to ER+ cancers; however, in 
those who do not achieve pCR, relapse rates are high.
9,11,15
 Other studies have also shown that 
TNBC tumors respond better to antimetabolite-based regimens, such as cyclophosphamide, 
methotrexate, and 5-fluorouracil (CMF) or doxorubicin and cyclophosphamide (AC), compared 
to other tumor types.
15,16
 Additionally, other studies have shown that, compared to conventional 
chemotherapy agents, platinum compounds may be more effective for TNBC tumors.
15
 
Radiotherapy is also used in the treatment of TNBC; although chemotherapy is generally 
considered to be the more effective component of treatment.
11,15
 
Due to a lack of consensus in the medical literature as to which provides the best 
response in TNBC tumors;
3,4,17,18
 the chemotherapy regimen that a TNBC patient receives often 
depends upon practices of the patient’s physician and treatment hospital.4 The molecular 
mechanisms which underlie response to chemotherapy and achieving pCR are not understood. 
Research aimed at identifying predictors for treatment response and survival is critically 
important for delivering effective treatments to TNBC patients with minimal toxicity.  
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Drug Metabolism of Chemotherapeutic Agents 
The efficacy and cytotoxic effects of chemotherapeutic agents are largely determined by 
the metabolism and transport of the agents in tumor cells and non-tumor tissue.
19
 Drug 
sensitivity and resistance are controlled by drug metabolism and pharmacogenetic variability in 
metabolism may account for differences in treatment efficacy.
20
 The plasma concentration of a 
drug over time determines the pharmacological effect with too little exposure being associated 
with an ineffective treatment while too much may lead to adverse events, including toxicity.
21
 
Individual differences in drug response and cancer survival may be predictable with a better 
understanding of the genetic variability in drug metabolizing genes.
21
 
Metabolism of Cyclophosphamide 
Cyclophosphamide belongs to the class of chemotherapy drugs called alkylating agents 
and is used in the treatment of various cancers.
22
 It undergoes both activating and inactivating 
metabolic reactions in the body.
23
 Cyclophosphamide is activated to 4-
hydroxycyclophosphomide through catalyzation by cytochrome P450 (CYP) isozymes in the 
liver; the primary metabolizing enzymes are CYP2B6, CYP2C9, and CYP3A4 while CYP3A5, 
CYP2A6, CYP2C8, and CYP2C19 metabolize cyclophosphamide to a lesser extent.
24-26
 4-
hydroxycyclophosphamide rapidly interconverts to aldophosphamide; both molecules are 
thought to passively leave liver cells, circulate, and passively enter other cells, including tumor 
cells.
24,27
 Therefore, individual variation in CYP metabolism likely plays a role in the amount of 
the circulating active metabolite of cyclophosphamide which is available to enter tumor cells. 
Aldophosphamide yields phosphoramide mustard, likely the clinically important DNA cross-
linking agent, through a spontaneous elimination reaction, which is associated with bladder 
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toxicity.
24
 Phosphoramide mustard does not readily enter cells in its anionic form so the 
intracellular formation of this metabolite from aldophosphamide is important.
24
 Aldehyde 
dehydrogenase 1A1 (ALDH1A1) is primarily responsible for the detoxification of 
aldophosphamide, with aldehyde dehydrogenase 3A1 (ALDH3A1) involved to a lesser 
extent.
23,28
 Both 4-hydroxycyclophosphamide and phosphoramide mustard are detoxified by 
glutathione S-transferases (GSTs); GSTA1 and GSTP1 are the main isoforms involved, while 
GSTT1 and GSTM1 are involved to a lesser extent.
23
  
Germline Genetic Variability in Cyclophosphamide Metabolism 
Genetic variability in genes involved in the metabolism of cyclophosphamide has been 
shown to affect breast cancer outcomes following treatment, although the evidence is not entirely 
consistent.
20,29-31
 We have reviewed all of the available evidence regarding the SNPs of interest 
and metabolism of cyclophosphamide and all cancer types due to the paucity of information in 
breast cancer alone. 
CYP2B6 
A cohort study of 230 breast cancer patients (97% Caucasian) treated with 
cyclophosphamide and doxorubicin observed shorter progression-free survival and overall 
survival (OS) in patients with certain germline genotypes of two variants, rs12721655 and 
rs3745274, in CYP2B6.
16
 However, a clinical trial in 882 breast cancer patients (83% Caucasian) 
found no association between the rs3745274 polymorphism and disease-free survival (DFS) in 
breast cancer patients treated with cyclophosphamide, 5-fluorouracil, and methotrexate or 
doxorubicin versus those who did not receive chemotherapy treatment.
32
 The rs3211371 
polymorphism in the CYP2B6 gene has also been shown to be associated with 
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leucopenia/neutropenia resulting in dose delay and dose reduction.
16
 A study in 107 leukemia 
patients treated with cyclophosphamide found certain CYP2B6 variants (rs8192709, rs3745274, 
and rs2279343) were associated with risk of adverse side effects.
33
  
CYP3A4 
One SNP in the CYP3A4 gene has been previously identified as playing a role in 
response to cyclophosphamide treatment.
34
 In that study, 127 premenopausal breast cancer cases 
(89% Caucasian) treated with a cyclophosphamide-based chemotherapy regimen found an 
increased risk of ovarian failure among young women (<45 years) with the variant alleles in the 
rs2740574 SNP compared to wild type alleles.
34
 Additionally, another study showed that slower 
metabolism of cyclophosphamide is associated with shorter survival times in 85 chemotherapy-
naïve breast cancer patients (87% Caucasian) and that variant genotypes of the rs2740574 
polymorphism of the CYP3A4 gene were associated with slower drug activation and decreased 
survival.
35
  
CYP2C19  
In the CYP2C19 gene, one SNP (rs4244285) was found to be associated with overall 
survival in 230 breast cancer patients (97% Caucasian) receiving cyclophosphamide treatment in 
combination with doxorubicin, with reduced survival observed for individuals that were 
homozygous for the variant allele.
16
 This indicates that those carrying the variant allele are 
slower metabolizers than those homozygous for the wild type allele. 
ALDH1A1/ALDH3A1  
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Five SNPs in the ALDH1A1 gene have been suggested to play a role in the inactivation 
of aldophosphamide, a metabolite of cyclophosphamide, in cancer patients. In 882 breast cancer 
patients (83% Caucasian) enrolled in a clinical trial who were treated with cyclophosphamide 
and doxorubicin, three SNPs in the ALDH1A1 gene (rs3764435, rs8187996, and rs63319) were 
associated with drug toxicity before correcting for multiple comparisons (p<0.05).
36
 However, 
none remained significant when a corrected p-value was used. The two SNP haplotype 
(rs3764435-rs168351) was associated with increased drug toxicity and this remained significant 
after correction for multiple comparisons.
36
 Another SNP in the ALDH1A1 gene, rs6151031, 
was associated with drug toxicity in a small study of 113 Caucasian cancer patients, mostly 
breast cancer, treated with cyclophosphamide, thiotepa, and carboplatin.
37
 This study also 
identified a SNP in the ALDH3A1 gene (rs2228100) as associated with likelihood of developing 
cystitis.
37
  
GSTP1/GSTA1/GSTM1/GSTT1 
In a study of 87 Yakut ovarian cancer patients treated with cyclophosphamide and 
cisplatin, the SNP, rs3957357, in GSTA1 was shown to be associated with anemia, but not with 
other adverse side effects, including neutropenia.
38
 These authors previously reported a 
significant association between this polymorphism and overall survival in a population of 104 
Russian ovarian cancer patients.
39
 However, the authors found no association between this 
variant and overall or progression-free survival in 87 Yakut ovarian cancer patients.
38
 
Furthermore, when the 104 Russian patients were reanalyzed with additional follow-up time, the 
association between this polymorphism and overall survival was no longer significant.
38
 This 
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study also found no association between GSTP1 SNP, rs1138272, and drug toxicity, progression-
free, or overall survival in these ovarian cancer patients.
38
  
Another functional SNP, rs1695, in the GSTP1 gene has been shown to be associated 
with increased drug response
40,41
 and increased severity of toxicity
40
 in populations of breast 
cancer patients in China (n=122)
40
 and Brazil (n=40)
41
 treated with cyclophosphamide and 
epirubicin. This SNP was shown to be associated with progression-free survival in a population 
of 104 Russian ovarian cancer patients treated with cyclophosphamide and cisplatin;
39
 however, 
this association was not observed when that cohort was reanalyzed with additional follow-up 
time or in similar patients of Yakut ethnicity (n=87).
38
 
No studies were identified which assessed the association between single nucleotide 
polymorphisms in the GSTM1 or GSTT1 genes and cancer outcomes among those who 
underwent chemotherapy with cyclophosphamide. Some studies have shown that deletion of the 
GSTT1 gene,
42
 GSTM1 gene,
35,43
 or both
44,45
 was associated with a significantly better breast 
cancer prognosis. However, several other studies have shown no association with either the 
deletion of GSTT1 or GSTM1 and breast cancer outcomes
20,41,46,47
 and one study showed an 
association between deletion of the GSTM1 gene and poorer breast cancer survival.
48
 
Metabolism of 5-Fluorouracil 
5-fluorouracil belongs to the class of chemotherapy drugs called antimetabolites and is 
one of the most frequently used chemotherapy drugs for solid tumors, including breast 
cancer.
49,50
 The efficacy of 5-fluorouracil depends on the activation of the drug to the active 
metabolite in the body and the subsequent deactivation.
51
 5-fluorouracil is activated 
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intracellularly into several active metabolites by thymidine phosphorylase (TYMP) and uridine 
monophosphate synthetase (UMPS) (also known as orotate phosphoribosyltransferase 
(OPRT)).
52
 The active metabolites inhibit the conversion from deoxyuridine monophosphate 
(dUMP) to deoxythymidine monophosphate (dTMP).
52,53
 It does this by targeting the enzyme, 
thymidylate synthase (TS), encoded by the TYMS gene, which is responsible for catalyzing the 
methylation of dUMP to dTMP.
54
 This step is critical for DNA replication of the cell. Thus, the 
active metabolites of 5-fluorouracil block dTMP production in cancer cells which prevents DNA 
synthesis and replication. This step occurs when the active metabolite forms a stable complex 
with TS, along with folate as a co-factor.
55,56
 Due to the role of folate as a co-factor in this step, 
methylenetetrahydrofolate reductase (MTHFR), which metabolizes folate and forms the co-
factor required for inhibition of TS, has been suggested as potential factor in fluorouracil 
metabolism.
57,58
 Reduced MTHFR activity, resulting from mutations in the MTHFR gene, may 
increase the rate of activity of TS due to the resulting increased folate metabolites.
57
 Mutations in 
the TYMS gene may result in reduced expression of TS which may be associated with greater 
response to 5-fluorouracil.  
Dihydropyrimidine dehydrogenase (DPD), an enzyme encoded by the DPYD gene, is the 
rate-limiting step in 5-fluorouracil metabolism and is responsible for greater than 80% of the 
degradation and inactivation of 5-fluorouracil.
52,59
 This gene has been widely implicated as a 
strong predictor of fluorouracil response.
49,57,60,61
 Studies have shown that reduced DPYD 
activity may lead to increased efficacy and/or increased risk of toxicity due to slower clearance 
of the drug and accumulation of dUMP.
57
 Degradation of 5-fluorouracil by DPYD is highest in 
the liver but occurs in all tissues, including tumor tissue.
62,63
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Germline Genetic Variability in 5-Fluorouracil Metabolism 
Genetic variability in genes involved in the metabolism of 5-fluorouracil has been shown 
to affect breast cancer outcomes following treatment, although the evidence is not entirely 
consistent.
29-31
  
DPYD 
The primary gene of interest in 5-fluorouracil metabolism is DPYD due to its role in 
degrading and inactivating greater than 80% of 5-fluorouracil. However, the association between 
DPYD polymorphisms and clinical outcomes is not fully understood due to the rarity and 
heterogeneity of functional variants in different populations.
64,65
 The majority of research on 
genetic variability, 5-fluorouracil response, and cancer outcomes has been done in colorectal 
cancer (CRC) patients due to the impact of this drug in treatment of CRC; however, it is 
commonly used in breast cancer patients as well.
52
 Additionally, the majority of research on this 
gene has been conducted in primarily Caucasian populations. There are three SNPs in the DPYD 
gene—rs67376798, rs3918290, and rs55886062—for which there is a high level of evidence that 
variant alleles are associated with decreased DPYD activity and increased risk of toxicity.
24
 The 
results from these studies are summarized below. 
In studies of CRC patients receiving fluorouracil in combination with other 
chemotherapy agents, the rs67376798 SNP was associated with altered DPYD activity,
66
 
decreased clearance of fluorouracil,
67
 and increased risk or severity of toxicity,
67-72
 though some 
studies have shown no association with toxicity.
73
 A meta-analysis of 7 studies evaluating the 
association between this SNP and drug toxicity in cancer (primarily CRC) patients treated with 
5-fluorouracil (either alone or in combination with other chemotherapy drugs) found an 
10 
 
increased risk of severe toxicity in patients carrying at least one variant allele.
74
 The majority of 
the patients included in these studies were Caucasian. 
The rs3918290 SNP has been shown to be associated with altered DPD activity and 
decreased 5-fluorouracil clearance,
67,75
 increased risk of adverse side effects,
57,70,76,77
 and 
increased risk of severity of toxicity
48,67-69,71,72,78-81
 among cancer patients receiving combination 
chemotherapy including 5-fluorouracil. However, some studies which investigated this 
polymorphism did not observe an association with drug toxicity.
73,82,83
 In a meta-analysis of 13 
studies, which included various types of cancer patients who were treated with 5-fluorouracil (in 
combination or alone), an association was found between the variant allele in this SNP and risk 
of drug toxicity.
74
 One study found an increased risk of death in cancer patients treated with 5-
fluorouracil who carried a variant allele
84
 and another study, in one patient heterozygous for the 
variant, also showed an association with death.
85
 A study in various types of cancer patients 
treated with fluorouracil showed no association between this variant and risk of death; however, 
only two heterozygotes were included in the study and these patients did not experience fatal 
toxicity.
86
 In all of the studies, very few, if any, homozygotes for the rs3918290 variant allele 
were observed; these studies found increased risk associated with carrying only one variant 
allele. 
The rs55886062 SNP has been shown to be associated with DPYD deficiency
87
 and risk 
of severity of toxicity
72
 in cancer patients (various types, including breast cancer) who received 
fluorouracil. Decreased DPD activity was also observed in heterozygotes from a population of 
healthy European-Americans.
88
 
11 
 
Numerous other alleles in the DPYD gene have been shown to be associated with 
response to fluorouracil though the evidence for these polymorphisms is not as strong. In 
populations of patients with various cancer types (primarily CRC) treated with fluorouracil, it 
has been suggested that the following polymorphisms are associated with drug toxicity, 
rs115232898,
89
 rs17376848,
48
 rs1801158,
90,91
 rs1801160,
76
 rs2297595,
69,91,92
 rs45589337,
91
 
rs56038477,
73
 or adverse side effects, rs1801159,
93
 rs1801265
93
 (although this polymorphism 
was found to have no association with toxicity in other studies
67,72,91
), and rs75017182
94
 (an 
association was found in CRC patients but another study which included various cancer types 
found no association with toxicity
95
). Additionally, the following polymorphisms have been 
shown to be associated with DPD activity in healthy populations, rs115232898,
88
 rs115632870,
88
 
rs1801160,
88
 and rs72728438,
88
 and in cancer patients, rs1801158
87
. Other polymorphisms in the 
DPYD gene have not been found to be associated with response or toxicity to 5-fluorouracil—
rs17116806
96
 and rs4970722
96—although the studies on these polymorphisms are very limited.  
TYMS 
It has been suggested that polymorphisms in the TYMS gene may be associated with 
response to 5-fluorouracil. The rs2847153 was found to be associated with survival in 211 
pancreatic cancer patients (93% Caucasian) treated with fluorouracil.
97
 The rs34489327 6-base 
pair insertion/deletion polymorphism was found to be associated with risk of disease progression 
in a population of 146 Caucasian CRC patients treated with fluorouracil, leucovorin, and 
irinotecan.
98
 The rs34743033 tandem repeat polymorphism was associated with gene expression 
of TYMS
99,100
 and toxicity
48,101
 and response
99,102-106
 to fluorouracil in cancer patients (various 
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types); the number of repeats was found to be associated with gene expression and outcomes; 
although the evidence was not consistent.
107-110
 
MTHFR 
MTHFR genetic variants, namely rs1801131 and rs1801133, lead to decreased enzyme 
activity in vitro although studies have shown inconsistent results in terms of effects on tumor 
response to chemotherapy treatment, disease progression, and survival.
51,53,64,111
 The rs1801131 
polymorphism has been shown to be associated with response to chemotherapy treatment in 
CRC patients treated with fluorouracil, in combination with other chemotherapy drugs.
104,112
 
Similarly, the rs1801133 polymorphism has been shown to be associated with drug toxicity
108,110
 
and neutropenia
113
 in cancer patients (primarily CRC) treated with fluorouracil, although not all 
studies have observed an association.
48,95
 The majority of this research on the association 
between 5-fluorouracil and MTHFR has been conducted in CRC; however, a previous study 
from our research group showed that the TT genotype of the MTHFR 677C>T polymorphism 
(rs1801133) was associated with shorter survival in Chinese breast cancer patients with advanced 
stage disease treated with chemotherapy.
114
 Another Spanish study of MTHFR in 93 breast 
cancer patients showed no association with disease-free survival for this polymorphism.
115
 It 
should be noted that the majority of patients included in the previous studies were of European 
descent. 
TYMP 
The rs11479 polymorphism has been shown to be associated with response to 5-
fluorouracil and capecitabine. In a study of 253 CRC patients treated with 5-fluorouracil or 
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capecitabine, those who carried at least one A allele were at a significantly increased risk of 
toxicity as compared to those that were homozygous for the G allele.
94
 
UMPS 
Three polymorphisms in the UMPS gene have been evaluated for their associations with 
cancer outcomes in a population of 89 CRC patients with liver metastases treated with 5-
fluorouracil or capecitabine.
116
 Those who carried one or more A alleles in the rs2291078 
polymorphism had a significantly worse response to chemotherapy as compared to those that 
were homozygous for the T allele. In the rs3772809 polymorphism, those patients with one or 
more A alleles had a significantly improved response to chemotherapy as compared to those who 
were homozygous for the G allele. In the rs3772810 polymorphism, those patients with one or 
more A alleles had a significantly improved response to chemotherapy as compared to those who 
were homozygous for the G allele. 
Somatic Variation in Chemotherapy Metabolizing Genes 
It has been suggested that somatic variation in genes involved in chemotherapy 
metabolism within the tumor may account for differences in response to chemotherapy and 
cancer prognosis. Few studies have evaluated tumor-level expression of genes involved in 
chemotherapy metabolism and response to chemotherapy or prognosis among breast cancer 
patients. While several reviews on germline genetic variability in chemotherapy metabolizing 
genes and breast cancer outcomes have been conducted,
23,29,30
 no systematic reviews or meta-
analyses summarizing previous research on tumor-level gene or protein expression of 
chemotherapy metabolizing genes in breast cancer patients were found.   
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Tumor Expression of Chemotherapy Metabolizing Genes and Breast Cancer Outcomes: A 
Systematic Review 
Due to the known toxic effects and variation in tumor response to chemotherapy and 
cancer prognosis, there is a continued need for prognostic and predictive biomarkers to guide 
clinical decision making in chemotherapy drug selection. It has been suggested that somatic 
variations in chemotherapy metabolizing genes within the tumor may account for differences in 
response to chemotherapy and cancer prognosis. We performed a systematic search of 
epidemiologic studies investigating associations between expression of chemotherapy 
metabolizing genes and breast cancer outcomes. We included any survival outcomes, including 
overall, disease-free, and progression-free survival, and response outcomes, including pCR and 
response rate. We focused on those classes of genes known to metabolize the majority of 
chemotherapy drugs. Full methods for the systematic review can be found in Appendix 1. A total 
of 15 studies were included in the review (Table 1). 
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Table 1: Summary of Study Characteristics and Results 
Author  
Study 
Location 
Years of 
diagnosis  
Number of 
participants  
Length of 
follow-up 
(median(range)) 
Age at 
diagnosis 
(median 
(range) or 
mean (SD)) Exposure(s) Outcomes Chemotherapy 
Unit of 
Analysis Univariate results Multivariable results 
 
Cytochrome P450 Genes 
       
Chang et 
al117 
(2008) 
USA, UK 2000-
2004 
72 n/a 49 (not 
reported) 
CYP1B1 
gene 
expression 
CR Docetaxel gene 
expression 
(per unit 
increase) 
Higher expression 
associated with increased 
likelihood of CR: 
OR=1.70, 95% CI: 1.02, 
2.95, p=0.0421 per 1-unit 
increment in expression 
None reported for 
CYP1B1 
Kolacinska 
et al118 
(2012) 
Poland  42 n/a 55.6 (32-80) CYP2D6 
gene 
expression 
pCR Doxorubicin 
and docetaxel 
(n=29), 
doxorubicin 
and 
cyclophospham
ide (n=13) 
gene 
expression 
ANOVA: CYP2D6 
expression higher among 
those who achieve pCR 
compared to partial and 
non-responders (p=0.0063) 
None reported 
Gianni et 
al119 
(2005) 
Italy, USA 1998-
2002 
Italy: n=89;  
USA: n=82 
n/a 49.9 (29-65) CYP3A4 and 
ALDH1A1 
gene 
expression 
pCR Neoadjuvant 
doxorubicin 
and paclitaxel, 
adjuvant CMF 
gene 
expression 
(per unit 
increase) 
Italy: per unit increase 
CYP3A4: OR=1.82, 95% 
CI: 0.94-3.52, p=0.0462; 
ALDH1A1: OR=2.12, 
95% CI: 0.93-4.81, 
p=0.0415; USA: no 
specific data for genes of 
interest 
None reported for 
individual genes of 
interest 
Aldehyde Dehydrogenase Genes 
Khoury et 
al120 
(2012) 
USA 1995-
2007 
513 Not reported Not reported;  
≤50 (n=190) 
>50 (n=323) 
ALDH1A1 
via Tissue 
Microarray 
DFS and 
OS 
None (n=29); 
Neoadjuvant 
cyclophospham
ide (n=36); 
Adjuvant 
cyclophospham
ide (n=377) in 
combination 
with 
methotrexate 
and 5-FU or 
adriamycin 
with or without 
taxane 
ALDH1A1-
positive 
(≥10% 
tumor cell 
staining) vs 
ALDH1A1-
negative 
(<10% 
staining) 
KM survival curves, All 
patients: ALDH1A1 
significantly associated 
with worse OS (p=0.04) 
but not DFS 
Patients treated in 
neoadjuvant setting 
with 
cyclophosphamide 
without trastuzumab: 
OS (ALDH1A1+ vs -) 
HR=11.56 (2.13, 
62.86) p=0.005, DFS 
HR=3.05 (0.85, 10.93) 
p=0.09; Patients 
treated in the 
neoadjuvant setting 
without trastuzumab: 
OS HR=7.08 (1.61, 
31.13) p=0.01, DFS 
HR=2.57 (0.78, 8.52) 
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Author  
Study 
Location 
Years of 
diagnosis  
Number of 
participants  
Length of 
follow-up 
(median(range)) 
Age at 
diagnosis 
(median 
(range) or 
mean (SD)) Exposure(s) Outcomes Chemotherapy 
Unit of 
Analysis Univariate results Multivariable results 
Liu et 
al121  
(2015) 
China, 
USA 
China: 
2002-
2006 
USA: 
2001-
2011 
China: 463; 
USA: 133 
Not reported  China: 51.6 
(26.1-74.3) 
USA: 54 
(28-75) 
ALDH1A1 
gene 
expression 
DFS and 
OS 
China: mostly 
CMF or CEF, 
no chemo 
(n=28); USA: 
unknown 
Gene 
expression  
KM survival curves: 
China: High ALDH1A1 
expression associated with 
better DFS (p=0.01) and 
better OS (p=0.048) 
Per unit increase 
ALDH1A1 expression: 
China: DFS: HR=0.87, 
95% CI: 0.80, 0.95; 
OS: HR=0.85, 95% 
CI: 0.78-0.93);  
USA: OS: HR=0.88, 
95% CI: 0.79, 0.93 
Nogami et 
al122 
(2014) 
Japan 1998-
2006 
40 46 (6-143) 
months 
53 (28-78) ALDH1A1 
protein 
expression 
DFS Adjuvant 
chemotherapy 
(either 
anthracycline or 
anthracycline + 
taxane (n=10) 
or CMF (n=3)) 
ALDH1 
positive 
(>5% 
tumor cells 
stained) vs 
negative 
KM survival 
curves/Univariate Cox 
models: No association 
with disease-free survival 
for ALDH1 expression in 
primary tumor tissue (KM 
log rank p=0.148; 
OR=2.26, 95% CI: 0.63, 
6.54, p=0.19) ; ALDH1 
expression in axillary 
lymph node metastasis 
associated with poorer 
DFS (KM log rank 
p=0.037; OR=2.75, 95% 
CI: 0.98, 7.46, p=0.055) 
No significant 
association with 
ALDH1 expression in 
primary tumor or 
axillary lymph node 
metastasis and DFS 
Tiezzi et 
al123 
(2013) 
Brazil 2000-
2005 
90 Not reported 49 (11.5) ALDH1A1 
protein 
expression 
OS and 
DFS 
Neoadjuvant 
epirubicin and 
docetaxel; 
adjuvant CMF 
ALDH 
positive 
(staining of 
at least 5 
cells in a 
cluster) vs 
ALDH 
negative 
KM survival curves: The 
presence of ALDH-
positive cells after 
neoadjuvant chemotherapy 
associated with worse 
disease-free (p=0.01) and 
worse overall survival 
(0.01) 
ALDH-positive cells 
compared to negative: 
OS HR=2.54 (1.04, 
6.23); Multivariable 
disease-free survival 
results not reported 
Table 1 continued 
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Author  
Study 
Location 
Years of 
diagnosis  
Number of 
participants  
Length of 
follow-up 
(median(range)) 
Age at 
diagnosis 
(median 
(range) or 
mean (SD)) Exposure(s) Outcomes Chemotherapy 
Unit of 
Analysis Univariate results Multivariable results 
Zhou et 
al124 
(2013) 
China 2003-
2009 
113 4.5 years 56.3 (33-78) ALDH1A1 
protein 
expression 
OS and RR None (n=22); 
CMF (n=11); 
CEF (n=52); 
Paclitaxel + 
epirubicin 
(n=28) 
ALDH1 
positive 
(>1% 
tumor cell 
staining) vs 
ALDH1 
negative 
(≤1% cell 
staining) 
KM survival curves, 
ALDH1+ associated with 
worse survival: Patients 
receiving chemotherapy 
without endocrine therapy: 
OS p=0.001, Relapse rate 
p=0.003; Patients 
receiving chemotherapy 
and endocrine therapy: 
p=0.003; No differences in 
relapse rate by ALDH1 
positivity in patients 
receiving chemotherapy + 
endocrine therapy or 
endocrine therapy alone 
Patients receiving 
chemotherapy without 
endocrine therapy: No 
association with OS 
after adjustment 
(p=0.295), Relapse 
rate, ALDH1+ vs 
ALDH1-: RR=7.493 
(1.828, 3.744) 
p=0.005; Patients 
receiving 
chemotherapy and 
endocrine therapy: 
ALDH1+ vs ALDH1-: 
RR=6.759 (1.607, 
28.433) p=0.009 
Glutathione S-transferase Genes 
Miyake et 
al125 
(2012) 
Japan 2004-
2010 
123 n/a Not reported GSTP1 
protein 
expression 
pCR Paclitaxel 
followed by 
CEF (n=123) 
GSTP1 
positive 
(≥10% cells 
stained) vs 
GSTP1 
negative 
ER+ breast cancer: No 
association with pCR 
(OR=0.45, 95% CI: 0.11, 
1.86, p=0.267); ER- breast 
cancer: GSTP1 expression 
associated with increased 
likelihood of pCR 
(OR=9.09, 95% CI: 1.65, 
50.00, p=0.009) 
After adjustment for 
menopausal status, 
tumor size, nodal 
status, tumor grade, 
ER, PR, and HER2 
status, and 
Ki67expression, 
GSTP1 expression was 
associated with pCR 
among ER- breast 
cancer cases 
(OR=8.70, 95% CI: 
1.58, 47.62, p=0.013) 
Table 1 continued 
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Author  
Study 
Location 
Years of 
diagnosis  
Number of 
participants  
Length of 
follow-up 
(median(range)) 
Age at 
diagnosis 
(median 
(range) or 
mean (SD)) Exposure(s) Outcomes Chemotherapy 
Unit of 
Analysis Univariate results Multivariable results 
Peters et 
al126 
(1993) 
Netherlands 1978-
1987 
139 Not reported 45.5 GSTA1, 
GSTM1, and 
GSTP1 
protein 
expression 
OS and 
DFS 
Adjuvant CMF 
(n=139) 
GSTA1 
expressed 
vs not 
detectable; 
GSTM1 
non-
detectable 
vs low 
expression 
vs high 
expression; 
GSTP1 low 
vs 
intermediat
e vs high 
expression 
(tertile cut 
point) 
KM survival 
curves/Univariate Cox 
Models: No association 
with disease-free survival 
for all GSTA1 (p=0.27), 
GSTM1 (p=0.24), or 
GSTP1 (p=0.72); No 
association with overall 
survival for all GSTs (all 
p-values 0.42-0.63)  
No multivariable 
analyses reported 
Arun et 
al127 
(2010) 
USA 1997-
2000 
166 80 (4-163) 
months 
57 (25-86) GSTP1 
protein 
expression 
DFS None (n=89); 
Anthracycline 
(n=45); 
Anthracycline + 
Taxane (n=31); 
CMF (n=1) 
High 
GSTP1 
expression 
(>70% 
tumor cell 
staining) vs 
low 
expression 
(≤70%) 
KM survival curves, : high 
expression associated with 
better DFS: All patients 
p=0.09; Patients receiving 
chemotherapy: p=0.055 
No multivariable 
analyses reported 
Other Genes Involved in Chemotherapy Metabolism 
Horiguchi 
et al128 
(2002) 
Japan 1985-
1996 
119 66 (5-126) 
months 
51 (30-85) DPYD 
protein 
expression 
DFS and 
OS 
None (n=32); 5-
fluorouracil or 
derivative 
(n=87) 
DPYD-
positive 
(intermedia
te to strong 
tumor cell 
staining) vs 
DPD-
negative 
(weak or no 
staining) 
KM survival curves, All 
patients: Patients with 
DPD-positive tumors had 
significantly poorer DFS 
and OS compared to those 
with DPD-negative tumors 
(p<0.05); Patients 
receiving 5-FU 
chemotherapy: DPD 
expression significantly 
associated with poorer 
DFS (p<0.05) 
DPD expression 
associated with poorer 
DFS (RR (se)= 0.502 
(0.333) p=0.038) but 
not OS (RR (se)=0.629 
(0.356) p=0.192) 
Table 1 continued 
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Author  
Study 
Location 
Years of 
diagnosis  
Number of 
participants  
Length of 
follow-up 
(median(range)) 
Age at 
diagnosis 
(median 
(range) or 
mean (SD)) Exposure(s) Outcomes Chemotherapy 
Unit of 
Analysis Univariate results Multivariable results 
Yu et al129 
(2005) 
China 1990-
1993 
197 142 (28-176) 
months 
51 (29-76) DPYD and 
TYMS 
protein 
expression 
OS and 
DFS 
Adjuvant CMF 
(n=197) 
positive 
(>25% of 
cancer cells 
were 
stained) vs 
negative 
KM survival curves: TS 
expression associated with 
shorter DFS (p<.0001) and 
OS (p<.0001); DPD 
expression was not 
associated with DFS 
(p=0.23) or OS (p=0.68) 
Using Cox regression, 
TS expression: DFS 
OR=8.4034 (5.618, 
12.5000) p<.0001; OS 
OR=9.1743 (5.4645, 
15.3846) p<.0001 
Fox et al130 
(1997) 
UK 1989-
1993 
328 45 (5-100) 
months 
55 (26-83) TYMP 
protein 
expression 
OS and 
RFS 
CMF (n=127) High 
TYMP 
expression 
(≥25% 
tumor cell 
staining, 
n=166) vs 
low 
expression 
(<25%, 
n=162)) 
KM survival curves, 
TYMP expression 
associated with better 
survival: All patients: RFS 
p=0.015, OS p=0.14; 
Patients receiving 
chemotherapy: RFS 
p=0.02, OS=0.02; No 
association observed in 
patients who did not 
receive chemotherapy 
treatment 
Among node-positive 
patients: HR (95% CI): 
OS 0.4 (0.2-0.9) 
p=0.03, RFS 0.6 (0.3, 
1.1) p=0.1; Among 
node-positive patients 
who received 
chemotherapy 
treatment: OS p=0.06; 
Among node-positive 
patients with no 
chemotherapy 
treatment: OS p=0.24 
Tominaga 
et al131 
(2002) 
Japan 1990-
1992 
579 8 years Not reported;  
<75 
TYMP 
protein 
expression 
RFS and 
OS 
Treatment 
group: 5'-
FDUR for 6 
months; 
Control group: 
no 
chemotherapy 
TYMP 
scale (-, ±, 
+, ++): 
coded as 1, 
2, 3, 4, a 
composite 
score 
including 
all 3 
pathologist'
s scores 
was used 
for analysis 
KM survival curves: RFS 
and OS more favorable in 
patients with higher TYMP 
expression scores in both 
the treatment and control 
groups (RFS: 5'-DFUR 
p=0.094; OS: 5'-DFUR 
p=0.050, Control p=0.108) 
TP score 
independently 
associated with RFS in 
5'-DFUR group 
(RR=0.856 (0.755, 
0.972), p=0.016) but 
not in the surgery only 
group (p=0.35) 
Table 1 continued 
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Author  
Study 
Location 
Years of 
diagnosis  
Number of 
participants  
Length of 
follow-up 
(median(range)) 
Age at 
diagnosis 
(median 
(range) or 
mean (SD)) Exposure(s) Outcomes Chemotherapy 
Unit of 
Analysis Univariate results Multivariable results 
Yang et 
al132 
(2002) 
Italy 1984-
1991 
182 78 (3-177) 
months 
Not 
Reported 
TYMP 
protein 
expression 
OS and 
DFS 
Adjuvant CMF 
(n=51) 
TYMP 
positive 
(≥50% of 
tumor cells 
showed 
similar or 
stronger 
staining 
compared 
to normal 
epithelium) 
vs negative 
KM survival curves: 
TYMP expression 
associated with better DFS 
(p=0.0038) and OS 
(p=0.0070) 
TP expression not 
associated with DFS or 
OS after adjustment 
Aki et al133 
(2010) 
Japan 1988-
2006 
217 7.6 years 53 (24-83) TYMS, 
DPYD, 
TYMP, and 
OPRT 
mRNA 
expression 
RFS Adjuvant oral 
5-FU (n=147) 
mRNA 
expression 
level 
computed 
from its 
ratio to the 
expression 
of β-actin 
High TS expression 
associated with worse 
survival: HR=6.67, 
p<0.01); High DPD 
expression associated with 
better survival: HR=0.66, 
p=NS; High TYMP 
expression: HR=1.78, 
p=NS; High OPRT 
expression: HR=3.56, 
p=NS compared to low 
expression 
High TS expression: 
HR=10.9, p<0.01 
Abbreviations: Immunohistochemical, IHC; Disease-Free Survival, DFS; Overall Survival, OS; Relapse-Free Survival, RFS; Relapse Rate, RR; Clinical Response, CR; Pathologic Complete Response, pCR 
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Results from Systematic Review 
Cytochrome P450s 
Three studies were identified which assessed the relationship between expression of 
cytochrome P450 genes and breast cancer outcomes, defined as survival or response to 
treatment.  
CYP1B1 is involved in the metabolism of taxanes (e.g. paclitaxel and docetaxel). In a 
study of 72 breast cancer patients, CYP1B1 gene expression was associated with an increased 
likelihood of clinical response to chemotherapy treatment with docetaxel (unadjusted OR=1.70, 
95% CI: 1.02, 2.95, p=0.0421).
117
 Tissue used to measure gene expression in this study was 
collected prior to chemotherapy treatment. In total, 192 genes were evaluated in this study and 
14 were significantly associated with clinical response (p<0.05); CYP1B1 was the only 
metabolizing gene which was significantly associated with clinical response. No adjustments 
were made for multiple comparisons. No multivariable analyses were reported. 
CYP3A4 is involved in the metabolism of several chemotherapy drugs. It is involved in 
the deactivation of taxanes and the activation of cyclophosphamide. In a study of 89 breast 
cancer patients, CYP3A4 gene expression was associated with an increased likelihood of pCR 
(OR=1.82, 95% CI: 0.94, 3.52, p=0.0462).
119
 Gene expression was measured in tumor tissue 
prior to chemotherapy treatment. All patients were treated with doxorubicin and paclitaxel prior 
to surgery and CMF (cyclophosphamide, methotrexate, and fluorouracil) after surgery. No 
multivariable analyses were reported for CYP3A4. 
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In a study of 42 breast cancer patients, CYP2D6 gene expression was significantly 
associated with increased likelihood of pCR (ANOVA: F=5.797, p=0.0063).
134
 Gene expression 
was measured in tissue collected prior to chemotherapy treatment. Patients were treated with AT 
(doxorubicin and docetaxel) (n=29) or AC (doxorubicin and cyclophosphamide) (n=13). No 
multivariable analyses were reported. 
Aldehyde Dehydrogenases 
ALDH1A1 is involved in the metabolism of cyclophosphamide, specifically the 
deactivation of the active metabolite. In a study of 89 breast cancer patients, ALDH1A1 gene 
expression was associated with an increased likelihood of pCR (OR=2.12, 95% CI: 0.93, 4.81, 
p=0.0415).
119
 Gene expression was measured in tumor tissue prior to chemotherapy treatment. 
All patients were treated with doxorubicin and paclitaxel prior to surgery and CMF 
(cyclophosphamide, methotrexate, and fluorouracil) after surgery. No multivariable analyses 
were reported for ALDH1A1.  
ALDH1A1 expression was shown to be significantly associated with worse overall 
survival in 3 studies.
123,135,136
 One of these studies also found a significant association between 
ALDH1A1 expression and worse disease-free survival;
123
 however, two studies found no 
association with disease-free survival.
122,135
 Additionally, one study looked at relapse rate and 
found a significant association with ALDH1A1 expression after adjustment for expression of 
several other genes (see Table 1) among patients treated with chemotherapy with or without 
endocrine therapy.
136
 The definition of ALDH1A1 positivity differed among these studies 
making comparability difficult (see Table 1). Another study found that ALDH1A1 tumor gene 
expression was associated with better DFS and OS among TNBC patients in China and the 
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United States; the association persisted after adjustment for age at diagnosis, TNM stage, 
radiotherapy and chemotherapy treatment, and basal-like breast cancer subtype.
121
 No further 
analyses were done by type of chemotherapy received. 
No studies were identified which investigated the effect of tumor tissue gene expression 
levels of ALDH3A1. 
Glutathione-S-Transferases 
Tumor tissue gene expression of GSTP1 has been shown to be associated with worse 
pCR in ER-negative breast cancer patients.
125
 In that study, the investigators examined GSTP1 
expression in tumors in 123 Japanese breast cancer patients and its association with response to 
chemotherapy treatment.
125
 Prior to surgery, these patients were treated with paclitaxel, followed 
by a combination of 5-fluorouracil, epirubicin, and cyclophosphamide. The study results suggest 
that GSTP1 expression may predict response to chemotherapy in ER-negative breast cancer 
patients, but not in ER-positive breast cancer patients.
125
 
In a study of 166 breast cancer patients, high GSTP1 protein expression was marginally 
associated with better disease-free survival (unadjusted p=0.09)
127
. When restricted to only 
patients who underwent chemotherapy treatment (with anthracycline + taxane (n=31) or 
anthracycline alone (n=45)), the association was strengthened (p=0.055). When stratified by 
chemotherapy drug, GSTP1 expression was associated with marginally better disease-free 
survival among those who took a taxane (p=0.06) but not those who took anthracycline alone. 
An earlier study reported no association between disease-free or overall survival and protein 
expression of GSTP1, GSTA1, or GSTM1 in a population of 139 breast cancer patients with 
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tumor samples collected prior to chemotherapy treatment with CMF (cyclophosphamide, 
methotrexate, and fluorouracil);
126
 however, protein expression detection methods differed 
between the studies. No multivariable analyses were reported for either study.  
No studies were identified which investigated the effect of tumor tissue gene expression 
levels of GSTA1.  
Other 
Several genes involved in fluoropyrimidine (e.g. 5-fluorouracil, capecitabine) metabolism 
have been investigated in tumor level expression studies. While the majority of these studies 
were done in CRC patients, several studies have also investigated breast cancer.  
 DPYD is the most widely studied drug with respect to fluorouracil metabolism as it 
accounts for 80% of deactivation of this drug in the body. In a study of 119 Japanese breast 
cancer patients, patients with strong tumor staining for DPYD protein expression had poorer 
disease-free and overall survival as compared to those with weak or no DPYD staining 
(p<0.05).
128
 The association with disease-free survival persisted when restricted to patients who 
received 5-fluorouracil or a derivative and after additional adjustment for tumor factors 
(RR=0.502, standard error (se)=0.333, p=0.038). However, another study in 197 Chinese breast 
cancer patients did not observe an association between DPYD protein expression and disease-
free or overall survival.
129
 The latter study did find an association between TYMS protein 
expression and disease-free and overall survival (p<.0001). This association persisted after 
adjustment for tumor characteristics (DFS: OR=8.40, 95% CI: 5.62, 12.50; OS: OR=9.17, 95% 
CI: 5.46, 15.38), although the magnitude of the ORs are unusually high. Another study, which 
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looked at mRNA expression of DPYD, TYMS, TYMP, and OPRT (also known as UMPS) in 
217 Japanese breast cancer patients, found that high TYMS expression was significantly 
associated with poorer relapse-free survival (p<0.01).
133
 This association persisted after 
adjustment for tumor characteristics (HR=10.9, p<0.01). This study did not find an association 
between DPYD, TYMP, or OPRT and relapse-free survival.  
 Three other studies also assessed the association between TYMP and breast cancer 
outcomes. In a study of 328 ER+ breast cancer patients, high TYMP expression was significantly 
associated with relapse-free survival (p=0.015), but not overall survival (p=0.14).
130
 When the 
analyses were restricted to only those patients who received chemotherapy treatment (CMF; 
cyclophosphamide, methotrexate, and 5-fluorouracil), TYMP protein expression was 
significantly associated with better disease-free survival and overall survival, while no 
association was observed among those who did not receive chemotherapy treatment (p=0.06 vs 
p=0.24). After adjustment for patient and tumor characteristics, the association remained. 
Stratification for lymph node status showed that the relationship was only observed in node-
positive breast cancer patients who were treated with chemotherapy (OS: HR=0.4, 95% CI: 0.2, 
0.9). Similarly, another study in 182 breast cancer patients (both ER+ and ER-) found an 
association between high TYMP protein expression and better disease-free survival and overall 
survival; however, adjustment for tumor characteristics attenuated the observed association.
132
 
When stratified by chemotherapy treatment (CMF), TYMP expression was associated with better 
disease-free survival and overall survival among those who underwent chemotherapy (DFS: 
p=0.01; OS: p=0.009). A randomized trial of chemotherapy treatment with a fluorouracil 
derivative versus surgery only found that high TYMP protein expression was associated with 
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better relapse-free survival and overall survival among both groups.
131
 After adjustment for 
patient and tumor characteristics, high TYMP expression was only associated with relapse-free 
survival among those treated with chemotherapy (RR=0.856, 95% CI: 0.755, 0.972, p=0.016).  
Need for Consideration of Molecular Subtypes in Studies of Drug Metabolizing Enzymes and 
Breast Cancer Prognosis 
The majority of previous studies which have examined the effect of genetic variation on 
chemotherapy response were done in CRC patients or in a variety of cancer types. Among those 
which utilized breast cancer populations, almost all of them treated breast cancer as a single 
disease and did not account for the heterogeneity of breast cancer. It is widely accepted that 
breast cancer is a heterogeneous disease and the different subtypes respond differently clinically 
to chemotherapy agents.
9,137
 These differences in response likely stem from genetic variation in 
these subtypes of breast cancer. 
Breast cancer is generally clinically differentiated by the expression of ER, PR, and 
HER2 receptors; however, evidence from research studies that measured multiple gene 
expression suggests that there may be more molecular subtypes based on gene expression 
profiling and that these subtypes may be useful in providing further prognostic information.
138-140
 
An algorithm was developed which differentiates breast cancer subtypes based on the expression 
of 50 genes, resulting in five intrinsic subtypes—basal-like, HER2-enriched, luminal A, luminal 
B, and normal; it was named the Prediction Analysis of Microarray 50 (PAM50).
137
 The ability 
to further differentiate tumors on the basis of gene expression has been correlated with breast 
cancer outcomes, namely disease-free progression and overall survival.
141
 PAM50 intrinsic 
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subtypes have also been shown to improve prognostic prediction compared to established clinical 
predictors such as IHC-based markers.
142
  
Due to many similarities between TNBC and basal-like breast cancer (BLBC) tumors, 
such as aggressive tumor growth
138,142
 and poor clinical outcomes,
9,11,143
 TNBC tumors were 
previously considered to be overlapping with this subtype and were treated as such in many 
studies.
3,144
 In a previous study using gene expression profiling, about 71% TNBC tumors (123 
samples out of 172) were also classified as BLBC by gene expression profiling
145
 and subsequent 
studies substantiated these findings.
146,147
 Furthermore, it has been suggested that differences in 
chemotherapy response may be more heterogeneous in TNBC tumors than BLBC tumors.
148
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CHAPTER II 
SPECIFIC AIMS 
Specific Aims/Hypotheses 
Aim 1: To systematically review the epidemiologic evidence available on the role of gene 
expression of chemotherapy metabolizing genes and breast cancer survival and response to 
chemotherapy. 
We performed a systematic literature review in order to summarize the current state of 
the epidemiologic literature on the role of gene expression of chemotherapy metabolizing genes 
and breast cancer survival.  
Aim 2: To investigate known and potentially functional genetic variants in genes known to 
metabolize cyclophosphamide and 5-fluorouracil for their association with disease-free survival 
and overall survival among all breast cancer subtypes.  
We hypothesized that known and potentially functional genetic variants in genes known 
to metabolize cyclophosphamide and 5-fluorouracil were associated with disease-free and overall 
survival.  
Aim 3: To investigate whether the tumor tissue expression levels of genes known to metabolize 
particular chemotherapy drugs are associated with disease-free and overall survival among 
TNBC patients.  
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We hypothesized that tumor tissue expression level of genes known to metabolize 
particular chemotherapy drugs, by influencing intracellular (or tissue) exposure dose of the drug, 
were associated with disease-free survival and overall survival.  
Aim 4: To evaluate the correlation between germline polymorphisms and gene expression level 
in tumor tissue as well as the joint effect of the SNP-based gene metabolizing score and the gene 
expression level-based gene metabolizing score on disease-free and overall survival.  
We hypothesized that the joint effect of the SNP metabolizing score, which may 
influence the circulating exposure of medication, and gene expression level score in tumor tissue, 
which may affect drug exposure at the local level, was associated with decreased disease-free 
and overall survival.  
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CHAPTER III 
METHODS 
Study Overview 
The Shanghai Breast Cancer Survival Study (SBCSS), an established longitudinal, 
population-based cohort study with ongoing follow-up of outcomes, was used for the current 
study.
149
 In brief, the cohort consists of 5,042 breast cancer survivors diagnosed with incident 
breast cancer between March 2002 and April 2006 and identified through the Shanghai Cancer 
Registry. Participants, ages 20 to 75 years, were permanent residents of Shanghai, China and 
recruited to the study approximately 6 months after diagnosis of primary breast cancer (range: 
5.1-9.1 months). Cases were diagnosed with stage 0-IV breast cancer (based on AJCC, 6
th
 
edition); a combination of medical record review and central review of pathology slides was used 
to confirm breast cancer diagnoses.  
Data Collection and Biological Samples 
Baseline: For eligible women, information on demographic and lifestyle variables, as 
well as clinical and treatment variables, was collected by trained interviewers using structured 
questionnaires approximately 6 months following diagnosis (range 5.1-9.1 months). Information 
collected included demographic information, reproductive history, lifestyle factors (including 
smoking status, physical activity, and body mass index), and medical history (including 
comorbidities, usual dietary intakes, and vitamin, supplement, and alternative medicine use). 
Additionally, comprehensive information on cancer diagnosis and treatment, including 
chemotherapy, radiotherapy, Tamoxifen use, and surgery, and tumor characteristics, including 
31 
 
stage, grade, histology, and hormone receptor status, was obtained. Clinical data was verified 
through medical chart review. Tumor sections (9 5-um and 1 15-um) were obtained for 4,036 
participants (80%) from the referring hospital and stored covered in paraffin at -4°C in a vacuum 
chamber. Exfoliated buccal cells and saliva samples were collected as the genomic DNA source 
for 98% of the participants. This data has been used for several studies investigating breast 
cancer risk and survival and genetic variants.
114,150-152
 
  Follow-up: Additional in-person follow-up surveys occurred at 18, 36, and 60 months 
post-diagnosis. Information on disease progression, recurrence, and survival was collected, as 
well as information on treatment, including chemotherapy. The date of last in-person contact or 
December 2013 (6-months prior to date of latest record linkage), whichever was more recent, 
was used as the censor date for event-free subjects.  
Study components relevant to the specific aims of this proposal are described in further 
detail below.  
Study Design 
Using resources available in the SBCSS cohort, we investigated individual genetic 
variants in drug metabolizing genes among all breast cancer patients with available data 
(n=3,740) and tumor tissue expression levels of drug metabolizing genes in TNBC patients 
(n=469) and their association with disease-free and overall survival. Additionally, we evaluated 
the joint effect of tumor expression levels and individual genetic variants in drug metabolizing 
genes on disease-free and overall survival in TNBC patients with genotyping and gene 
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expression data available (n=312). Details on populations and specific methodologies utilized for 
each aim in this study are described below. 
Participant Population for Aim 2 
Aim 2 will be conducted among all SBCSS participants, regardless of breast cancer 
subtype, with available data for the SNPs of interest (see Table 2).  
Participant Population for Aim 3 
Of the 469 TNBC participants from the SBCSS study with available gene expression 
data, we excluded those whose tissue samples were collected after chemotherapy treatment 
(n=34) or those where the information of timing of chemotherapy treatment in relation to tissue 
collection was unknown (n=17). This resulted in 418 TNBC SBCSS participants being included 
in the analyses for Aim 3.  
Participant Population for Aim 4 
 Participants with gene expression data available from Aim 3, who also have germline 
genetic information available from Aim 2, will be used in the analyses for Aim 4 (n=312). Not 
all overlapping cases have germline genetic information available for every SNP of interest (see 
Table 2). 
Gene Expression Measurement 
The methods for gene expression profiling were part of a large gene expression effort 
previously described by Baglia et al.
153
 Briefly, using NanoString technology, gene expression 
levels for 311 selected genes were measured from formalin-fixed paraffin-embedded (FFPE) 
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breast cancer tumor tissues.
154
 Using methods developed by Parker et al, breast cancer tumors 
were classified into subtypes: Basal-like, Luminal A, Luminal B, HER2-enriched or Normal-like 
breast cancer based on PAM50 genes.
137
 For analysis, gene expression values were log base 2 
transformed to account for non-normal distribution of the data. From the SBCSS cohort, only 
those patients with TNBC were included in the gene expression profiling and were included in 
the associated aims in the current study. More information on exclusion criteria, quality control, 
and normalization of the samples can be found in the Baglia et al paper.
153
 
Selection of SNPs 
Relevant SNPs in the drug metabolizing pathways of cyclophosphamide and 5-
fluorouracil were selected through two methods. First, the Pharmacogenomics Knowledgebase 
(PharmGKB) database
24
 (https://www.pharmgkb.org/) was searched to identify SNPs in the drug 
metabolizing genes of interest which were previously reported as being associated with cancer 
outcomes (toxicity, adverse side effects, response, and survival) or were previously shown in 
healthy populations to alter metabolic rate. Additionally, a literature search in PubMed was 
conducted to find additional studies. Secondly, the University of California, Santa Cruz (UCSC) 
Genome Browser
155
 (http://genome.ucsc.edu/cgi-bin/hgGateway) and the Exome Aggregation 
Consortium (ExAC) Browser
156
 (http://exac.broadinstitute.org/) were both searched to identify 
all SNPs in the genes of interest. SNPs which were identified as functional, either nonsense, 
missense, frameshift, or splicing variants, were considered for inclusion in the current study. 
Intron variants were only included if previous research showed a correlation with cancer 
outcomes. The UCSC Genome Browser
155
 and Ensembl Variant Effect Predictor (VEP)
157
 
(http://www.ensembl.org/info/docs/tools/vep/index.html) were used to predict the functional 
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consequence of each SNP. Variants were excluded if the minor allele frequency (MAF) in 
Asians was <5%, resulting in 16 SNPs in cyclophosphamide metabolizing genes and 18 SNPs in 
5-fluorouracil metabolizing genes being excluded. Rare variants were not included due to 
reduced power to detect an association and low potential utility as predictive markers. Using 
HaploReg v3, SNPs were evaluated for linkage disequilibrium (LD) with other remaining SNPs 
identified in the previous step. The 1000 Genomes Phase 1 Asian population was used to 
calculate LD with a R
2
 threshold of 0.5. In order to avoid redundancy, only one SNP was 
included for those in high LD. For SNPs in strong LD (>0.8) where only one SNP was 
functional, the functional SNP was chosen for analysis; this resulted in the exclusion of 2 DPYD 
SNPs (rs17116806 which was in high LD with rs1801159 (R
2
=0.96) and rs4970722 which was 
in high LD with rs1801265 (R
2
=1)) and 2 UMPS SNPs (rs2291078 and rs3772810) which were 
both in high LD with rs3772809 (R
2
=0.84 and R
2
=1, respectively)). In the GSTM1 gene, two 
missense SNPs were in strong LD (rs202002774 and rs199816990); the SNP with the higher 
Asian MAF (0.17 vs 0.16) was chosen for genotyping (rs202002774). There were 15 SNPs in 
genes involved in cyclophosphamide metabolism and 14 SNPs in genes involved in 5-
fluorouracil metabolism which met all criteria. 
Existing germline genetic data for members of the SBCSS cohort was collected from 
several previous studies and combined for the SNPs identified in genes involved in metabolism 
of cyclophosphamide and 5-fluorouracil (Figure 1).
158,159
 Imputation was performed using 
established methods which have been published previously.
160,161
 Briefly, genotypes were 
imputed for SNPs using the program MACH 1.0 and dosage data was used for statistical 
analyses. Quality control measures were performed prior to the statistical analyses. Both 
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genotyping and imputation data was available from previous studies; when available, genotyping 
data was used. Imputed SNP data with poor imputation scores, i.e. R
2
 values less than 0.5, were 
removed from further analysis; although a R
2
 threshold of 0.5 was chosen, all imputation scores 
for included data were ≥0.6. After removing duplicate imputation data and poor quality 
imputation data, the allele frequencies for each available SNP were calculated by dataset and 
compared with the published allele frequencies in Asian populations from the 1000 Genomes 
Phase 1 study.  
36 
 
Figure 1: Pre-Existing Data Available for SNPs Identified for Inclusion in the Current Study in the SBCSS and Final Sample Size 
After Quality Control 
 
DATA SOURCE     SNP INCLUSION/EXCLUSION and MISSING DATA  FINAL DATA 
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After quality control measures were taken, data was available for 11 SNPs in genes 
involved in cyclophosphamide metabolism and 12 SNPs in genes involved in 5-fluorouracil 
metabolism (Table 2). 
 
Table 2: Available Data on Single Nucleotide Polymorphisms Investigated in Current Study 
 
Chemotherapy Drug Gene rs ID TNBC (N) All Breast Cancer (N) 
Cyclophosphamide CYP2B6 rs3745274 107 1144 
 
CYP2C19 rs4244285 341 3736 
 
CYP2C19 rs4986893 341 3736 
 
CYP2C8 rs2071426 341 3736 
 
ALDH1A1 rs3764435 105 1124 
 
ALDH1A1 rs63319 105 1124 
 
ALDH3A1 rs2228100 342 3739 
 
ALDH3A1 rs887241 342 3739 
 
ALDH3A1 rs3744692 341 3736 
 
GSTA1 rs3957357 105 1124 
 
GSTP1 rs1695 341 3736 
 
  
  
5-Fluorouracil DPYD rs17376848 105 1124 
 
DPYD rs1801159 341 3736 
 
DPYD rs1801265 341 3736 
 
DPYD rs72728438 105 1124 
 
MTHFR rs1801131 342 3739 
 
MTHFR rs1801133 105 1124 
 
MTHFR rs2274976 341 3736 
 
TYMP rs11479 341 3736 
 
TYMS rs2847153 107 1145 
 
TYMS rs2853533 105 1124 
 
UMPS rs1801019 341 3736 
  UMPS rs3772809 342 3739 
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Chemotherapy Information Collection 
Information on chemotherapy administration was collected at the baseline interview via 
patient report. The most commonly prescribed chemotherapy drugs and associated sample sizes 
can be found in Table 3. In addition to the chemotherapy drug type, information on the dates that 
each specific therapy was started and stopped, the dose, the number of cycles of the therapy, and 
the total duration of treatment was collected for each chemotherapy drug administered to the 
patient. Due to this granular data collection, we are able to account for concurrent 
chemotherapies as well as duration of treatment. Of the 469 TNBC participants, 418 tumor tissue 
samples were collected prior to chemotherapy treatment, including 28 who did not undergo 
chemotherapy treatment. For 17 participants, the timing of chemotherapy could not be 
determined because information was only collected for month and year and treatment, not day; 
for these samples, surgery and chemotherapy treatment occurred in the same month. Aim 3, 
which evaluates tumor level gene expression data, will only include those participants whose 
tissues samples were known to be collected prior to chemotherapy treatment because it has been 
shown that chemotherapy can alter tumor tissue gene expression.
162,163
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Table 3: Chemotherapy Use in the Current Study 
 
 
All Breast Cancer (Aim 2) TNBC (Aim 3) 
Chemotherapy N(%) N(%) 
Any 3397 (90.9) 441 (94.0) 
Neoadjuvant 181 (5.3) 34 (7.7) 
Adjuvant 1528 (45.0) 390 (88.4) 
Unknown 1688 (49.7) 17 (3.9) 
   Cyclophosphamide 2594 (69.4) 337 (71.9) 
Neoadjuvant 97 (3.7) 26 (7.7) 
Adjuvant 1167 (45.0) 296 (87.8) 
Unknown 1330 (51.3) 15 (4.5) 
   5-Fluorouracil 2626 (70.2) 354 (75.5) 
Neoadjuvant 93 (3.5) 25 (7.1) 
Adjuvant 1183 (45.1) 316 (89.3) 
Unknown 1350 (51.4) 13 (3.7) 
   
Other Chemotherapy Drugs  
Anthracyclines
1
 2078 (55.6) 264 (56.3) 
Taxanes
2
 264 (7.1) 36 (7.7) 
Note: Information on timing of chemotherapy not relevant for Aim 2 
study objectives 
1
Including doxorubicin and epirubicin  
2
Including paclitaxel and docetaxel  
 
Outcome Ascertainment 
The primary outcomes of interest are disease-free survival and overall survival which 
were calculated from the date of initial breast cancer diagnosis for all patients. Participants were 
followed-up to obtain information on survival status and cancer recurrence at 18, 36, and 60 
months after breast cancer diagnosis. The follow-up rates for the in-person interviews are 92.8%, 
86.4%, and 78.9% for the 18, 36, and 60 month interviews, respectively. Survival information 
was obtained using annual record linkage with the Shanghai Vital Statistics Registry for all 
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participants, including those lost to follow-up. Observation time was censored at the time of the 
event of interest (recurrence or death) or, for those who did not experience an event, date of last 
follow-up, the later of either last in-person survey or annual record linkage. For the disease-free 
analysis, individuals who died of non-breast cancer-related causes were censored at date of 
death. 
General Analytic Approach 
In this study, we examined expression levels of drug metabolizing genes in the tumor 
tissue and germline genetic variants within the individual to better understand how these factors 
individually and jointly influence variability in prognosis following treatment. We focused on 
cyclophosphamide and 5-fluorouracil since they were the two most commonly used 
chemotherapy drugs in the SBCSS. In the United States, these two drugs, in combination with 
other chemotherapy agents, are among the most commonly used chemotherapy drugs to treat 
breast cancer.
164
 
The primary outcomes of interest for the current study were disease-free survival (DFS) 
and overall survival (OS). Kaplan-Meier survival curves were generated to evaluate the 
univariate association between exposures of interest and DFS and OS. The log-rank p-value was 
used to test significance. 
Using linear models for continuous variables and χ2 contingency tables for categorical 
variables, the association between selected demographic, lifestyle, treatment, and clinical 
variables was characterized prior to multivariable modeling.  
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Cox models were used to estimate the associated hazards ratios (HRs) and to calculate 
resulting 95% confidence intervals and associated p-values.
165
 The proportional hazards 
assumption was formally tested through the inclusion of an interaction term between exposures 
and time since diagnosis; no interactions with survival were observed. Entry time was defined as 
date of diagnosis and exit time was defined as date of event (either recurrence or death) or date 
of last follow-up/record linkage. For variables treated as categorical, p-values for trends were 
calculated by treating the variable as a continuous variable. Analyses were stratified by various 
factors, including whether the chemotherapy drug of interest was taken and timing of events 
(defined as early events (<3 years since diagnosis) and later events (≥3 years post diagnosis), to 
evaluate potential effect measure modifiers; likelihood ratio tests were used to test potential 
effect measure modification.  
Information on toxicity was not available for the SBCSS cohort. However, due to the 
comprehensive collection of chemotherapy use, including number of cycles of chemotherapy 
received for each chemotherapy drug, number of cycles of drug taken was used as a surrogate for 
toxicity. Logistic regression was used to assess whether the outcomes of interest were associated 
with number of cycles (≥6 cycles (median) vs <6 cycles). The completion of 6 cycles was chosen 
because a typical chemotherapy regimen including cyclophosphamide or 5-fluorouracil is 6 
cycles.
166
 This was further corroborated in our data where 74% of patients treated with 
cyclophosphamide completed 6 cycles and 73% of patients treated with 5-fluorouracil completed 
6 cycles.  
More detailed specific statistical analyses for each aim are described in the chapter 
pertaining to that aim.  
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CHAPTER IV 
POLYMORPHISMS IN CHEMOTHERAPY METABOLIZING GENES AND BREAST 
CANCER OUTCOMES 
Aim 2-Specific Methods 
Based on knowledge of cyclophosphamide and 5-fluorouracil metabolism and previous 
research which found associations between polymorphisms of interest and cancer outcomes 
(toxicity, side effects, dose delay, survival, and drug clearance), the predicted effect of each SNP 
was hypothesized (Table 4 for cylcophosphamide and Table 5 for 5-fluorouracil).  
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Table 4: Hypothesized Effects of SNPs in Genes Involved in Cyclophosphamide Metabolism  
 
Gene rs ID 
Functional 
Consequence
1
 
Phenotype Summation of Evidence
2
 
Predicted Effect on 
Activity
3
 
Activation     
CYP2B6     
 rs3745274 Missense GG Increased likelihood of dose reduction, increased risk of adverse side effects Increased activity 
   GT Increased likelihood of dose reduction, decreased risk of adverse side effects Slightly decreased activity 
   TT Decreased likelihood of dose reduction, decreased risk of adverse side effects Decreased activity 
CYP2C19     
 rs4244285 Synonymous GG Increased risk of ovarian toxicity, decreased survival Increased activity 
   AA + AG Decreased risk of ovarian toxicity, increased survival Decreased activity 
      
 rs4986893 Nonsense Allele G 
No evidence in cyclophosphamide; Other drugs: Associated with increased 
metabolism to active metabolite and increased response 
Increased activity 
   Allele A 
No evidence in cyclophosphamide; Other drugs: Associated with decreased 
metabolism to active metabolite and decreased response 
Decreased activity 
CYP2C8     
 rs2071426 Splice Acceptor  No published evidence found Unknown 
Deactivation     
ALDH1A1 
    
 rs3764435 Intronic 
Allele A Increased risk of toxicity Decreased activity 
 
Allele C Decreased risk of toxicity Increased activity 
      
 rs63319 Intronic 
GG No association with toxicity Unknown (No 
association?) 
 
GG + TT No association with toxicity 
ALDH3A1 
    
 rs2228100 Missense 
GG Decreased likelihood of cystitis Increased activity 
 
CC + CG Increased likelihood of cystitis Decreased activity 
      
 
rs887241 Missense 
 
No published evidence found Unknown 
      
 
rs3744692 Missense 
 
No published evidence found Unknown 
GSTP1 
    
 
rs1695 Missense 
AA Increased response, decreased severity of toxicity, increased progression-free survival Decreased activity 
 
AG Increased response, decreased severity of toxicity, decreased progression-free survival Slightly decreased activity 
 
GG Decreased response, increased severity of toxicity, decreased progression-free survival Increased activity 
GSTA1 
    
 
rs3957357 
Upstream 
variant 2KB 
AA Increased risk of anemia Decreased activity 
  
AG Increased risk of anemia Slightly decreased activity 
  
GG Decreased risk of anemia Increased activity 
1Source: HaploReg v3 
 
2Source: PharmGKB 
 3Based on results from previous studies and role in chemotherapy metabolism pathway 
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Table 5: Hypothesized Effects of SNPs in Genes Involved in 5-Fluorouracil Metabolism 
 
Gene rs ID Functional Consequence
1
 Phenotype Summation of Evidence
2
 Predicted Effect on Activity
3
 
Activation     
TYMP 
     
 
rs11479 Missense 
GG Decreased risk of drug toxicity Decreased activity 
 
GA Increased risk of drug toxicity Increased activity 
 
AA Increased risk of drug toxicity Increased activity 
UMPS 
     
 
rs1801019 Missense 
GG Decreased risk of toxicity Decreased activity 
 
GC Decreased risk of toxicity Slightly increased activity? 
 
CC Increased risk of toxicity Increased activity 
      
 
rs3772809 Missense 
AA Improved response Increased activity 
 
AG Intermediate response Slightly increased activity 
 
GG Worse response Decreased activity 
Deactivation     
DPYD 
     
 rs17376848 Synonymous 
AA + AG Increased risk of toxicity Decreased activity 
 
GG Decreased risk of toxicity Increased activity 
      
 rs1801265 Missense 
GG + GA Increased risk of adverse side effects, no association with toxicity Decreased activity 
 
AA Decreased risk of adverse side effects, no association with toxicity Increased activity 
      
 rs1801159 Missense 
TT + CT Decreased risk of adverse side effects, no association with response Increased activity 
 
CC Increased risk of adverse side effects, no association with response Decreased activity 
      
 
rs72728438 Intronic 
TT Normal DPYD activity Increased activity 
CC + CT Decreased DPYD activity Decreased activity 
Response     
MTHFR 
     
 rs1801131 Missense 
TT Reduced response to treatment Increased activity 
 
GG + GT Better response to treatment Decreased activity 
      
 rs1801133 Missense 
GG + GA Decreased risk of toxicity Increased activity 
 
AA Increased risk of toxicity Decreased activity 
      
 
rs2274976 Missense 
 
No published evidence found Unknown 
TYMS 
     
 rs2847153 Intronic 
GG + GA Decreased likelihood of survival Increased expression 
 
AA Increased likelihood of survival Decreased expression 
      
 
rs2853533 Missense 
 
No published evidence found Unknown 
1Source: HaploReg v3 
2Source: PharmGKB 
3Based on results from previous studies and role in chemotherapy metabolism pathway 
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In addition to findings from previous studies, Gene-Tissue Expression (GTEx) expression 
quantitative trait loci (eQTL) data in normal breast tissue was used to inform the effect that the 
selected SNPs had on gene expression of the genes of interest. The correlation between SNPs of 
interest and genes of interest is in Table 6.  
 
Table 6: Gene-Tissue Expression (GTEx) eQTL Results 
 
Gene SNP rs ID Chr:Position
1
 
Reference 
Allele 
Effect 
Allele Beta p-value 
ALDH1A1 rs3764435 9:75516876 A C -0.024 0.70 
ALDH1A1 rs63319 9:75524784 G T 0.004 0.95 
ALDH3A1 rs2228100 17:19642952 G C -0.248 0.01 
ALDH3A1 rs887241 17:19645938 A C -0.104 0.29 
CYP2C8 rs4244285 10:96541616 G A 0.341 0.02 
CYP2C8 rs2071426 10:96828323 T C 0.010 0.93 
DPYD rs72728438 1:97847874 T C -0.195 0.01 
DPYD rs17376848 1:97915624 A G -0.091 0.58 
DPYD rs1801159 1:97981395 T C 0.094 0.25 
GSTP1 rs1695 11:67352689 A G -0.361 <.0001 
MTHFR rs2274976 1:11850927 C T 0.145 0.38 
MTHFR rs1801131 1:11854476 T G 0.061 0.37 
MTHFR rs1801133 1:11856378 G A -0.044 0.55 
TYMP rs11479 22:50964236 G A -0.220 0.04 
TYMS rs2853533 18:658064 G C 0.217 0.09 
TYMS rs2847153 18:661647 G A 0.121 0.28 
UMPS rs1801019 3:124456742 G C -0.032 0.61 
1
Build 37 
       
 
 
We created gene scores using an additive model to incorporate all of the SNPs into a 
single score. This approached has been used previously in order to account for the effects of 
multiple alleles on outcomes of interest.
167
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For cyclophosphamide, three gene scores were created based on a priori hypotheses as to 
the effect of each SNP in genes involved in cyclophosphamide metabolism and the association 
with disease-free and overall survival was evaluated for each score. The first score included 
SNPs in genes which are involved in the activation of cyclophosphamide into the active 
metabolite (CYP genes). Alleles in the SNP associated with faster metabolism were coded as 1; 
therefore an individual with two such alleles would be given a score of 2 while heterozygotes 
would get a score of 1. Individuals who do not carry the allele associated with faster metabolism 
would be given a score of 0. The scores from the four SNPs identified for study in the CYP 
genes were then summed to create the cyclophosphamide activation gene score. The possible 
range of this score was 0-8; in our data, the range was 2.67-8.0 with a median value of 6.0. We 
would expect that individuals with higher scores would have higher circulating levels of the 
active metabolite and would have a longer exposure to cyclophosphamide as compared with 
those with lower scores (HR<1.0).  
Similarly, SNPs in genes involved in the deactivation, or clearance, of the active 
metabolite of cyclophosphamide (ALDHs and GSTs) were coded so that faster metabolizers 
were given higher scores. The scores from the seven SNPs identified for study in the ALDH and 
GST genes were then summed to create the cyclophosphamide deactivation gene score. The 
possible range of this score was 0-14; in our data, the range was 3.1-14.0 with a median value of 
8.75. We would expect that those with higher scores would have a shorter exposure period to the 
active metabolite and would have poorer survival rates as compared with those with lower scores 
(HR>1.0). 
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A total score was calculated by combining the activation and deactivation scores. Coding 
was done such that individuals with higher scores had longer exposure to the active metabolite of 
cyclophosphamide; that is, more SNPs associated with faster activation and fewer SNPs 
associated with faster clearance. The possible range of this score was 0-22; in our data, the range 
was 2.67-18.84 with a median value of 11.9. We would expect that those with higher scores 
would have a longer exposure period to the active metabolite and would have better survival as 
compared to those with lower scores (HR<1.0). 
For 5-fluorouracil, five gene scores were created based on a priori hypotheses as to the 
effect of each SNP in genes involved in 5-fluorouracil metabolism and response and the 
association with disease-free and overall survival was evaluated for each score. The first score 
included SNPs in genes which are involved in the activation of 5-fluorouracil into the active 
metabolite (TYMP and UMPS genes). As previously described, 5-fluorouracil SNPs were coded 
using the same methods described for cyclophosphamide SNPs. The scores from the three SNPs 
identified for study in the TYMS and UMPS genes were then summed to create the 5-
fluorouracil activation gene score. The possible range of this score was 0-6; in our data, the range 
was 0.0-6.0 with a median value of 2.9. We would expect that those with higher scores would 
have a higher level of active metabolite and would have better survival as compared to those 
with lower scores (HR<1.0). 
Similarly, SNPs in the DPYD gene involved in the deactivation, or clearance, of the 
active metabolite of 5-fluorouracil were coded so that faster metabolizers were given higher 
scores. The scores from the four SNPs identified for study in the DPYD gene were then summed 
to create the 5-fluorouracil deactivation gene score. The possible range of this score was 0-8; in 
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our data, the range was 0.0-8.0 with a median value of 6.0. We would expect that those with 
higher scores would have a shorter exposure period to the active metabolite and would have 
poorer survival as compared with those with lower scores (HR>1.0). 
A third score was calculated which included genes involved in the response of the 5-
fluorouracil active metabolite in the tumor cell. SNPs in the TYMS and MTHFR genes were 
coded based on the hypothesis that individuals with higher scores had potentially improved 
treatment response compared to those with lower scores. The scores from the five SNPs 
identified for study in the TYMS and MTHFR genes were then summed to create the 5-
fluorouracil response gene score. The possible range of this score was 0-10; in our data, the 
range was 2.17-8.88 with a median value of 5.0. We would expect that those with higher scores 
would have lower levels of TS and higher levels of folate and would have better survival as 
compared with those with lower scores (HR<1.0). 
Two total scores were calculated for 5-fluorouracil. The first total score was calculated by 
combining the activation and deactivation scores. Coding was done such that individuals with 
higher scores had longer exposure to the active metabolite of 5-fluorouracil; that is, more SNPs 
associated with faster activation and fewer SNPs associated with faster clearance. The possible 
range of this score was 0-14; in our data, the range was 0.0-11.0 with a median value of 4.6. We 
would expect that those with higher scores would have a longer exposure period to the active 
metabolite and would have better survival as compared to those with lower scores (HR<1.0). 
The second total score additionally included the TYMS and MTHFR SNPs. The 
reasoning for the creation of this second gene score was that TYMS and MTHFR are involved in 
response to 5-fluorouracil rather than metabolism; however, these genes have been studied in 
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conjunction with the activating and deactivating genes in previous studies in CRC patients. The 
possible range of this score was 0-24; in our data, the range was 5.7-16.5 with a median value of 
10.6. We would expect that those with higher scores would have a longer exposure period to the 
active metabolite and would have better survival as compared to those with lower scores 
(HR<1.0). 
Using Cox proportional hazards models, the associations between each of these scores, 
which were treated as categorical variables, and survival outcomes were evaluated. The p-values 
for trends were calculated by treating the SNP score as a continuous variable. 
Results 
 Among the 3,739 breast cancer cases included in Aim 2 of this study, there were 516 
recurrences/breast cancer-specific deaths and 465 all-cause deaths over a median follow-up of 
5.3 years (range: 0.7-8.9 years). As shown in Table 7, 5-year DFS and OS rates were associated 
with age at diagnosis and were significantly positively correlated with education level, 
Tamoxifen use, estrogen and progesterone receptor positivity, and having had a mastectomy. We 
also found that 5-year DFS and OS rates were inversely associated with TNM stage, tumor 
grade, BMI, HER2 positivity, and radiotherapy. Additionally, 5-year OS was inversely 
associated with number of live births and menopausal status. 
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Table 7: Demographic and Clinical Predictors for Breast Cancer Survival in Breast Cancer Cases 
Included in Aim 2 
 
 
 
   
Disease-Free Survival 
 
Overall Survival 
Characteristics N 
Event, 
No. 
5-Yr Survival 
Rate, %
1
 P   
Deaths, 
No. 
5-Yr Survival 
Rate, %
1
 P 
Age at diagnosis, y 
        
 
<40 176 33 79.6 
0.04 
 
28 88.5 
0.001 
 
40-49 1464 174 87.3 
 
146 91.6 
 
50-59 1118 164 84.7 
 
138 90.2 
 
≥60 981 145 85.0 
 
153 88.0 
Education 
        
 
Elementary School or Less 426 88 79.3 
<.0001 
 
90 84.5 
<.0001 
 
Middle School 1275 190 84.6 
 
169 89.2 
 
High or Vocational School 1421 180 86.7 
 
156 90.8 
 
College or University 617 58 89.7 
 
50 94.0 
Income (yuan/person/month) 
        
 
<500 373 62 82.5 
0.09 
 
53 88.4 
0.13  
500 - <700 580 83 85.3 
 
79 88.9 
 
700 - <1000 1092 168 84 
 
151 89.1 
 
1000 - <2000 1220 151 87.2 
 
135 91.0 
 
≥2000 473 52 87.9 
 
47 92.9 
Body Mass Index (kg/m
2
) 
        
 
<25 2394 304 86.7 
0.0003  
279 90.9 
0.02 
 
25-29.99 1133 163 85.2 
 
149 89.2 
 
≥30 213 49 75.9 
 
37 85.3 
Menopausal Status 
        
 
Premenopausal 1812 237 86.2 
0.53 
 
194 91.2 
0.002 
 
Postmenopausal 1928 279 85.1 
 
271 89.0 
Tamoxifen Use 
        
 
No 1802 294 82.6 
<.0001 
 
276 86.9 
<.0001 
 
Yes 1936 222 88.4 
 
189 93.1 
TNM Stage 
        
 
0-I 1397 82 93.8 
<.0001 
 
77 95.7 
<.0001 
 
IIA 1233 141 88.1 
 
111 93.0 
 
IIB 573 117 78.9 
 
110 85.4 
 
III-IV 362 151 56.4 
 
146 66.2 
 
Unknown 175 25 84.9 
 
 
21 89.6 
 
Grade 
   
 
   
 
 
1 428 34 91.4 
<.0001  
24 96.2 
<.0001 
 
2 1429 160 88.0 
 
153 92.0 
 
3 1049 207 79.7 
 
193 84.9 
 
Unknown 834 115 85.8 
 
 
95 90.3 
 
Estrogen Receptor Status 
   
 
   
 
 
+ 2401 286 87.7 
<.0001 
 
246 92.3 
<.0001 
 
- 1293 216 82.3 
 
205 86.6 
 
Unknown 46 14 65.6 
 
 
14 71.7 
 
Progesterone Receptor Status 
   
 
   
 
 
+ 2189 263 87.6 
0.0002 
 
222 92.4 
<.0001 
 
- 1497 238 83.1 
 
228 87.2 
 
Unknown 54 15 71.4 
 
 
15 75.9 
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HER2 Status 
 
+ 778 132 82.2 
0.004  
119 87.3 
0.01 
 
Borderline 219 24 88.4 
 
19 92.2 
 
- 1859 236 86.8 
 
223 91.1 
 
Unknown 884 124 85.3 
 
 
104 89.9 
 
Chemotherapy 
        
 
No 342 39 87.9 
0.19 
 
42 90.5 
0.98 
 
Yes 3398 477 85.3 
 
423 90.1 
Radiotherapy 
        
 
No 2540 272 88.8 
<.0001 
 
251 92.2 
<.0001 
 
Yes 1200 244 78.8 
 
214 85.5 
Mastectomy 
        
 
No 236 42 80.2 
0.01 
 
38 85.4 
0.04 
 
Yes 3504 474 85.9 
 
427 90.4 
No. of Live Births 
        
 
0 30 5 82.4 
0.29 
 
5 89.7 
0.0002 
 
1 2531 329 86.3 
 
275 91.1 
 
2 627 92 85.1 
 
88 88.6 
 
≥3 403 72 82.2 
 
79 87.0 
Family History of BC 
        
 
No 3533 490 85.6 
0.74 
 
446 89.9 
0.14 
 Yes 207 26 86.0   19 93.7 
1
Survival rate calculated using life table analysis method 
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Twenty-three SNPs were investigated in the current study. The frequencies of alleles for 
each SNP were compared with the published allele frequencies in Asian populations. Genotyped 
and imputed data were checked individually (see Appendix B: Table B1for allele frequencies by 
study). The allele frequencies in all datasets were similar to the published values from 1000 
Genomes (http://www.1000genomes.org/). To check allele frequencies of imputed data, dosage 
data was rounded to the nearest whole number (0, 1, or 2); however, dosage data was used for all 
analyses involving imputed data. After quality checks of the data, all data were combined into 
one dataset and the overall allele frequencies were again compared to 1000 Genomes
168
 data 
(Table 8).   
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Table 8: Information on SNPs Included in Current Study 
  Gene rs ID 
Chromosome 
Position
1
 Alleles
3
 
Allele 
Frequency 
in Asians
3
 
Allele 
Frequency 
in Study 
Population
4
 
Functional 
Consequence
2
 
Cyclophosphamide 
     
Activation 
      
 
CYP2B6 rs3745274 chr19:41512841 G, T G=0.82 G=0.81 Missense 
 
CYP2C19 rs4244285 chr10:96541616 G, A A=0.33 A=0.33 Synonymous 
 
CYP2C19 rs4986893 chr10:96540410 G, A G=0.95 G=0.94 Nonsense 
 
CYP2C8 rs2071426 chr10:96828323 T, C T=0.93 T=0.93 
Splice 
Acceptor 
Deactivation 
      
 
ALDH1A1 rs3764435 chr9:75516876 A, C C=0.54 C=0.53 Intronic 
 
ALDH1A1 rs63319 chr9:75524784 G, T G=0.42 G=0.44 Intronic 
 
ALDH3A1 rs2228100 chr17:19642952 G, C G=0.57 G=0.58 Missense 
 
ALDH3A1 rs887241 chr17:19645938 A, C C=0.94 C=0.94 Missense 
 
ALDH3A1 rs3744692 chr17:19643672 C, T T=0.06 T=0.07 Missense 
 
GSTA1 rs3957357 chr6:52668687 A, G G=0.88 G=0.86 Unknown 
 
GSTP1 rs1695 chr11:67352689 A, G A=0.83 A=0.80 Missense 
5-Fluorouracil      
Activation 
      
 
TYMP rs11479 chr22:50964236 G, A A=0.25 A=0.21 Missense 
 
UMPS rs1801019 chr3:124456742 G, C C=0.19 C=0.18 Missense 
 
UMPS rs3772809 chr3:124462824 A, G A=0.94 A=0.94 Missense 
Deactivation 
      
 
DPYD rs17376848 chr1:97915624 A, G G=0.12 G=0.10 Synonymous 
 
DPYD rs1801159 chr1:97981395 T, C T=0.74 T=0.73 Missense 
 
DPYD rs1801265 chr1:98348885 G, A A=0.94 A=0.91 Missense 
 
DPYD rs72728438 chr1:97847874 T, C T=0.80 T=0.77 Intronic 
 Response 
  
    
 
MTHFR rs1801131 chr1:11854476 T, G G=0.19 G=0.18 Missense 
 
MTHFR rs1801133 chr1:11856378 G, A G=0.63 G=0.56 Missense 
 
MTHFR rs2274976 chr1:11850927 C, T C=0.90 C=0.91 Missense 
 
TYMS rs2847153 chr18:661647 G, A A=0.40 A=0.36 Intronic 
 
TYMS rs2853533 chr18:658064 G, C G=0.46 G=0.49 Missense 
1
Build 19             
2
Source: HaploReg v3; forward strand alleles 
    3Source: 1000 Genomes, forward strand alleles 
   4Includes genotyped and imputed data 
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Cyclophosphamide 
The association between each SNP in genes involved in metabolism of 
cyclophosphamide and DFS and OS among all breast cancer participants was evaluated (Table 9) 
where the allele associated with faster metabolism was coded as 1 and the allele associated with 
slower metabolism was coded as 0. After adjustment for age at breast cancer diagnosis and tumor 
grade, the G allele in SNP rs4986893 in the CYP2C19 gene was associated with better DFS 
(HR=0.76, 95% CI: 0.60, 0.97) and OS (HR=0.76, 95% CI: 0.59, 0.97); however, the association 
was no longer significant after adjustment for multiple comparisons (corrected p>.005). No 
significant associations between any other SNPs and DFS or OS were observed. Additional 
adjustment for education, BMI, menopausal status, tamoxifen use, ER status, PR status, HER2 
status, radiotherapy, and mastectomy did not materially alter the observed associations. 
When the results were stratified by whether cyclophosphamide was received, the 
association between SNP rs4986893 and DFS and OS was similar among those who took 
cyclophosphamide and those who did not (Table 10). The inverse correlation between the T 
allele in the SNP rs2071426 and survival appears to be limited to those who did not take 
cyclophosphamide (DFS: HR=0.75, 95% CI: 0.53, 1.06; OS: HR=0.67, 95% CI: 0.47, 0.97); 
however, the interaction was not significant.  
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Table 9: Associations Between Individual SNPs in Cyclophosphamide Metabolizing Genes and DFS and OS Among All Breast Cancer Cases 
 
    
All Participants 
  
Effect 
Allele 
Frequency 
 
Disease-Free Survival Overall Survival 
Gene rs ID N HR (95% CI)
1
 P HR (95% CI)
2
 P HR (95% CI)
1
 P HR (95% CI)
2
 P 
Activation
3
 
  
                
CYP2B6 rs3745274 G=0.81 1144 1.26 (0.91, 1.74) 0.16 1.26 (0.91, 1.75) 0.16 1.08 (0.77, 1.51) 0.67 1.10 (0.79, 1.55) 0.57 
CYP2C19 rs4244285 A=0.33 3736 0.98 (0.86, 1.12) 0.81 0.98 (0.86, 1.12) 0.76 0.96 (0.84, 1.10) 0.56 0.94 (0.82, 1.08) 0.39 
CYP2C19 rs4986893 G=0.94 3736 0.76 (0.60, 0.97) 0.03 0.74 (0.58, 0.94) 0.01 0.76 (0.59, 0.97) 0.03 0.75 (0.58, 0.96) 0.02 
CYP2C8 rs2071426 T=0.93 3736 0.89 (0.70, 1.12) 0.31 0.85 (0.67, 1.08) 0.18 0.81 (0.64, 1.04) 0.10 0.79 (0.62, 1.01) 0.06 
Deactivation
4
 
          
ALDH1A1 rs3764435 C=0.53 1124 1.11 (0.85, 1.44) 0.44 1.08 (0.83, 1.39) 0.57 1.23 (0.93, 1.63) 0.15 1.18 (0.89, 1.57) 0.25 
ALDH1A1 rs63319 G=0.44 1124 1.05 (0.80, 1.37) 0.73 1.03 (0.79, 1.34) 0.82 1.06 (0.80, 1.42) 0.68 1.05 (0.78, 1.40) 0.74 
ALDH3A1 rs2228100 G=0.48 3739 1.10 (0.97, 1.25) 0.13 1.14 (1.01, 1.30) 0.04 1.01 (0.88, 1.15) 0.89 1.04 (0.91, 1.19) 0.57 
ALDH3A1 rs887241 C=0.94 3739 1.05 (0.81, 1.36) 0.70 1.00 (0.77, 1.29) 0.98 1.16 (0.87, 1.54) 0.32 1.09 (0.82, 1.46) 0.54 
ALDH3A1 rs3744692 T=0.07 3736 1.12 (0.90, 1.41) 0.32 1.18 (0.94, 1.47) 0.16 1.16 (0.92, 1.47) 0.21 1.20 (0.95, 1.51) 0.13 
GSTA1 rs3957357 G=0.86 1124 1.05 (0.75, 1.47) 0.77 1.01 (0.72, 1.42) 0.94 1.06 (0.73, 1.53) 0.78 1.02 (0.70, 1.49) 0.92 
GSTP1 rs1695 A=0.80 3736 1.14 (0.97, 1.34) 0.12 1.18 (1.00, 1.38) 0.05 1.05 (0.89, 1.24) 0.57 1.07 (0.90, 1.26) 0.44 
1
Adjusted for age at diagnosis and tumor grade 
2
Adjusted for age at diagnosis, tumor grade, education, BMI, menopausal status, tamoxifen use, ER status, PR status, HER2 status, radiotherapy, and 
mastectomy 
3
Allele associated with faster metabolism coded as 1, HR<1 expected 
      
4
Allele associated with faster metabolism coded as 1, HR>1 expected 
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Table 10: Associations Between Individual SNPs in Cyclophosphamide Metabolizing Genes and DFS and OS Among All Breast Cancer Cases 
Stratified by Whether Cyclophosphamide was Taken 
 
  
Participants who Took Cyclophosphamide 
 
Participants who Did Not Take 
Cyclophosphamide 
   
  
Disease-Free Survival Overall Survival 
 
Disease-Free Survival Overall Survival 
 
DFS OS 
Gene rs ID HR (95% CI)
1
 P HR (95% CI)
1
 P 
 
HR (95% CI)
1
 P HR (95% CI)
1
 P   Pint Pint 
Activation
3
         
 
        
 
  
CYP2B6 rs3745274 1.38 (0.94, 2.04) 0.10 1.14 (0.76, 1.72) 0.52 
 
0.95 (0.52, 1.75) 0.88 0.87 (0.47, 1.62) 0.66 
 
0.27 0.39 
CYP2C19 rs4244285 0.97 (0.82, 1.15) 0.69 0.98 (0.82, 1.17) 0.82 
 
1.01 (0.82, 1.24) 0.94 0.93 (0.74, 1.15) 0.49 
 
0.76 0.65 
CYP2C19 rs4986893 0.77 (0.56, 1.05) 0.10 0.75 (0.54, 1.04) 0.09 
 
0.78 (0.54, 1.14) 0.20 0.79 (0.53, 1.16) 0.22 
 
0.95 0.82 
CYP2C8 rs2071426 1.02 (0.74, 1.41) 0.91 0.93 (0.67, 1.31) 0.69 
 
0.75 (0.53, 1.06) 0.10 0.67 (0.47, 0.97) 0.03 
 
0.18 0.15 
Deactivation
4
     
 
    
 
  
ALDH1A1 rs3764435 1.02 (0.75, 1.38) 0.90 1.13 (0.81, 1.56) 0.48 
 
1.33 (0.79, 2.22) 0.28 1.59 (0.90, 2.80) 0.11 
 
0.25 0.27 
ALDH1A1 rs63319 1.04 (0.76, 1.42) 0.82 0.98 (0.70, 1.38) 0.93 
 
0.98 (0.58, 1.66) 0.94 1.29 (0.73, 2.29) 0.38 
 
0.94 0.36 
ALDH3A1 rs2228100 1.06 (0.90, 1.24) 0.49 0.96 (0.81, 1.14) 0.63 
 
1.17 (0.96, 1.44) 0.13 1.08 (0.88, 1.34) 0.45 
 
0.44 0.37 
ALDH3A1 rs887241 1.06 (0.75, 1.49) 0.75 1.18 (0.81, 1.72) 0.38 
 
1.07 (0.72, 1.59) 0.73 1.14 (0.73, 1.77) 0.57 
 
0.95 0.81 
ALDH3A1 rs3744692 1.17 (0.87, 1.56) 0.29 1.20 (0.89, 1.62) 0.23 
 
1.08 (0.75, 1.55) 0.69 1.13 (0.78, 1.63) 0.53 
 
0.74 0.77 
GSTA1 rs3957357 1.17 (0.79, 1.74) 0.44 1.16 (0.75, 1.79) 0.50 
 
0.80 (0.43, 1.49) 0.48 0.80 (0.39, 1.62) 0.53 
 
0.34 0.41 
GSTP1 rs1695 1.10 (0.89, 1.35) 0.39 1.21 (0.93, 1.57) 0.44 
 
1.09 (0.88, 1.36) 0.15 0.98 (0.76, 1.27) 0.88 
 
0.55 0.56 
1
Adjusted for age at diagnosis and tumor grade 
2
Adjusted for age at diagnosis, tumor grade, education, BMI, menopausal status, tamoxifen use, ER status, PR status, HER2 status, radiotherapy, and 
mastectomy 
3
Allele associated with faster metabolism coded as 1, HR<1 expected  
 
    
 
  
4
Allele associated with faster metabolism coded as 1, HR>1 expected  
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Each of the three gene scores created for SNPs in genes involved in cyclophosphamide 
metabolism were evaluated for their association with DFS and OS among all breast cancer cases 
(Table 11). Although no significant associations were observed, the point estimate of each score 
was in the hypothesized direction for OS; for DFS, the point estimate was in the hypothesized 
direction for the total score and activation score. 
When stratified by whether cyclophosphamide was taken, no significant associations 
were observed among the three gene scores and DFS or OS among those who underwent 
treatment with cyclophosphamide and those who did not (Table 11). The effect estimate for the 
total score was very similar between those who took cyclophosphamide and those who did not. 
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Table 11: Association between Cyclophosphamide Gene Scores and Breast Cancer Outcomes 
Among All Breast Cancer Cases and Stratified by Whether Cyclophosphamide was Taken 
 
    
Disease-Free Survival Overall Survival 
Role in Metabolism 
# of 
SNPs 
N HR (95% CI)
4
 P HR (95% CI)
4
 P 
All Participants 
 
    
 
Activation
1
 4 1141 1.01 (0.85, 1.19) 0.93 0.94 (0.78, 1.12) 0.47 
 
Deactivation
2
 7 1124 1.07 (0.97, 1.18) 0.20 1.03 (0.92, 1.15) 0.64 
 
Total Score
3
 11 1124 0.95 (0.88, 1.04) 0.29 0.96 (0.88, 1.06) 0.44 
 
   
    
Participants Who Took Cyclophosphamide 
 
Activation
1
 4 889 0.99 (0.81, 1.21) 0.94 0.90 (0.73, 1.12) 0.36 
 
Deactivation
2
 7 878 1.06 (0.94, 1.19) 0.36 1.01 (0.89, 1.15) 0.85 
 
Total Score
3
 11 878 0.96 (0.87, 1.06) 0.43 0.97 (0.87, 1.08) 0.56 
 
   
    
Participants who Did Not Take Cyclophosphamide 
 
Activation
1
 4 252 1.07 (0.76, 1.50) 0.71 0.99 (0.70, 1.42) 0.97 
 
Deactivation
2
 7 246 1.12 (0.92, 1.36) 0.27 1.06 (0.86, 1.32) 0.58 
  Total Score
3
 11 246 0.93 (0.78, 1.10) 0.39 0.95 (0.79, 1.14) 0.57 
1
Includes SNPs from CYP genes, allele associated with faster metabolism coded as 1, HR<1 
expected 
2
Includes SNPs from ALDH and GST genes, allele associated with faster metabolism coded as 
1, HR>1 expected 
3
Includes all SNPs included in activation and deactivation scores, allele associated with longer 
exposure to drug coded as 1, HR<1 expected 
4
Adjusted for age at diagnosis and tumor grade    
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Using logistic regression, completion of 6 or more cycles of cyclophosphamide was 
evaluated as a proxy for toxicity (Table 12). No association was observed between any of the 
gene scores and completion of 6 or more cycles of cyclophosphamide treatment. We would 
expect that those who activated the drug more quickly or deactivated the drug more slowly, 
resulting in longer exposure to the active metabolite, may be more likely to experience a toxicity 
event and may be more likely to complete less than 6 cycles of chemotherapy treatment with 
cyclophosphamide. 
 
Table 12: Association Between Cyclophosphamide Genes Scores and Cycles of 
Cyclophosphamide Completed 
 
Role in Metabolism  OR (95% CI)
3
 P 
Activation
1
 0.96 (0.82, 1.12) 0.58 
Deactivation
2
 0.97 (0.88, 1.06) 0.45 
Total Score
1,2
 1.02 (0.94, 1.10) 0.68 
1
Includes SNPs from CYP genes  
2
Includes SNPs from ALDH and GST genes  
3
Adjusted for age at diagnosis and tumor grade 
 
 
The association between cyclophosphamide gene scores and breast cancer survival 
among those who took cyclophosphamide was further evaluated through additional adjustment 
for the number of cycles of cyclophosphamide taken (Table 13). The observed associations 
between cyclophosphamide gene scores and survival outcomes were not materially changed after 
adjustment for number of cycles completed.  
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Table 13: Association Between Cyclophosphamide Gene Scores and Survival Outcomes 
Additionally Adjusted for Cycles of Cyclophosphamide Completed 
 
    
Disease-Free Survival Overall Survival 
Role in Metabolism 
# of 
SNPs 
N HR (95% CI)
4
 P HR (95% CI)
4
 P 
 
Activation
1
 4 889 0.98 (0.81, 1.20) 0.87 0.90 (0.73, 1.12) 0.34 
 
Deactivation
2
 7 878 1.05 (0.94, 1.19) 0.38 1.01 (0.89, 1.15) 0.87 
  Total Score
3
 11 878 0.96 (0.87, 1.06) 0.42 0.97 (0.87, 1.08) 0.56 
1
Includes SNPs from CYP genes, allele associated with faster metabolism coded as 1, 
HR<1 expected 
2
Includes SNPs from ALDH and GST genes, allele associated with faster metabolism 
coded as 1, HR>1 expected 
3
Includes all SNPs included in activation and deactivation scores, allele associated with 
longer exposure to drug coded as 1, HR<1 expected 
4
Adjusted for age at diagnosis, tumor grade, and number of cyclophosphamide cycles 
completed 
 
 
We stratified our results by timing of survival events, those that occurred in the first three 
years of follow-up and those that occurred after 3 years, among all women and restricted to those 
who took cyclophosphamide (Table 14). No clear differences were observed between any of the 
scores among those who had events in the first 3 years and those who had later events.  
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Table 14: Association Between Cyclophosphamide Gene Scores Stratified by Early vs. Late Events Among All Participants and Only 
Those Who Took Cyclophosphamide 
 
   
Event <3 years 
 
Event ≥3 years 
   
Disease-Free Survival Overall Survival 
 
Disease-Free Survival Overall Survival 
Role in 
Metabolism 
# of 
SNPs 
HR (95% CI)
4
 P HR (95% CI)
4
 P 
  
HR (95% CI)
4
 P HR (95% CI)
4
 P 
All Participants (N=1124)       
 
        
 
Activation
1
 4 1.00 (0.81, 1.24) 0.97 1.03 (0.76, 1.40) 0.83 
 
1.01 (0.76, 1.35) 0.94 0.88 (0.71, 1.10) 0.27 
 
Deactivation
2
 7 1.09 (0.96, 1.24) 0.17 1.06 (0.89, 1.28) 0.51 
 
1.03 (0.87, 1.22) 0.75 1.01 (0.88, 1.16) 0.92 
 
Total Score
3
 11 0.94 (0.84, 1.05) 0.25 0.96 (0.82, 1.12) 0.63 
 
0.98 (0.85, 1.13) 0.78 0.96 (0.86, 1.08) 0.53 
 
  
    
 
    
Participants who Took Cyclophosphamide (N=884) 
 
Activation
1
 4 0.98 (0.77, 1.27) 0.90 0.96 (0.67, 1.38) 0.83 
 
1.01 (0.73, 1.39) 0.96 0.86 (0.66, 1.13) 0.29 
 
Deactivation
2
 7 1.09 (0.93, 1.27) 0.29 1.12 (0.90, 1.38) 0.32 
 
1.01 (0.84, 1.22) 0.89 0.96 (0.82, 1.12) 0.61 
  Total Score
3
 11 0.94 (0.83, 1.07) 0.36 0.91 (0.76, 1.09) 0.33   0.99 (0.85, 1.16) 0.90 1.00 (0.87, 1.14) 0.98 
1
Includes SNPs from CYP genes, allele associated with faster metabolism coded as 1, HR<1 expected 
2
Includes SNPs from ALDH and GST genes, allele associated with faster metabolism coded as 1, HR>1 expected 
3
Includes all SNPs included in activation and deactivation scores, allele associated with longer exposure to drug coded as 1, HR<1 
expected 
4
Adjusted for age at diagnosis and tumor grade 
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5-Fluorouracil 
The association between each SNP in genes involved in metabolism of 5-fluorouracil and 
DFS and OS among all breast cancer participants was evaluated (Table 15). After adjustment for 
age at breast cancer diagnosis and tumor grade, no significant associations between any SNPs 
and DFS or OS were observed. Additional adjustment for education, BMI, menopausal status, 
tamoxifen use, ER status, PR status, HER2 status, radiotherapy, and mastectomy did not 
materially alter the observed associations. 
When the results were stratified by whether 5-fluorouracil was taken, no significant 
associations were observed between SNPs in genes involved in the metabolism of 5-fluorouracil 
and DFS or OS among those who took 5-fluorouracil or those who did not (Table 16). No 
significant interactions were observed between those who took 5-fluorouracil and those who did 
not.
 63 
 
Table 15: Associations Between Individual SNPs in 5-Fluorouracil Metabolizing Genes and DFS and OS Among All Breast Cancer Cases 
 
  
  
All Participants 
  
  
Disease-Free Survival Overall Survival 
Gene rs ID 
Effect 
Allele 
Frequency 
N HR (95% CI)
1
 P HR (95% CI)
2
 P HR (95% CI)
1
 P HR (95% CI)
2
 P 
Activation
3
 
  
                
TYMP rs11479 A=0.21 3736 0.99 (0.85, 1.16) 0.95 0.99 (0.85, 1.16) 0.90 1.00 (0.85, 1.18) 1.00 0.98 (0.83, 1.16) 0.84 
UMPS rs1801019 C=0.18 3736 0.92 (0.78, 1.08) 0.31 0.93 (0.79, 1.09) 0.36 0.95 (0.81, 1.13) 0.59 0.97 (0.82, 1.15) 0.71 
UMPS rs3772809 A=0.94 3739 1.11 (0.84, 1.47) 0.47 1.15 (0.87, 1.52) 0.33 1.17 (0.87, 1.57) 0.31 1.20 (0.89, 1.62) 0.22 
Deactivation
4
 
          
DPYD rs17376848 G=0.10 1124 1.00 (0.64, 1.56) 0.98 1.00 (0.63, 1.58) 1.00 1.24 (0.78, 1.96) 0.36 1.20 (0.75, 1.93) 0.45 
DPYD rs1801159 T=0.73 3736 0.99 (0.87, 1.14) 0.91 1.00 (0.87, 1.15) 0.98 0.97 (0.85, 1.12) 0.73 0.98 (0.85, 1.13) 0.81 
DPYD rs1801265 A=0.91 3736 1.02 (0.82, 1.27) 0.85 1.05 (0.84, 1.30) 0.69 1.06 (0.84, 1.34) 0.64 1.06 (0.84, 1.34) 0.63 
DPYD rs72728438 T=0.77 1124 1.24 (0.92, 1.67) 0.16 1.24 (0.92, 1.67) 0.16 1.27 (0.92, 1.76) 0.15 1.28 (0.92, 1.77) 0.15 
Response
5
 
  
        
MTHFR rs1801131 G=0.18 3739 0.91 (0.77, 1.08) 0.28 0.90 (0.76, 1.07) 0.24 0.91 (0.76, 1.08) 0.29 0.89 (0.75, 1.07) 0.22 
MTHFR rs1801133 G=0.56 1124 0.93 (0.71, 1.22) 0.61 0.93 (0.71, 1.23) 0.61 0.94 (0.71, 1.25) 0.66 0.93 (0.69, 1.24) 0.60 
MTHFR rs2274976 C=0.91 3736 1.00 (0.81, 1.24) 0.97 1.02 (0.82, 1.26) 0.87 0.97 (0.78, 1.21) 0.81 0.98 (0.78, 1.22) 0.85 
TYMS rs2847153 A=0.36 1145 1.18 (0.93, 1.50) 0.17 1.12 (0.88, 1.43) 0.36 0.95 (0.73, 1.23) 0.70 0.90 (0.69, 1.18) 0.46 
TYMS rs2853533 G=0.49 1124 0.86 (0.66, 1.12) 0.26 0.90 (0.69, 1.18) 0.44 0.95 (0.72, 1.25) 0.70 0.99 (0.75, 1.32) 0.95 
1
Adjusted for age at diagnosis and tumor grade 
2
Adjusted for age at diagnosis, tumor grade, education, BMI, menopausal status, tamoxifen use, ER status, PR status, HER2 status, radiotherapy, and 
mastectomy 
3
Allele associated with faster metabolism coded as 1, HR<1 expected 
      4Allele associated with faster metabolism coded as 1, HR>1 expected 
      5Allele associated with better survival coded as 1, HR<1 expected 
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Table 16: Associations Between Individual SNPs in 5-Fluorouracil Metabolizing Genes and DFS and OS Among All Breast Cancer Cases Stratified 
by Whether 5-Fluorouracil was Taken 
  Participants who Took 5-Fluorouracil 
 
Participants who Did Not Take 5-Fluorouracil 
   
  Disease-Free Survival Overall Survival 
 
Disease-Free Survival Overall Survival 
 
DFS OS 
Gene rs ID HR (95% CI)
1
 P HR (95% CI)
1
 P 
 
HR (95% CI)
1
 P HR (95% CI)
1
 P   Pint Pint 
Activation
3
         
 
        
 
  
TYMP rs11479 1.04 (0.85, 1.27) 0.72 1.06 (0.86, 1.31) 0.59 
 
0.92 (0.72, 1.17) 0.48 0.90 (0.69, 1.18) 0.45 
 
0.47 0.37 
UMPS rs1801019 0.87 (0.71, 1.08) 0.22 0.88 (0.71, 1.10) 0.26 
 
0.98 (0.76, 1.27) 0.88 1.08 (0.82, 1.41) 0.59 
 
0.49 0.24 
UMPS rs3772809 1.07 (0.75, 1.52) 0.71 1.06 (0.73, 1.52) 0.77 
 
1.18 (0.75, 1.85) 0.48 1.38 (0.83, 2.29) 0.22 
 
0.70 0.37 
Deactivation
4
 
    
 
    
 
  
DPYD rs17376848 0.87 (0.51, 1.47) 0.60 1.27 (0.76, 2.13) 0.36 
 
1.63 (0.66, 4.04) 0.29 1.36 (0.49, 3.75) 0.55 
 
0.22 0.99 
DPYD rs1801159 1.07 (0.90, 1.28) 0.43 1.05 (0.87, 1.27) 0.58 
 
0.90 (0.73, 1.12) 0.34 0.88 (0.71, 1.10) 0.28 
 
0.22 0.22 
DPYD rs1801265 1.02 (0.77, 1.35) 0.90 1.03 (0.76, 1.40) 0.83 
 
1.03 (0.72, 1.47) 0.86 1.11 (0.76, 1.61) 0.59 
 
0.93 0.66 
DPYD rs72728438 1.20 (0.86, 1.67) 0.29 1.13 (0.79, 1.62) 0.51 
 
1.33 (0.68, 2.60) 0.41 1.92 (0.86, 4.28) 0.11 
 
0.71 0.19 
Response
5
     
 
    
 
  
MTHFR rs1801131 0.93 (0.75, 1.16) 0.51 0.88 (0.70, 1.11) 0.29 
 
0.87 (0.67, 1.14) 0.31 0.95 (0.72, 1.24) 0.68 
 
0.72 0.72 
MTHFR rs1801133 0.99 (0.73, 1.34) 0.96 1.00 (0.73, 1.37) 0.99 
 
0.74 (0.39, 1.39) 0.35 0.73 (0.37, 1.43) 0.35 
 
0.37 0.39 
MTHFR rs2274976 0.98 (0.74, 1.29) 0.87 0.93 (0.70, 1.24) 0.63 
 
1.08 (0.77, 1.52) 0.66 1.04 (0.73, 1.48) 0.83 
 
0.63 0.56 
TYMS rs2847153 1.11 (0.85, 1.46) 0.45 0.87 (0.64, 1.18) 0.37 
 
1.45 (0.88, 2.41) 0.15 1.35 (0.79, 2.32) 0.27 
 
0.36 0.15 
TYMS rs2853533 0.87 (0.64, 1.17) 0.34 1.02 (0.74, 1.39) 0.91   0.80 (0.45, 1.43) 0.46 0.68 (0.37, 1.26) 0.22   0.96 0.30 
1
Adjusted for age at diagnosis and tumor grade 
2
Adjusted for age at diagnosis, tumor grade, education, BMI, menopausal status, tamoxifen use, ER status, PR status, HER2 status, radiotherapy, and 
mastectomy 
3
Allele associated with faster metabolism coded as 1, HR<1 expected 
         4Allele associated with faster metabolism coded as 1, HR>1 expected 
         5Allele associated with better survival coded as 1, HR<1 expected 
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Each of the five gene scores created for SNPs in genes involved in 5-fluorouracil 
metabolism were evaluated for their association with DFS and OS among all breast cancer cases 
(Table 17). No significant associations were observed between the gene scores and survival 
outcomes among all breast cancer patients, although the total scores were in the expected 
direction (longer exposure to drug associated with better survival).  
When stratified by whether 5-fluorouracil was taken, no significant associations were 
observed among the five gene scores and DFS among those who underwent treatment with 5-
fluoruracil (Table 17). The total genes scores were more strongly associated with better OS 
among those who took 5-fluorouracil compared to those who did not, although the association 
was not statistically significant. Additionally, no significant interactions were observed between 
those who took 5-fluorouracil and those who did not. 
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Table 17: Association between 5-Fluorouracil Gene Scores and Breast Cancer Outcomes Among 
All Breast Cancer Cases and Stratified by Whether 5-Fluorouracil was Taken 
 
    
Disease-Free Survival Overall Survival 
Role in Metabolism 
# of 
SNPs 
N HR (95% CI)
6
 P HR (95% CI)
6
 P 
All Participants 
 
    
 
Activation
1
 3 3736 0.98 (0.89, 1.08) 0.69 1.00 (0.90, 1.11) 0.96 
 
Deactivation
2
 4 1124 1.00 (0.84, 1.19) 0.98 1.01 (0.84, 1.21) 0.95 
 
Other
3
 5 1124 0.97 (0.82, 1.15) 0.71 0.91 (0.76, 1.09) 0.29 
 
Total Score
4
 7 1124 0.99 (0.86, 1.13) 0.87 0.91 (0.78, 1.05) 0.19 
 
Total Score
5
 12 1124 0.98 (0.88, 1.09) 0.70 0.90 (0.80, 1.01) 0.08 
 
   
    
Participants Who Took 5-Fluorouracil 
 
Activation
1
 3 2625 0.97 (0.85, 1.11) 0.68 0.98 (0.86, 1.12) 0.79 
 
Deactivation
2
 4 882 1.01 (0.84, 1.23) 0.88 1.03 (0.84, 1.27) 0.75 
 
Other
3
 5 882 0.97 (0.80, 1.17) 0.75 0.93 (0.76, 1.13) 0.45 
 
Total Score
4
 7 882 0.98 (0.84, 1.13) 0.74 0.87 (0.74, 1.02) 0.09 
 
Total Score
5
 12 882 0.97 (0.86, 1.10) 0.64 0.88 (0.77, 1.00) 0.06 
 
   
    
Participants who Did Not Take 5-Fluorouracil 
 
Activation
1
 3 1111 0.98 (0.83, 1.14) 0.76 1.03 (0.87, 1.22) 0.76 
 
Deactivation
2
 4 242 0.96 (0.65, 1.40) 0.82 0.92 (0.62, 1.37) 0.68 
 
Other
3
 5 242 0.98 (0.66, 1.44) 0.90 0.85 (0.56, 1.29) 0.45 
 
Total Score
4
 7 242 1.11 (0.79, 1.56) 0.56 1.05 (0.73, 1.50) 0.79 
  Total Score
5
 12 242 1.05 (0.81, 1.35) 0.72 0.96 (0.73, 1.26) 0.77 
1
Includes SNPs from TYMP and UMPS genes, allele associated with faster metabolism 
coded as 1, HR<1 expected 
2
Includes SNPs from DPYD gene, allele associated with faster metabolism coded as 1, 
HR>1 expected 
3
Includes SNPs from TYMS and MTHFR genes, allele associated with better survival coded 
as 1, HR<1 expected 
4
Includes all SNPs included in activation and deactivation scores, allele associated with 
longer exposure to drug coded as 1, HR<1 expected 
5
Includes all SNPs included in activation, deactivation, and other scores, allele associated 
with longer exposure to drug coded as 1, HR<1 expected 
6
Adjusted for age at diagnosis and tumor grade 
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Using logistic regression, completion of 6 or more cycles of 5-fluorouracil was evaluated 
as a surrogate for toxicity (Table 18). We would expect that those who activated the drug more 
quickly or deactivated the drug more slowly, resulting in longer exposure to the active 
metabolite, may be more likely to experience a toxicity event and may be more likely to 
complete less than 6 cycles of chemotherapy treatment with 5-fluorouracil. Among breast cancer 
participants who underwent treatment with 5-fluorouracil, there was a 10% decrease in 
likelihood of completing 6 or more cycles of 5-fluorouracil for each additional SNP associated 
with increased activation of 5-fluorouracil (OR=0.90, 95% CI: 0.81, 1.00, p=0.04). The 5-
fluorouracil response gene score was not associated with number of cycles completed and neither 
was the combined gene score which included these SNPs. No other associations between 5-
fluorouracil gene scores and number of cycles of 5-fluorouracil completed were observed. 
 
Table 18: Association Between 5-Fluorouracil Genes Scores and Cycles of 5-Fluorouracil 
Completed 
 
Role in Metabolism OR (95% CI)
4
 P 
Activation
1
 0.90 (0.81, 1.00) 0.04 
Deactivation
2
 1.05 (0.90, 1.23) 0.51 
Response
3
 1.08 (0.93, 1.26) 0.31 
Total Score
1,2
 0.97 (0.87, 1.09) 0.62 
Total Score
1,2,3
 1.01 (0.92, 1.11) 0.83 
1
Includes SNPs from TYMP and UMPS genes 
2
Includes SNPs from DPYD gene 
3
Includes SNPs from TYMS and MTHFR genes 
4
Adjusted for age at diagnosis and tumor grade 
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The association between 5-fluorouracil gene scores and breast cancer survival among 
those who took 5-fluorouracil was further evaluated through additional adjustment for the 
number of cycles of 5-fluorouracil taken (Table 19). The observed associations between 5-
fluorouracil gene scores and survival outcomes were not materially changed after adjustment for 
number of cycles completed.  
 
Table 19: Association Between 5-Fluorouracil Gene Scores and Survival Outcomes Additionally 
Adjusted for Cycles of 5-Fluorouracil Completed 
 
    
Disease-Free Survival Overall Survival 
Role in Metabolism 
# of 
SNPs 
N HR (95% CI)
6
 P HR (95% CI)
6
 P 
 
Activation
1
 3 2623 0.97 (0.85, 1.10) 0.60 0.99 (0.86, 1.13) 0.83 
 
Deactivation
2
 4 881 1.02 (0.84, 1.23) 0.86 1.03 (0.83, 1.27) 0.79 
 
Response
3
 5 881 0.97 (0.80, 1.18) 0.79 0.93 (0.76, 1.14) 0.51 
 
Total Score
4
 7 881 0.98 (0.84, 1.13) 0.74 0.88 (0.75, 1.04) 0.13 
  Total Score
5
 12 881 0.97 (0.86, 1.10) 0.65 0.89 (0.78, 1.02) 0.09 
1
Includes SNPs from TYMP and UMPS genes, allele associated with faster metabolism coded as 1, 
HR<1 expected 
2
Includes SNPs from DPYD gene, allele associated with faster metabolism coded as 1, HR>1 
expected 
3
Includes SNPs from TYMS and MTHFR genes, allele associated with better survival coded as 1, 
HR<1 expected 
4
Includes all SNPs included in activation and deactivation scores, allele associated with longer 
exposure to drug coded as 1, HR<1 expected 
5
Includes all SNPs included in activation, deactivation, and other scores, allele associated with 
longer exposure to drug coded as 1, HR<1 expected 
6
Adjusted for age at diagnosis and tumor grade 
    
 
We stratified our results by timing of survival events, those that occurred in the first three 
years of follow-up and those that occurred after 3 years, among all women and restricted to those 
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who took 5-fluorouracil (Table 20). The 5-fluorouracil gene scores were both associated with 
better OS for events which occurred after the first 3 years, particularly among those who took 5-
fluorouracil (total score including SNPs in activating and deactivating genes only HR=0.76, 95% 
CI: 0.62, 0.93, p=0.008, total score including all SNPs HR=0.78, 95% CI: 0.67, 0.92, p=0.004) 
and the association was significant even after correction for multiple comparisons. No 
association was observed in those who had events in the first 3 years following cancer diagnosis.
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Table 20: Association Between 5-fluorouracil Gene Scores Stratified by Early vs. Late Events Among All Participants and Only Those who Took 5-
Fluorouracil 
 
 
   
Event <3 years 
 
Event ≥3 years 
   
Disease-Free Survival Overall Survival 
 
Disease-Free Survival Overall Survival 
Role in 
Metabolism 
# of 
SNPs 
HR (95% CI)
6
 P HR (95% CI)
6
 P 
  
HR (95% CI)
6
 P HR (95% CI)
6
 P 
All Participants
 
 
 
Activation
1
 3 0.98 (0.87, 1.11) 0.80 0.98 (0.84, 1.15) 0.81 
 
0.96 (0.81, 1.15) 0.68 1.02 (0.89, 1.18) 0.78 
 
Deactivation
2
 4 0.99 (0.80, 1.23) 0.93 0.90 (0.66, 1.21) 0.48 
 
1.01 (0.76, 1.36) 0.92 1.07 (0.85, 1.35) 0.56 
 
Response
3
 5 1.06 (0.86, 1.31) 0.57 0.94 (0.70, 1.26) 0.68 
 
0.81 (0.60, 1.08) 0.15 0.89 (0.71, 1.12) 0.32 
 
Total Score
4
 7 1.00 (0.85, 1.19) 0.96 1.05 (0.83, 1.33) 0.71 
 
0.97 (0.77, 1.22) 0.78 0.83 (0.69, 1.00) 0.05 
 
Total Score
5
 12 1.03 (0.90, 1.18) 0.68 1.00 (0.83, 1.22) 0.97 
 
0.90 (0.74, 1.08) 0.25 0.84 (0.73, 0.98) 0.02 
 
  
    
 
    
Participants who Took 5-Fluorouracil 
   
 
    
 
Activation
1
 3 0.98 (0.83, 1.15) 0.76 1.01 (0.82, 1.25) 0.92 
 
0.96 (0.78, 1.19) 0.73 0.96 (0.80, 1.14) 0.62 
 
Deactivation
2
 4 1.03 (0.80, 1.32) 0.84 0.87 (0.61, 1.23) 0.42 
 
0.99 (0.73, 1.34) 0.94 1.14 (0.88, 1.48) 0.32 
 
Response
3
 5 1.11 (0.87, 1.42) 0.40 1.05 (0.75, 1.47) 0.79 
 
0.77 (0.57, 1.06) 0.11 0.87 (0.68, 1.12) 0.27 
 
Total Score
4
 7 0.96 (0.79, 1.16) 0.66 1.10 (0.84, 1.43) 0.50 
 
1.01 (0.80, 1.28) 0.92 0.76 (0.62, 0.93) 0.008 
  Total Score
5
 12 1.02 (0.87, 1.19) 0.85 1.09 (0.87, 1.35) 0.47   0.91 (0.75, 1.11) 0.36 0.78 (0.67, 0.92) 0.004 
1
Includes SNPs from TYMP and UMPS genes, allele associated with faster metabolism coded as 1, HR<1 expected 
2
Includes SNPs from DPYD gene, allele associated with faster metabolism coded as 1, HR>1 expected 
3
Includes SNPs from TYMS and MTHFR genes, allele associated with better survival coded as 1, HR<1 expected 
4
Includes all SNPs included in activation and deactivation scores, allele associated with longer exposure to drug coded as 1, HR<1 
expected 
5
Includes all SNPs included in activation, deactivation, and other scores, allele associated with longer exposure to drug coded as 1, HR<1 
expected 
6
Adjusted for age at diagnosis and tumor grade 
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Joint Effect of Cyclophosphamide Gene Score and 5-Fluorouracil Gene Score 
Approximately 65% of our population underwent chemotherapy with both 
cyclophosphamide and 5-fluorouracil. We further evaluated the joint effect of the two total 
scores which we created (Table 21). For comparability, we used the 5-fluorouracil gene score 
which included SNPs in genes involved in activation and deactivation only. No joint effect of the 
two gene scores was observed. No difference in survival was observed between all participants 
and those participants who took both drugs. 
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Table 21: Joint Effect of the Cyclophosphamide Gene Score and the 5-Fluorouracil Gene Score 
 
  
Disease-Free Survival 
 
Overall Survival 
  
Cyclophosphamide Score (HR
1
 (95%CI)) 
 
Cyclophosphamide Score (HR
1
 (95%CI)) 
5-Fluorouracil Score 4.00-10.59 10.60-12.33 12.34-18.50   4.00-10.59 10.60-12.33 12.34-18.50 
         Overall (n=1124) 
    
 
0.0-4.0 1.00 (reference) 1.52 (0.74, 3.13) 0.98 (0.45, 2.12) 
 
1.00 (reference) 1.00 (0.45, 2.24) 1.11 (0.52, 2.40) 
 
4.0-5.0 2.19 (1.13, 4.26) 1.43 (0.72, 2.82) 1.09 (0.52, 2.30) 
 
1.90 (0.95, 3.80) 1.19 (0.58, 2.45) 1.19 (0.55, 2.58) 
 
5.0-11.0 0.91 (0.39, 2.12) 0.98 (0.45, 2.13) 1.07 (0.52, 2.23) 
 
0.95 (0.41, 2.16) 0.60 (0.25, 1.44) 0.90 (0.42, 1.95) 
         Those who Took Cyclophosphamide and 5-Fluorouracil (n=845) 
    
 
0.0-4.0 1.00 (reference) 1.42 (0.62, 3.23) 0.94 (0.39, 2.24) 
 
1.00 (reference) 1.08 (0.43, 2.68) 1.17 (0.50, 2.77) 
 
4.0-5.0 1.97 (0.93, 4.19) 1.57 (0.75, 3.30) 1.08 (0.48, 2.47) 
 
1.57 (0.69, 3.56) 1.37 (0.62, 3.02) 1.12 (0.47, 2.64) 
 
5.0-11.0 0.68 (0.24, 1.93) 0.59 (0.22, 1.58) 1.05 (0.46, 2.40) 
 
0.93 (0.36, 2.41) 0.29 (0.08, 1.05) 0.91 (0.39, 2.15) 
1
Adjusted for age at diagnosis and tumor grade 
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Conclusions/Discussion 
In this study, we evaluated 11 SNPs in genes involved in cyclophosphamide metabolism 
and 12 SNPs in genes involved in 5-fluorouracil metabolism and response. We found that the C 
allele in the rs2228100 SNP in the ALDH3A1 gene and the G allele in the rs1695 SNP in the 
GSTP1 gene were associated with better DFS, though associations were not significant after 
adjustment for multiple comparisons. The A allele in the rs4986893 SNP in the CYP2C19 gene 
was associated with poorer DFS and OS, though the association was not significant after 
adjustment for multiple comparisons. No significant interactions were observed between those 
who took cyclophosphamide and those that did not. The cyclophosphamide gene score was not 
associated with DFS or OS. No individual alleles in genes involved in 5-fluorouracil metabolism 
were associated with DFS or OS. The 5-fluorouracil gene score was associated with improved 
OS, particularly among those who took 5-fluorouracil who survived at least three years without 
an event. 
The effects of germline genetic variation in enzymes involved in chemotherapy 
metabolism have the potential to explain differences in response to chemotherapy drugs and 
cancer prognosis. However, the effect of a single polymorphism may not be great enough to 
observe an association. Our pathway approach increased power to detect associations between 
SNPs in these genes and breast cancer survival outcomes. We chose a priori to incorporate all 
potentially functioning SNPs investigated in this study by creating gene score variables. While 
previous studies have shown an association between individual SNPs and chemotherapy 
response or breast cancer outcomes, the evidence for most of the SNPs included in this study was 
inconsistent. Inclusion of SNPs in the gene score which do not affect chemotherapy response and 
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breast cancer outcomes would decrease our power to detect an association between our gene 
score and survival. Furthermore, SNPs in the promoter regions of our genes of interest were not 
included in this study. Future studies should also consider inclusion of these SNPs. 
We did not observe significant differences in the cyclophosphamide gene scores we 
created between those who took cyclophosphamide and those who did not. The genes which we 
evaluated in this study are also involved in other biological processes, such as cell proliferation 
and angiogenic activity, some of which may have an effect of tumor progression and survival. 
Therefore, our scores may not only be measuring potential effects on chemotherapy activation 
and degradation but also other biological function of the genes. Additionally, there are other 
factors that could affect drug metabolism and potentially gene expression levels including 
comorbidities, medications, and dietary factors. While some of these factors were formally tested 
as potential confounders, we were unable to account for all of these factors in our analyses. 
The 5-fluorouracil total gene scores were marginally associated with better overall 
survival, particularly among those participants who were treated with 5-fluorouracil. As 
expected, those with a longer exposure period to the active metabolite had better outcomes. 
We included all breast cancer types in order to maximize sample size. We further 
adjusted our results for ER, PR, and HER2 status, as well as Tamoxifen use, which is used to 
treat hormone receptor positive cancers and is associated with breast cancer survival, and there 
was no difference in the observed associations. Further studies which could evaluate these 
associations by molecular intrinsic subtypes, particularly in TNBC patients and patients 
diagnosed with late stage breast cancer where chemotherapy is standard, are needed.  
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CHAPTER V 
TUMOR-LEVEL EXPRESSION OF CHEMOTHERAPY METABOLIZING GENES AND 
TRIPLE-NEGATIVE BREAST CANCER OUTCOMES 
Aim 3-Specific Methods 
As previously mentioned, gene expression data was log2 transformed prior to analysis to 
account for non-normal data distributions. Gene expression data was analyzed as a continuous 
measure and as a categorical variable with a median cut point and a tertile cut point.  
The potential effect of gene expression levels of genes involved in cyclophosphamide 
metabolism was hypothesized based on knowledge of cyclophosphamide metabolism as well as 
results from previous studies.
24
 As previously discussed, cyclophosphamide is activated in the 
liver by cytochrome P450 genes prior to entering the cell; therefore, we expect that the breast 
tumor level expression of these genes will have little or no effect on cyclophosphamide 
metabolism and breast cancer survival outcomes. The aldehyde dehydrogenase genes and 
glutathione-S-transferase genes are involved in clearance of the active cyclophosphamide 
metabolite; therefore, we expect high expression of these genes to be associated with shorter 
exposure to the active drug and worse survival compared to those with low expression. 
The potential effect of gene expression levels for genes involved in 5-fluorouracil 
metabolism was hypothesized based on knowledge of 5-fluorouracil metabolism as well as 
results from previous studies.
24
 As previously discussed, TYMP and UMPS are involved in 
activation of 5-fluorouracil to the active metabolite in the cell; therefore we expect higher 
expression of these genes to be associated with longer exposure to the active drug and better 
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survival compared to those with low expression. DPYD clears (deactivates) the active form of 5-
fluorouracil; therefore we expect those with high DPYD expression to have shorter exposure to 
treatment and worse survival. TYMS is the target of 5-fluorouracil and 5-fluorouracil works 
through inhibiting this gene; therefore, we expect that those with high TYMS expression would 
have a decreased response and worse survival compared with those with low expression. 
MTHFR catalyzes the conversion of methylenetetrahydrofolate to methyltetrahydrofolate, the 
latter acts as a cofactor in the inhibition of TYMS; therefore, we would expect that those with 
low MTHFR expression would have increased response to treatment and better survival 
compared with those with low expression. 
 Genes which were expressed in more than 85% of tumor samples were analyzed as 
continuous variables, as well as categorical variables using median and tertile cut points. Genes 
expressed in less than 50% of tumor samples were only analyzed as expressed versus not 
expressed. 
Five genes were included in the cyclophosphamide gene score, all of which are involved 
in cyclophosphamide deactivation; those with expression levels above the median were coded as 
1 and those with expression levels below the median were coded as 0. For genes with expression 
in less than 50% of the tumor samples, those with expression were coded as 1 and those with no 
expression were coded as 0. This resulted in a score with a possible range of 0 to 5. Those with 
higher scores clear the active metabolite of cyclophosphamide faster than those with lower 
scores. The top and bottom ends of the score were collapsed due to low sample size, resulting in 
a score with a range of 1 to 3 (Table 22). 
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Table 22: Creation of Cyclophosphamide Gene Expression Score Based on Median Cut Points 
 
Original Score Collapsed Score Frequency Percent 
0 1 25 6.0 
1 1 130 31.1 
2 2 150 35.9 
3 3 83 19.9 
4 3 28 6.7 
5 3 2 0.5 
 
 
Five genes were included in the 5-fluorouracil gene score, all of which were expressed in 
>85% of tumor samples. Two of the genes are involved in activation of 5-fluorouracil to the 
active metabolite, one is involved in clearance of the active metabolite, and two are involved in 
response. For the activating genes, those with expression levels above the median were coded as 
0 and those with expression levels below the median were coded as 1. For the deactivating genes, 
those with expression levels above the median were coded as 1 and those with expression levels 
below the median were coded as 0. The response genes were coded so that those with worse 
survival expected (based on expression level) were coded as 1 and those who were expected to 
respond better as 0. This resulted in a score with a possible range of 0 to 5 where those with 
higher scores are faster deactivators, slower activators, and worse responders. The top and 
bottom ends of the score were collapsed due to low sample size, resulting in a score with a range 
of 1 to 4 (Table 23). 
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Table 23: Creation of 5-Fluorouracil Gene Expression Score Based on Median Cut Points 
 
Original Score Collapsed Score Frequency Percent 
0 1 7 1.7 
1 1 60 14.4 
2 2 142 34.0 
3 3 138 33.0 
4 4 63 15.1 
5 4 8 1.9 
 
 
Results 
Among TNBC participants in the SBCSS cohort, 67 recurrences/breast cancer deaths and 
76 deaths were documented over a median follow-up of 5.3 years (range: 0.7-8.9 years). 
Advanced stage disease and radiotherapy treatment were inversely associated with 5-year DFS 
and OS (Table 24). Chemotherapy was inversely associated with DFS rate. Grade was inversely 
associated with OS rate. 
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Table 24: Demographic and Clinical Predictors for Breast Cancer Survival for TNBC Cases in the SBCSS 
 
   
Disease-Free Survival 
 
Overall Survival 
Characteristics N Events, No. 
5-Yr Survival 
Rate, %
1
 P   
Deaths, 
No. 
5-Yr Survival 
Rate, %
1
 P 
Age at diagnosis, y 
        
 
<40 29 4 84.3 
0.85 
 
5 82.8 
0.18 
 
40-49 154 23 84.6 
 
24 87.5 
 
50-59 108 16 84.5 
 
15 87.9 
 
≥60 127 24 79.6 
 
32 80.3 
Education 
        
 
Elementary School or 
Less 60 13 75.7 
0.18 
 
17 78.1 
0.14 
 
Middle School 140 27 80.3 
 
25 85.7 
 
High or Vocational 
School 151 16 89.3 
 
20 88.5 
 
College or University 67 11 81.2 
 
14 81.9 
Income (yuan/person/month) 
        
 
<500 53 12 75.2 
0.06 
 
14 81.1 
0.32  
500 - <700 60 15 74.9 
 
15 81.5 
 
700 - <1000 127 20 83.1 
 
23 83.3 
 
1000 - <2000 133 17 86.8 
 
18 88.6 
 
≥2000 44 3 92.1 
 
6 88.4 
Body Mass Index (kg/m
2
) 
        
 
<25 271 43 83.2 
0.70  
46 86.7 
0.68 
 
25-29.99 121 18 84.1 
 
24 82.5 
 
≥30 26 6 75.4 
 
6 80.3 
Menopausal Status 
        
 
Premenopausal 193 27 85.7 
0.37 
 
28 87.9 
0.08 
 
Postmenopausal 225 40 80.8 
 
48 82.6 
TNM Stage 
        
 
0-I 137 12 90.3 
<.0001 
 
14 90.4 
<.0001  
IIA 145 18 87.3 
 
20 89.6 
 
IIB 85 20 73.5 
 
25 75.1 
 
III-IV 38 16 58.2 
 
16 68.4 
 
Unknown 13 1 91.7 
 
1 92.3 
Grade 
   
 
   
 
 
1 50 5 89.0 
0.28  
3 94.0 
0.04 
 
2 132 19 83.9 
 
23 87.1 
 
3 236 43 81.2 
 
50 82.0 
Chemotherapy 
        
 
Yes 390 59 84.1 
0.04 
 
67 86.3 
0.06 
 
No 28 8 68.1 
 
9 67.9 
Radiotherapy 
        
 
Yes 103 27 71.8 
0.0009 
 
28 75.5 
0.002 
 
No 315 40 86.7 
 
48 88.1 
Mastectomy 
        
 
Yes 399 63 83.3 
0.36 
 
73 85.1 
0.73 
 
No 19 4 76.1 
 
3 84.2 
No. of Live Births 
        
 
0 2 0 100.0 
0.54 
 
0 100 
0.07 
 
1 268 39 84.7 
 
40 87.5 
 
2 79 16 78.8 
 
18 81.0 
 
≥3 53 11 76.9 
 
16 77.4 
Family History of BC 
        
 
Yes 29 6 76.2 
0.37 
 
5 85.9 
0.93 
 No 389 61 83.5   71 84.9 
1
Survival rate calculated using life table analysis method 
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The gene expression levels of each of the cyclophosphamide and 5-fluorouracil 
metabolizing genes of interest in our study population are shown in Table 25 and Table 26, 
respectively.  
 
Table 25: Expression Levels of Cyclophosphamide Metabolizing Genes Among TNBC 
Participants in the SBCSS Cohort 
 
Gene % Expressed Mean (SD) Median Minimum Maximum 
CYP2B6 9.3% 3.9 (1.8) 4.0 1.0 7.4 
CYP3A4 0.0% n/a n/a n/a n/a 
CYP2C9 data not available 
CYP3A5 8.6% 2.8 (1.5) 2.7 1.0 5.7 
CYP2A6 9.6% 6.5 (3.3) 6.2 1.0 14.7 
CYP2C8 12.0% 2.5 (1.0) 2.3 1.0 4.5 
CYP2C19 0.2% 1.0 (n/a) 1.0 1.0 1.0 
ALDH1A1 95.5% 7.1 (1.5) 7.2 1.0 11.8 
ALDH3A1 data not available 
GSTP1 100.0% 10.9 (1.0) 11.1 6.6 13.6 
GSTA1 10.0% 3.6 (1.7) 3.2 1.0 6.9 
GSTT1 44.0% 6.4 (1.4) 6.7 1.0 8.9 
GSTM1 37.6% 6.9 (2.3) 6.8 1.0 13.8 
Statistics among those with expression only 
   
 
Table 26: Expression Levels of 5-Fluorouracil Metabolizing Genes Among TNBC Participants 
in the SBCSS Cohort 
 
Gene % Expressed Mean (SD) Median Minimum Maximum 
DPYD 96.7% 7.8 (0.9) 7.9 2.0 10.1 
TYMS 96.7% 8.8 (1.3) 8.8 3.3 12.1 
MTHFR 95.5% 6.8 (0.9) 6.9 2.3 9.2 
TYMP 100.0% 10.7 (1.0) 10.7 5.6 14.4 
UMPS 90.2% 6.2 (0.9) 6.2 2.0 8.4 
Statistics among those with expression only 
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ALDH1A1, GSTP1, DPYD, TYMS, MTHFR, TYMP, and UMPS were expressed in the 
large majority (≥90%) of TNBC tumor tissue samples in our study. GSTA1, GSTM1, and 
GSTT1 were expressed in fewer than 50% of samples. As expected, the CYP genes were not 
expressed or expressed at very low levels in the tumor tissue. Therefore, the tumor level 
expression of the CYP genes will not be investigated in this study.  
Cyclophosphamide 
Participants with expression levels of ALDH1A1 below the median were more likely to 
have a higher grade tumor and more likely to have markers of the basal-like subtype compared to 
those with expression levels above the median (Table 27). Participants with expression levels of 
GSTP1 above the median were more likely to have a higher grade tumor and more likely to have 
markers of the basal-like subtype compared to those with expression levels below the median. 
Those with expression levels of GSTP1 above the median were also less likely to have received 
chemotherapy, particularly cyclophosphamide. Expression of GSTA1 was associated with higher 
tumor grade. Expression of GSTT1 was associated with higher tumor grade. Lack of expression 
of GSTA1 or GSTM1 was associated with markers of the basal-like subtype.  
Dual specificity phosphatase 4 (DUSP4) expression shows the strongest association with 
survival in this study population; this association was previously reported.
169
 We examined the 
correlation between the cyclophosphamide metabolizing genes being investigated in this study 
and DUSP4 expression (Table 28). ALDH1A1 and GSTT1 expressions were positively 
correlated with DUSP4 expression (p<.0001 and p=0.049, respectively) and GSTP1 and GSTA1 
were negatively associated with DUSP4 expression (p=0.0003 and p=0.002), respectively. No 
correlation between DUSP4 expression and GSTM1 expression was observed. 
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Table 27: Clinical and Treatment Factors by Expression of Cyclophosphamide Metabolizing Genes Among TNBC Participants in the SBCSS Cohort 
 
  
ALDH1A1 GSTP1 GSTA1 GSTM1 GSTT1 
    <Median ≥Median   <Median ≥Median   
Not 
Expressed Expressed   
Not 
Expressed Expressed   
Not 
Expressed Expressed   
    N(%1) N(%1) P N(%1) N(%1) P N(%1) N(%1) P N(%1) N(%1) P N(%1) N(%1) P 
N 
 
209 209 
 
209 209 
 
376 42 
 
261 157 
 
234 184 
 
                 TNM Stage 
  
0.65 
  
0.46 
  
0.16 
  
0.17 
  
0.75 
 
0-I 67 (48.9) 70 (21.1) 
 
70 (51.1) 67 (48.9) 
 
123 (89.8) 14 (10.2) 
 
76 (55.5) 61 (44.5) 
 
77 (56.2) 60 (43.8) 
 
 
IIA 70 (48.3) 75 (51.7) 
 
75 (51.7) 70 (48.3) 
 
133 (91.7) 12 (8.3) 
 
98 (67.6) 47 (32.4) 
 
80 (55.2) 65 (44.8) 
 
 
IIB 48 (56.5) 37 (43.5) 
 
37 (43.5) 48 (56.5) 
 
71 (83.5) 14 (16.5) 
 
56 (65.9) 29 (34.1) 
 
49 (57.7) 36 (42.4) 
 
 
III-IV 19 (50.0) 19 (50.0) 
 
22 (57.9) 16 (42.1) 
 
36 (94.7) 2 (5.3) 
 
23 (60.5) 15 (39.5) 
 
18 (47.4) 20 (52.6) 
 
 
Missing 5 8 
 
5 8 
 
13 0 
 
8 5 
 
10 3 
 
                 Grade 
  
<.0001 
  
<.0001 
  
0.02 
  
0.85 
  
0.04 
 
1 12 (24.0) 38 (76.0) 
 
30 (60.0) 20 (40.0) 
 
49 (98.0) 1 (2.0) 
 
30 (60.0) 20 (40.0) 
 
35 (70.0) 15 (30.0) 
 
 
2 56 (42.4) 76 (57.6) 
 
84 (63.6) 48 (36.4) 
 
123 (93.2) 9 (6.8) 
 
81 (61.4) 51 (38.6) 
 
65 (49.2) 67 (50.8) 
 
 
3 141 (59.8) 95 (40.3) 
 
95 (40.3) 141 (59.8) 
 
204 (86.4) 32 (13.6) 
 
150 (63.6) 86 (36.4) 
 
134 (56.8) 102 (43.2) 
 
                 Chemotherapy 198 (50.8) 192 (49.2) 0.24 200 (51.3) 190 (48.7) 0.05 351 (90.0) 39 (10.0) 0.90 244 (62.6) 146 (37.4) 0.85 216 (55.4) 174 (44.6) 0.36 
 
Cyclophosphamide 151 (51.0) 145 (49.0) 0.52 158 (53.4) 138 (46.6) 0.03 268 (90.5) 28 (9.5) 0.53 186 (62.8) 110 (37.2) 0.79 163 (55.1) 133 (44.9) 0.56 
                 Radiotherapy 59 (57.3) 44 (42.7) 0.09 50 (48.5) 53 (51.5) 0.73 89 (86.4) 14 (13.6) 0.17 65 (63.1) 38 (36.9) 0.87 58 (56.3) 45 (43.7) 0.94 
                 Mastectomy 201 (50.4) 198 (49.6) 0.48 198 (49.6) 201 (50.4) 0.48 358 (89.7) 41 (10.3) 0.48 250 (62.7) 149 (37.3) 0.68 223 (55.9) 176 (44.1) 0.86 
                 Subtype Classification 
  
<.0001 
  
<.0001 
  
<.0001 
  
0.01 
  
0.38 
 
Basal-like 124 (71.3) 50 (28.7) 
 
56 (32.2) 118 (67.8) 
 
141 (81.0) 33 (19.0) 
 
108 (62.1) 66 (37.9) 
 
98 (56.3) 76 (43.7) 
 
 
Her-2 Enriched 21 (35.0) 39 (65.0) 
 
30 (50.0) 30 (50.0) 
 
57 (95.0) 3 (5.0) 
 
38 (63.3) 22 (36.7) 
 
27 (45.0) 33 (55.0) 
 
 
Luminal A 32 (29.1) 78 (70.9) 
 
75 (68.2) 35 (31.8) 
 
110 (100.0) 0 (0.0) 
 
76 (69.1) 34 (30.9) 
 
65 (59.1) 45 (40.9) 
 
 
Luminal B 22 (53.7) 19 (46.3) 
 
31 (75.6) 10 (24.4) 
 
39 (95.1) 2 (4.9) 
 
16 (39.0) 25 (61.0) 
 
23 (56.1) 18 (43.9) 
  Normal 10 (30.3) 23 (69.7)   17 (51.5) 16 (48.5)   29 (87.9) 4 (12.1)   23 (69.7) 10 (30.3)   21 (63.6) 12 (36.4)   
1Percents shown are row percentages 
              Median Values: ALDH1A1 - 7.140; GSTP1 - 11.120 
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Table 28: Correlation Between Expression of Cyclophosphamide Metabolizing Genes and 
DUSP4 Expression Among TNBC Participants in the SBCSS Cohort 
 
 
Correlation with DUSP4 
  r p 
ALDH1A1 0.28 <.0001 
GSTP1 -0.18 0.0003 
GSTA1 -0.15 0.002 
GSTM1 0.01 0.81 
GSTT1 0.10 0.049 
 
 
Univariate analyses between survival, both disease-free and overall, and expression level 
of genes involved in cyclophosphamide among all TNBC patients are shown in Figure 2. 
ALDH1A1 expression above the median was significantly associated with better DFS (p=0.03) 
compared with expression levels below the median, but no significant difference was seen in OS 
(p=0.14). No difference was observed in DFS or OS by expression of GSTP1, GSTA1, GSTM1, 
or GSTT1.   
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Figure 2: Kaplan-Meier Curves For Disease-Free Survival and Overall Survival for Genes 
Involved in Cyclophosphamide Metabolism Among TNBC Participants in the SBCSS Cohort 
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As previously shown in our published paper,
121
 among all TNBC patients, high 
ALDH1A1 expression, analyzed continuously, was significantly associated with DFS and OS, 
after adjustment for age at diagnosis (DFS HR=0.91, 95% CI: 0.82, 1.00, OS HR=0.89, 95% CI: 
0.81, 0.98) (Table 29). This association was attenuated slightly after adjustment for tumor grade 
and markers of basal-like subtype. After further adjustment for DUSP4 expression, the 
association was further attenuated (DFS HR=0.97, 95% CI: 0.86, 1.08, OS HR=0.95, 95% CI: 
0.86, 1.06). ALDH1A1 expression above the median was significantly associated with DFS, but 
not OS, compared to the lower median, after adjustment for age at diagnosis and tumor grade 
(DFS HR=0.60, 95% CI: 0.36, 1.00, OS HR=0.74, 95% CI: 0.46, 1.18). Further adjustment for 
markers of the basal-like subtype and DUSP4 expression attenuated the association with DFS 
(HR=0.70, 95% CI: 0.40, 1.21). However, when the highest tertile of ALDH1A1 gene 
expression was compared to the lowest tertile, the significant association with better DFS 
remained, even after adjustment for age at diagnosis, tumor grade, markers of the basal-like 
subtype, and DUSP4 expression (HR=0.41, 95% CI: 0.19, 0.88). 
No association was observed between GSTP1, GSTA1, GSTM1, or GSTT1 expression 
and DFS or OS after adjustment for age at diagnosis, tumor grade, basal-like subtype, and 
DUSP4 expression. 
Next, the results were stratified by whether the drug of interest, cyclophosphamide, was 
taken (Table 30). No significant differences were seen in the associations between gene 
expression and survival outcomes based on whether cyclophosphamide was taken. However, 
among those who took cyclophosphamide, GSTP1 expression was associated with significantly 
better DFS (continuous HR=0.65, 95% CI: 0.47, 0.91).  
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Table 29: Disease-Free and Overall Survival by Expression of Genes Involved in Cyclophosphamide Metabolism Among TNBC Participants 
in the SBCSS Cohort 
 
  
5-yr 
Rate, %
1
 HR (95% CI)
2
 P HR (95% CI)
3
 P HR (95% CI)
4
 P HR (95% CI)
5
 P 
Disease-Free Survival 
ALDH1A1 
         
 
Continuous 83.0 0.91 (0.82, 1.00) 0.05 0.92 (0.83, 1.02) 0.10 0.93 (0.83, 1.03) 0.18 0.97 (0.86, 1.08) 0.55 
           
 
<median 79.1 Reference Reference Reference Reference 
 
≥median 86.7 0.55 (0.34, 0.91) 0.02 0.60 (0.36, 1.00) 0.05 0.65 (0.38, 1.11) 0.12 0.70 (0.40, 1.21) 0.20 
           
 
Tertile1 78.5 Reference Reference Reference Reference 
 
Tertile 2 79.4 0.86 (0.51, 1.45) 0.56 0.87 (0.51, 1.48) 0.61 0.96 (0.55, 1.64) 0.87 1.01 (0.58, 1.76) 0.96 
 
Tertile 3 91.1 0.31 (0.15, 0.63) 0.001 0.33 (0.16, 0.69) 0.003 0.37 (0.17, 0.78) 0.009 0.41 (0.19, 0.88) 0.02 
           GSTP1 
         
 
Continuous 83.0 0.96 (0.76, 1.21) 0.73 0.93 (0.73, 1.17) 0.52 0.82 (0.62, 1.08) 0.16 0.80 (0.61, 1.05) 0.10 
           
 
<median 83.8 Reference Reference Reference Reference 
 
≥median 82.2 1.20 (0.74, 1.95) 0.45 1.13 (0.69, 1.85) 0.63 1.03 (0.62, 1.71) 0.90 0.97 (0.58, 1.61) 0.90 
           
 
Tertile1 84.0 Reference Reference Reference Reference 
 
Tertile 2 80.4 1.40 (0.78, 2.53) 0.26 1.36 (0.75, 2.48) 0.32 1.03 (0.52, 2.04) 0.93 1.01 (0.52, 1.99) 0.97 
 
Tertile 3 
 
1.06 (0.57, 1.99) 0.85 0.98 (0.52, 1.86) 0.95 0.80 (0.40, 1.59) 0.52 0.70 (0.35, 1.42) 0.33 
           GSTA1 
         
 
Not expressed 83.4 Reference Reference Reference Reference 
 
Expressed 79.8 1.41 (0.67, 2.96) 0.37 1.28 (0.60, 2.72) 0.53 1.12 (0.52, 2.41) 0.77 1.09 (0.51, 2.33) 0.83 
           GSTM1 
         
 
Not expressed 83.4 Reference Reference Reference Reference 
 
Expressed 82.4 0.98 (0.92, 1.05) 0.64 1.11 (0.68, 1.82) 0.67 1.13 (0.69, 1.84) 0.64 1.14 (0.70, 1.88) 0.59 
           GSTT1 
         
 
Not expressed 81.4 Reference Reference Reference Reference 
 
Expressed 84.9 0.98 (0.91, 1.05) 0.51 0.88 (0.54, 1.43) 0.60 0.90 (0.55, 1.47) 0.68 0.97 (0.59, 1.58) 0.89 
 
 
 
 
 
 
          
 
 
 
  
 
 
      
 87 
 
  
Overall Survival 
ALDH1A1 
         
 
Continuous 85.0 0.89 (0.81, 0.98) 0.02 0.91 (0.82, 1.00) 0.05 0.92 (0.83, 1.02) 0.10 0.95 (0.86, 1.06) 0.40 
           
 
<median 82.5 Reference Reference Reference Reference 
 
≥median 87.5 0.65 (0.41, 1.04) 0.07 0.74 (0.46, 1.18) 0.21 0.80 (0.49, 1.30) 0.37 0.87 (0.52, 1.43) 0.57 
   
  
      
 
Tertile1 80.0 Reference Reference Reference Reference 
 
Tertile 2 84.5 0.70 (0.41, 1.17) 0.17 0.72 (0.43, 1.22) 0.23 0.77 (0.45, 1.32) 0.35 0.83 (0.48, 1.43) 0.50 
 
Tertile 3 90.5 0.45 (0.25, 0.80) 0.007 0.52 (0.28, 0.94) 0.03 0.56 (0.30, 1.04) 0.06 0.63 (0.33, 1.19) 0.15 
           GSTP1 
         
 
Continuous 85.0 1.07 (0.85, 1.33) 0.57 1.04 (0.83, 1.30) 0.73 0.97 (0.76, 1.25) 0.83 0.94 (0.74, 1.20) 0.63 
           
 
<median 86.5 Reference Reference Reference Reference 
 
≥median 83.5 1.30 (0.83, 2.04) 0.26 1.23 (0.78, 1.96) 0.37 1.14 (0.71, 1.84) 0.58 1.08 (0.67, 1.74) 0.77 
           
 
Tertile1 86.2 Reference Reference Reference Reference 
 
Tertile 2 85.2 1.16 (0.66, 2.04) 0.60 1.17 (0.66, 2.06) 0.59 0.93 (0.49, 1.78) 0.83 0.92 (0.49, 1.76) 0.81 
 
Tertile 3 83.6 1.20 (0.68, 2.09) 0.53 1.13 (0.64, 1.99) 0.68 0.95 (0.51, 1.77) 0.87 0.85 (0.45, 1.59) 0.61 
           GSTA1 
         
 
Not expressed 85.2 Reference Reference Reference Reference 
 
Expressed 83.1 1.20 (0.57, 2.50) 0.63 1.06 (0.50, 2.22) 0.89 0.95 (0.45, 2.01) 0.89 0.89 (0.42, 1.88) 0.76 
           GSTM1 
         
 
Not expressed 86.5 Reference Reference Reference Reference 
 
Expressed 82.5 1.16 (0.73, 1.84) 0.52 1.20 (0.76, 1.91) 0.43 1.21 (0.76, 1.92) 0.42 1.23 (0.77, 1.95) 0.39 
           GSTT1 
         
 
Not expressed 84.7 Reference Reference Reference Reference 
 Expressed 85.3 1.13 (0.72, 1.78) 0.58 1.11 (0.70, 1.74) 0.66 1.13 (0.72, 1.78) 0.60 1.24 (0.78, 1.96) 0.37 
1
Unadjusted, mean(se), DFS or OS, as appropriate 
2
Adjusted for age at diagnosis 
3
Adjusted for age at diagnosis and tumor grade 
4
Adjusted for age at diagnosis, tumor grade, and basal-like subtype 
5
Adjusted for age at diagnosis, tumor grade, basal-like subtype, and DUSP4 expression 
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Table 30: Disease-Free and Overall Survival by Expression of Genes Involved in Cyclophosphamide Metabolism Among TNBC Participants in the 
SBCSS Cohort Stratified By Whether Cyclophosphamide was Taken 
 
  
Disease-Free Survival 
 
Overall Survival 
  
Cyclophosphamide 
Taken (N=296)  
Cyclophosphamide Not 
Taken (N=122)   
Cyclophosphamide 
Taken (N=296)  
Cyclophosphamide Not 
Taken (N=122)  
 
HR (95% CI)
1
 P 
 
HR (95% CI)
1
 P Pint  
HR (95% CI)
1
 P 
 
HR (95% CI)
1
 P Pint 
ALDH1A1 
             
 
Continuous 1.01 (0.87, 1.17) 0.92 
 
0.91 (0.77, 1.08) 0.30 0.60 
 
1.02 (0.88, 1.17) 0.82 
 
0.88 (0.75, 1.04) 0.12 0.51 
               
 
<median Reference 
 
Reference 
  
Reference 
 
Reference 
 
 
≥median 0.60 (0.30, 1.20) 0.15 
 
0.92 (0.38, 2.20) 0.85 0.63 
 
0.81 (0.43, 1.52) 0.51 
 
1.01 (0.45, 2.25) 0.99 0.59 
               
 
Tertile 1 Reference 
 
Reference 
0.65 
 
Reference 
 
Reference 
0.88 
 
Tertile 2 0.88 (0.43, 1.81) 0.73 
 
1.14 (0.47, 2.74) 0.77 
 
0.82 (0.41, 1.65) 0.58 
 
0.77 (0.32, 1.83) 0.55 
 
Tertile 3 0.50 (0.20, 1.25) 0.14 
 
0.30 (0.07, 1.20) 0.09 
 
0.72 (0.33, 1.59) 0.42 
 
0.58 (0.20, 1.70) 0.32 
               GSTP1 
             
 
Continuous 0.65 (0.47, 0.91) 0.01 
 
1.08 (0.65, 1.80) 0.75 0.10 
 
0.84 (0.62, 1.12) 0.23 
 
1.06 (0.66, 1.70) 0.82 0.41 
               
 
<median Reference 
 
Reference 
  
Reference 
 
Reference 
 
 
≥median 0.73 (0.37, 1.44) 0.37 
 
1.33 (0.57, 3.12) 0.51 0.28 
 
0.87 (0.47, 1.61) 0.67 
 
1.25 (0.55, 2.84) 0.59 0.50 
               
 
Tertile 1 Reference 
 
Reference 
0.95 
 
Reference 
 
Reference 
0.66 
 
Tertile 2 1.33 (0.59, 2.99) 0.49 
 
0.38 (0.10, 1.39) 0.14 
 
1.09 (0.50, 2.38) 0.82 
 
0.39 (0.11, 1.37) 0.14 
 
Tertile 3 0.64 (0.25, 1.61) 0.35 
 
0.44 (0.13, 1.51) 0.19 
 
0.85 (0.39, 1.86) 0.68 
 
0.47 (0.14, 1.55) 0.22 
               GSTA1 
             
 
Not expressed Reference 
 
Reference 
  
Reference 
 
Reference 
 
 
Expressed 0.69 (0.21, 2.29) 0.54 
 
1.64 (0.59, 4.61) 0.35 0.22 
 
0.59 (0.18, 1.93) 0.38 
 
1.25 (0.45, 3.48) 0.66 0.36 
               GSTM1 
             
 
Not expressed Reference 
 
Reference 
  
Reference 
 
Reference 
 
 
Expressed 1.30 (0.71, 2.41) 0.40 
 
0.97 (0.41, 2.31) 0.94 0.50 
 
1.42 (0.80, 2.52) 0.23 
 
0.95 (0.42, 2.15) 0.91 0.42 
               GSTT1 
             
 
Not expressed Reference 
 
Reference 
  
Reference 
 
Reference 
 
 
Expressed 0.99 (0.52, 1.88) 0.98 
 
0.92 (0.41, 2.08) 0.85 1.00 
 
1.44 (0.79, 2.64) 0.23 
 
0.99 (0.46, 2.11) 0.97 0.59 
1
Adjusted for age at diagnosis, tumor grade, basal-like subtype, and DUSP4 expression 
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The association between individual gene expression levels and the number of cycles of 
cyclophosphamide completed was evaluated as a surrogate for toxicity (Table 31). No significant 
associations were observed. 
 
Table 31: Association Between Cyclophosphamide Gene Expression Levels and Cycles of 
Cyclophosphamide Completed 
 
  OR (95% CI)
1
 P 
ALDH1A1 0.82 (0.44, 1.52) 0.53 
GSTP1 0.66 (0.36, 1.24) 0.20 
GSTA1 2.23 (0.62, 8.04) 0.22 
GSTM1 1.22 (0.66, 2.23) 0.53 
GSTT1 0.87 (0.48, 1.57) 0.64 
1
Adjusted for age at diagnosis, tumor grade, 
basal-like subtype, and DUSP4 expression 
  
 
The association between expression of cyclophosphamide metabolizing genes and breast 
cancer survival among those who took cyclophosphamide was further evaluated through 
additional adjustment for the number of cycles of cyclophosphamide completed (Table 32). The 
observed associations between cyclophosphamide gene expression levels and survival outcomes 
were not materially changed after adjustment for cycles completed. 
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Table 32: Disease-Free and Overall Survival by Expression of Cyclophosphamide Metabolizing 
Genes Further Adjusted for Number of Cycles of Cyclophosphamide Completed  
 
  
Disease-Free Survival 
 
Overall Survival 
  HR (95% CI)
1
 P HR (95% CI)
1
 P 
ALDH1A1           
 Continuous 1.01 (0.87, 1.17) 0.94  1.01 (0.88, 1.17) 0.84 
       
 <median Reference  Reference 
 ≥median 0.60 (0.30, 1.20) 0.15  0.81 (0.43, 1.52) 0.51 
       
 Tertile 1 Reference  Reference 
 Tertile 2 0.87 (0.42, 1.80) 0.71  0.82 (0.41, 1.65) 0.57 
 Tertile 3 0.49 (0.19, 1.22) 0.13  0.71 (0.32, 1.57) 0.40 
       
GSTP1      
 Continuous 0.65 (0.47, 0.91) 0.01  0.84 (0.63, 1.12) 0.24 
       
 <median Reference  Reference 
 ≥median 0.74 (0.38, 1.45) 0.38  0.88 (0.48, 1.64) 0.69 
       
 Tertile 1 Reference 
 
Reference 
 Tertile 2 1.33 (0.59, 2.99) 0.49 
 
1.10 (0.50, 2.39) 0.82 
 Tertile 3 0.64 (0.26, 1.63) 0.35 
 
0.86 (0.39, 1.89) 0.71 
      
GSTA1      
 Not expressed Reference  Reference 
 Expressed 0.69 (0.21, 2.28) 0.54  0.59 (0.18, 1.92) 0.38 
       
GSTM1      
 Not expressed Reference  Reference 
 Expressed 1.32 (0.71, 2.44) 0.38  1.44 (0.81, 2.56) 0.22 
       
GSTT1      
 Not expressed Reference  Reference 
 Expressed 0.99 (0.52, 1.88) 0.98  1.45 (0.80, 2.65) 0.22 
1
Adjusted for age at diagnosis, tumor grade, basal-like subtype, DUSP4 expression, and 
number of cycles of cyclophosphamide 
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We stratified our results by timing of survival events, those that occurred in the first three 
years of follow-up and those that occurred after 3 years, among all women (Table 33) and 
restricted to those who took cyclophosphamide (Table 34). GSTP1 expression was more strongly 
associated with better DFS in the first 3 years following diagnosis, particularly in those who took 
cyclophosphamide (HR=0.45, 95% CI: 0.29, 0.70); no association was observed among those 
with later events (HR=1.14, 95% CI: 0.67, 1.94). GSTT1 expression was significantly associated 
with worse OS in the first 3 years following diagnosis among those who took cyclophosphamide 
(HR=2.76, 95% CI: 1.07, 7.11); no association was observed for OS for events occurring after 3 
years (HR=0.92, 95% CI: 0.40, 2.12). A similar pattern was seen for GSTM1 expression 
although the point estimates were not significant. 
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Table 33: Association Between Cyclophosphamide Gene Expression Levels Stratified by Early vs. Late Events Among All Participants 
 
  
Events <3 years 
 
Events ≥3 years 
  
Disease-Free Survival 
(47 events) 
 
Overall Survival  
(34 events) 
 
Disease-Free Survival  
(20 events) 
 
Overall Survival  
(42 events) 
  HR (95% CI)
1
 P  HR (95% CI)
1
 P  HR (95% CI)
1
 P  HR (95% CI)
1
 P 
ALDH1A1 
           
 Continuous 0.98 (0.85, 1.12) 0.72  1.10 (0.93, 1.32) 0.27 
 
0.94 (0.76, 1.16) 0.56  0.86 (0.75, 0.98) 0.03 
             
 <median Reference  Reference 
 
Reference  Reference 
 ≥median 0.93 (0.49, 1.78) 0.83  1.22 (0.57, 2.61) 0.61 
 
0.34 (0.12, 0.97) 0.04  0.65 (0.34, 1.27) 0.21 
             
 Tertile 1 Reference  Reference 
 
Reference  Reference 
 Tertile 2 1.19 (0.63, 2.27) 0.59  1.16 (0.53, 2.58) 0.71 
 
0.65 (0.22, 1.92) 0.43  0.63 (0.29, 1.33) 0.22 
 Tertile 3 0.36 (0.13, 0.96) 0.04  0.82 (0.30, 2.24) 0.70 
 
0.47 (0.14, 1.60) 0.23  0.50 (0.22, 1.11) 0.09 
             
GSTP1      
 
     
 Continuous 0.70 (0.50, 0.97) 0.03  0.86 (0.59, 1.25) 0.43 
 
1.03 (0.64, 1.67) 0.89  1.01 (0.73, 1.41) 0.93 
             
 <median Reference  Reference 
 
Reference  Reference 
 ≥median 0.81 (0.44, 1.49) 0.50  1.04 (0.50, 2.17) 0.91 
 
1.46 (0.57, 3.77) 0.43  1.07 (0.57, 2.03) 0.83 
             
 Tertile 1 Reference  Reference 
 
Reference  Reference 
 Tertile 2 0.75 (0.33, 1.67) 0.48  0.86 (0.32, 2.34) 0.77 
 
2.09 (0.60, 7.26) 0.25  0.96 (0.41, 2.23) 0.92 
 Tertile 3 0.55 (0.24, 1.28) 0.17  0.86 (0.32, 2.31) 0.77 
 
1.19 (0.32, 4.36) 0.80  0.82 (0.36, 1.90) 0.65 
             
GSTA1      
 
     
 Not Expressed Reference  Reference 
 
Reference  Reference 
 Expressed 1.31 (0.57, 2.99) 0.53  0.87 (0.30, 2.53) 0.80 
 
0.51 (0.07, 3.96) 0.52  0.96 (0.33, 2.77) 0.94 
             
GSTM1      
 
     
 Not Expressed Reference  Reference 
 
Reference  Reference 
 Expressed 1.47 (0.82, 2.63) 0.19  1.67 (0.84, 3.30) 0.14 
 
0.58 (0.21, 1.62) 0.30  0.94 (0.49, 1.80) 0.86 
             
GSTT1      
 
     
 Not Expressed Reference  Reference 
 
Reference  Reference 
 Expressed 0.94 (0.52, 1.70) 0.83  2.18 (1.08, 4.42) 0.03 
 
1.05 (0.42, 2.59) 0.92  0.79 (0.42, 1.51) 0.48 
1
Adjusted for age at diagnosis, tumor grade, basal-like subtype, and DUSP4 expression 
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Table 34: Association Between Cyclophosphamide Gene Expression Levels Stratified by Early vs. Late Events Among Those who Took 
Cyclophosphamide  
 
  
Events <3 years 
 
Events ≥3 years 
  
Disease-Free Survival  
(27 events) 
 
Overall Survival  
(22 events) 
 
Disease-Free Survival  
(15 events)  
 
Overall Survival  
(26 events) 
  HR (95% CI)
1
 P  HR (95% CI)
1
 P  HR (95% CI)
1
 P  HR (95% CI)
1
 P 
ALDH1A1 
           
 Continuous 1.01 (0.84, 1.21) 0.90  1.15 (0.96, 1.40) 0.14 
 
1.00 (0.76, 1.30) 0.99  0.90 (0.75, 1.08) 0.26 
             
 <median Reference  Reference 
 
Reference  Reference 
 ≥median 0.78 (0.33, 1.88) 0.58  1.18 (0.46, 3.08) 0.73 
 
0.36 (0.11, 1.17) 0.09  0.57 (0.24, 1.34) 0.20 
             
 Tertile 1 Reference  Reference 
 
Reference  Reference 
 Tertile 2 0.97 (0.40, 2.35) 0.95  1.52 (0.56, 4.14) 0.41 
 
0.71 (0.20, 2.49) 0.59  0.45 (0.16, 1.26) 0.13 
 Tertile 3 0.46 (0.13, 1.55) 0.21  0.91 (0.25, 3.32) 0.89 
 
0.50 (0.12, 2.08) 0.34  0.53 (0.19, 1.46) 0.22 
             
GSTP1      
 
     
 Continuous 0.45 (0.29, 0.70) 0.0004  0.68 (0.45, 1.03) 0.07 
 
1.14 (0.67, 1.94) 0.63  1.02 (0.67, 1.54) 0.93 
             
 <median Reference  Reference 
 
Reference  Reference 
 ≥median 0.48 (0.20, 1.12) 0.09  0.79 (0.31, 2.03) 0.62 
 
1.56 (0.52, 4.73) 0.43  0.84 (0.36, 1.93) 0.68 
             
 Tertile 1 Reference  Reference 
 
Reference  Reference 
 Tertile 2 0.78 (0.29, 2.10) 0.62  0.79 (0.25, 2.55) 0.70 
 
3.38 (0.87, 13.18) 0.08  1.25 (0.44, 3.52) 0.67 
 Tertile 3 0.35 (0.11, 1.14) 0.08  0.57 (0.17, 1.98) 0.38 
 
1.66 (0.37, 7.44) 0.51  1.07 (0.38, 3.03) 0.89 
             
GSTA1      
 
     
 Not Expressed Reference  Reference 
 
Reference  Reference 
 Expressed 0.61 (0.14, 2.65) 0.51  0.37 (0.05, 2.82) 0.34 
 
0.99 (0.12, 8.34) 1.00  0.82 (0.19, 3.55) 0.79 
             
GSTM1      
 
     
 Not Expressed Reference  Reference 
 
Reference  Reference 
 Expressed 1.90 (0.89, 4.06) 0.10  1.93 (0.83, 4.51) 0.13 
 
0.62 (0.20, 1.97) 0.42  1.11 (0.50, 2.45) 0.80 
             
GSTT1      
 
     
 Not Expressed Reference  Reference 
 
Reference  Reference 
 Expressed 1.00 (0.45, 2.22) 0.99  2.76 (1.07, 7.11) 0.04 
 
1.02 (0.35, 2.98) 0.97  0.92 (0.40, 2.12) 0.85 
1
Adjusted for age at diagnosis, tumor grade, basal-like subtype, and DUSP4 expression 
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As previously discussed, the gene expression score based on median cut points of 
expression was created and the association with clinical and treatment factors was evaluated 
(Table 35). None of the demographic or clinical factors were associated with the 
cyclophosphamide gene expression score. 
 
 
Table 35: Clinical and Treatment Factors by the Cyclophosphamide Gene Score Among TNBC 
Participants in the SBCSS Cohort 
 
   
Median Score 
  N mean (SD) P 
Age 
  
0.66  
<40 29 2.0 (0.9) 
 
40-49 154 1.8 (0.8) 
 
50-59 108 1.9 (0.8) 
 
≥60 127 1.9 (0.8) 
     TNM Stage 
  
0.83  
0-I 137 1.9 (0.8) 
 
IIA 145 1.9 (0.8) 
 
IIB 85 1.9 (0.8) 
 
III-IV 38 1.9 (0.8) 
 
Missing 13 1.8 (0.8) 
 
     Grade 
  
0.79 
 
1 50 1.8 (0.8) 
 
2 132 1.9 (0.8) 
 
3 236 1.9 (0.8) 
     Chemotherapy 
  0.35 
 
Yes 390 1.9 (0.8) 
 
No 28 2.0 (0.8) 
     Cyclophosphamide 
  0.26 
 
Yes 296 1.9 (0.8) 
 
No 122 2.0 (0.8) 
     Radiotherapy 
  0.71 
 
Yes 103 1.9 (0.8) 
 
No 315 1.9 (0.8) 
     Mastectomy 
  0.75 
 
Yes 399 1.9 (0.8) 
 
No 19 1.8 (0.8) 
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No association was observed between the additive cyclophosphamide gene expression 
score and DFS or OS (Table 36). When the association between the cyclophosphamide gene 
expression score and survival was stratified by whether cyclophosphamide was taken, no 
significant interaction was observed (Table 37).  
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Table 36: Disease-Free Survival and Overall Survival by Additive Cyclophosphamide Gene Expression Score Among TNBC 
Participants in the SBCSS Cohort 
 
 
 
    N HR (95% CI)
1
 P HR (95% CI)
2
 P HR (95% CI)
3
 P HR (95% CI)
4
 P 
  Disease-Free Survival 
Score
5
          
 Group 1 155 Reference Reference Reference Reference 
 Group 2  150 1.25 (0.72, 2.16) 0.43 1.25 (0.72, 2.16) 0.43 1.22 (0.70, 2.11) 0.48 1.37 (0.78, 2.41) 0.27 
 Group 3 113 0.89 (0.47, 1.71) 0.73 0.89 (0.47, 1.71) 0.73 0.90 (0.47, 1.73) 0.76 0.97 (0.50, 1.87) 0.93 
 Ptrend  0.83 0.81 0.85 0.96 
           
  Overall Survival 
Score
5
          
 Group 1 155 Reference Reference Reference Reference 
 Group 2  150 1.29 (0.76, 2.18) 0.35 1.29 (0.76, 2.18) 0.35 1.24 (0.73, 2.11) 0.42 1.39 (0.81, 2.39) 0.24 
 Group 3 113 1.17 (0.65, 2.10) 0.61 1.17 (0.65, 2.10) 0.61 1.17 (0.65, 2.10) 0.60 1.26 (0.69, 2.28) 0.45 
 Ptrend  0.56 0.55 0.57 0.41 
1
Adjusted for age at diagnosis
 
2
Adjusted for age at diagnosis and tumor grade 
3
Adjusted for age at diagnosis, tumor grade, and basal-like subtype 
4
Adjusted for age at diagnosis, tumor grade, basal-like subtype, and DUSP4 expression 
5
Score based on median cut point (higher score indicates faster metabolizer) 
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Table 37: Disease-Free Survival and Overall Survival by Additive Cyclophosphamide Gene 
Expression Score Among TNBC Participants in the SBCSS Cohort Stratified by Whether 
Cyclophosphamide was Taken  
 
  
Cyclophosphamide Taken Cyclophosphamide Not Taken 
  HR (95% CI)
1
 P HR (95% CI)
1
 P 
  Disease-Free Survival 
Score
2
     
 Group 1 Reference Reference 
 Group 2  1.38 (0.70, 2.74) 0.36 1.41 (0.52, 3.87) 0.50 
 Group 3 0.67 (0.27, 1.65) 0.38 1.57 (0.55, 4.45) 0.40 
 Ptrend 0.54 0.40 
      
  Overall Survival 
Score
2
     
 Group 1 Reference Reference 
 Group 2  1.54 (0.79, 3.00) 0.21 1.09 (0.43, 2.81) 0.85 
 Group 3 1.07 (0.48, 2.38) 0.86 1.38 (0.54, 3.54) 0.51 
 Ptrend 0.72 0.50 
1
Adjusted for age at diagnosis, tumor grade, basal-like subtype, and DUSP4 expression 
2
Score based on median cut point (higher score indicates faster metabolizer) 
 
 
The association between the cyclophosphamide gene expression score and the number of 
cycles of cyclophosphamide completed was evaluated as a surrogate for toxicity. No association 
was observed (HR=0.90, 95% CI: 0.62, 1.30, p=0.57). 
The association between the cyclophosphamide gene expression score and breast cancer 
survival among those who took cyclophosphamide was further evaluated through additional 
adjustment for the number of cycles of cyclophosphamide taken (Table 38). The observed 
associations between the cyclophosphamide gene expression score and survival outcomes were 
not materially changed after adjustment for cycles completed. 
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Table 38: Disease-Free and Overall Survival by Additive Cyclophosphamide Gene Score Further 
Adjusted for Number of Cycles of Cyclophosphamide Completed  
 
  
Disease-Free Survival 
 
Overall Survival 
  HR (95% CI)
1
 P HR (95% CI)
1
 P 
Score
2
      
 Group 1 Reference  Reference 
 Group 2 1.41 (0.70, 2.81) 0.33  1.58 (0.81, 3.10) 0.18 
 Group 3 0.67 (0.27, 1.65) 0.39  1.08 (0.49, 2.40) 0.85 
1
Adjusted for age at diagnosis, tumor grade, basal-like subtype, DUSP4 expression, and 
number of cycles of cyclophosphamide 
2
Score based on median cut point (higher score indicates faster metabolizer) 
 
 
We stratified our results by timing of survival events, those that occurred in the first three 
years of follow-up and those that occurred after 3 years, among all women and restricted to those 
who took cyclophosphamide (Table 39). Among all participants, there was a significant 
difference in the gene expression score for OS between those who had events in the first 3 years 
compared to those who had later events. The gene expression score was associated with an 
increased risk of death in the first 3 years (highest score compared to lowest HR=2.68, 95% CI: 
1.08, 1.69, Ptrend=0.03); a similar association was observed when restricted to only those who 
took cyclophosphamide, although the Ptrend was no longer significant, potentially due to 
decreased sample size (HR=2.17, 95% CI: 0.74, 6.33, Ptrend=0.16). No association was observed 
between the cyclophosphamide gene expression score and OS for events occurring after 3 years. 
No significant associations were observed for DFS.  
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Table 39: Association Between Disease-Free and Overall Survival and Additive Cyclophosphamide Gene Score Stratified by Early vs. 
Late Events Among All Participants and Only Those who Took Cyclophosphamide 
 
  
Events <3 years 
 
Events ≥3 years 
  
Disease-Free Survival 
(47 events) 
 
Overall Survival  
(34 events) 
 
Disease-Free Survival  
(20 events) 
 
Overall Survival  
(42 events) 
  HR (95% CI)
1
 P  HR (95% CI)
1
 P  HR (95% CI)
1
 P  HR (95% CI)
1
 P 
All Participants            
  Score
2
      
 
     
 Group 1 Reference  Reference 
 
Reference  Reference 
 Group 2  1.42 (0.71, 2.86) 0.32  2.03 (0.81, 5.10) 0.13 
 
1.26 (0.49, 3.26) 0.63  1.14 (0.57, 2.25) 0.71 
 Group 3 1.31 (0.62, 2.78) 0.49  2.68 (1.08, 6.65) 0.03 
 
0.36 (0.08, 1.69) 0.19  0.64 (0.26, 1.54) 0.32 
 Ptrend 0.46   0.03   0.28   0.40  
             
Among Those who Took Cyclophosphamide         
  Score
2
            
 Group 1 Reference  Reference  Reference  Reference 
 Group 2  1.11 (0.46, 2.70) 0.82  1.41 (0.47, 4.27) 0.54  1.92 (0.63, 5.90) 0.25  1.57 (0.68, 3.66) 0.29 
 Group 3 0.85 (0.31, 2.34) 0.75  2.17 (0.74, 6.33) 0.16  0.31 (0.04, 2.69) 0.29  0.34 (0.07, 1.56) 0.17 
 Ptrend 0.80   0.16   0.53   0.34  
1
Adjusted for age at diagnosis, tumor grade, basal-like subtype, and DUSP4 expression 
2
Score based on median cut point (higher score indicates faster metabolizer) 
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5-Fluorouracil 
Higher tumor grade was associated with expression levels of DPYD and MTHFR below 
the median and expression levels of TYMS and TYMP above the median (Table 40). Expression 
levels of TYMS, TYMP, and UMPS above the median were associated with basal-like tumor 
markers while expression levels of MTHFR below the median were associated with basal-like 
tumor markers.  
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Table 40: Clinical and Treatment Factors by Expression of 5-Fluorouracil Metabolizing Genes Among TNBC Participants in the SBCSS Cohort 
 
  
DPYD MTHFR TYMS TYMP UMPS 
  <Median ≥Median   <Median ≥Median   <Median ≥Median   <Median ≥Median   <Median ≥Median   
    N(%1) N(%1) P N(%1) N(%1) P N(%1) N(%1) P N(%1) N(%1) P N(%1) N(%1) P 
N 
 
210 208 
 
213 205 
 
209 209 
 
209 209 
 
211 207 
                  TNM Stage 
  
0.47 
  
0.42 
  
0.10 
  
0.14 
  
0.78 
 
0-I 65 (47.5) 72 (52.6) 
 
66 (48.2) 71 (51.8) 
 
72 (52.6) 65 (47.5) 
 
68 (49.6) 69 (50.4) 
 
72 (52.6) 65 (47.5) 
 
 
IIA 71 (49.0) 74 (51.0) 
 
71 (49.0) 74 (51.0) 
 
74 (51.0) 71 (49.0) 
 
65 (44.8) 80 (55.2) 
 
73 (50.3) 72 (49.7) 
 
 
IIB 49 (57.7) 36 (42.4) 
 
50 (58.8) 35 (41.2) 
 
33 (38.8) 52 (61.2) 
 
44 (51.8) 41 (48.2) 
 
40 (47.1) 45 (52.9) 
 
 
III-IV 18 (47.4) 20 (52.6) 
 
20 (52.6) 18 (47.4) 
 
23 (60.5) 15 (39.5) 
 
25 (65.8) 13 (34.2) 
 
17 (44.7) 21 (55.3) 
 
 
Missing 7 6 
 
6 7 
 
7 6 
 
7 6 
                     Grade 
  
0.01 
  
<.0001 
  
<.0001 
  
0.0007 
  
0.52 
 
1 16 (32.0) 34 (68.0) 
 
11 (22.0) 39 (78.0) 
 
41 (82.0) 9 (18.0) 
 
37 (74.0) 13 (26.0) 
 
25 (50.0) 25 (50.0) 
 
 
2 65 (49.2) 67 (50.8) 
 
54 (40.9) 78 (59.1) 
 
90 (68.2) 42 (31.8) 
 
67 (50.8) 65 (49.2) 
 
72 (54.6) 60 (45.5) 
 
 
3 129 (54.7) 107 (45.3) 
 
148 (62.7) 88 (37.3) 
 
78 (33.1) 158 (67.0) 
 
105 (44.5) 131 (55.5) 
 
114 (48.3) 122 (51.7) 
 
 
Missing 
                                Chemotherapy 197 (50.5) 193 (49.5) 0.68 200 (51.3) 190 (48.7) 0.62 191 (49.0) 199 (51.0) 0.12 193 (49.5) 197 (50.5) 0.43 193 (49.5) 197 (50.5) 0.13 
 
5-fluorouracil 160 (50.6) 156 (49.4) 0.78 157 (49.7) 159 (50.3) 0.36 157 (49.7) 159 (50.3) 0.82 163 (51.6) 153 (48.4) 0.25 160 (50.6) 156 (49.4) 
                  Radiotherapy 59 (57.3) 44 (42.7) 0.10 57 (55.3) 46 (44.7) 0.31 46 (44.7) 57 (55.3) 0.21 57 (55.3) 46 (44.7) 0.21 45 (43.7) 58 (56.3) 0.11 
                 Mastectomy 203 (50.9) 196 (49.1) 0.23 207 (51.9) 192 (48.1) 0.08 198 (49.6) 201 (50.4) 0.48 201 (50.4) 198 (49.6) 0.48 201 (50.4) 198 (49.6) 0.85 
                 Subtype Classification 
 
0.13 
  
<.0001 
  
<.0001 
  
0.0006 
  
0.001 
 
Basal-like 97 (55.8) 77 (44.3) 
 
126 (72.4) 48 (27.6) 
 
23 (13.2) 151 (86.8) 
 
69 (69.7) 105 (60.3) 
 
81 (46.6) 93 (53.5) 
 
 
Her-2 Enriched 28 (46.7) 32 (53.3) 
 
23 (38.3) 37 (61.7) 
 
40 (66.7) 20 (33.3) 
 
27 (45.0) 33 (55.0) 
 
38 (63.3) 22 (36.7) 
 
 
Luminal A 48 (43.6) 62 (56.4) 
 
29 (26.4) 81 (73.6) 
 
99 (90.0) 11 (10.0) 
 
65 (59.1) 45 (40.9) 
 
59 (53.6) 51 (46.4) 
 
 
Luminal B 24 (58.5) 17 (41.5) 
 
22 (53.7) 19 (46.3) 
 
20 (48.8) 21 (51.2) 
 
24 (58.5) 17 (41.5) 
 
11 (26.8) 30 (73.2) 
  Normal 13 (39.4) 20 (60.6)   13 (39.4) 20 (60.6)   27 (81.8) 6 (18.2)   24 (72.7) 9 (27.3)   22 (66.7) 11 (33.3)   
1Percents shown are row percentages  
Median Values: DPYD - 7.877; MTHFR - 6.794; TYMS - 8.785; TYMP - 10.690; UMPS - 6.150 
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We examined the correlation between the 5-fluorouracil metabolizing genes being 
investigated in this study and DUSP4 expression (Table 41). DPYD and MTHFR expression was 
positively correlated with DUSP4 expression (p<.0001 for both) and TYMS expression was 
negatively associated with DUSP4 expression (p<.0001). No correlation between DUSP4 
expression and TYMP or UMPS expression was observed. 
 
Table 41: Correlation between Expression of 5-Fluorouracil Metabolizing Genes and DUSP4 
Expression Among TNBC Participants in the SBCSS Cohort 
 
 
Correlation with DUSP4 
  r p 
DPYD 0.28 <.0001 
TYMS -0.26 <.0001 
MTHFR 0.34 <.0001 
TYMP -0.02 0.68 
UMPS 0.06 0.23 
 
 
Univariate analyses between survival, both disease-free and overall, and expression level 
of genes involved in 5-fluorouracil among all TNBC participants are shown in Figure 3. DPYD 
expression above the median was significantly associated with better DFS (p=0.007) and better 
OS (p=0.02) compared with expression levels below the median. MTHFR expression above the 
median was significantly associated with better DFS (p<.0001) and better OS (p=0.0003) 
compared with expression levels below the median. No difference was observed in DFS or OS 
by expression of TYMS, TYMP, or UMPS. 
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Figure 3: Kaplan-Meier Curves For Disease-Free Survival and Overall Survival for Genes 
Involved in 5-Fluorouracil Metabolism Among TNBC Participants in the SBCSS Cohort 
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Among all TNBC participants, DPYD expression above the median was significantly 
associated with better DFS, compared to the lower median, after adjustment for age at diagnosis 
and tumor grade (DFS HR=0.59, 95% CI: 0.36, 0.97) (Table 42). Further adjustment for markers 
of the basal-like subtype and DUSP4 expression slightly attenuated the association but it 
remained marginally significant for DFS (HR=0.64, 95% CI: 0.38, 1.06). Similar results were 
observed for analysis by tertile distribution.  
TYMS expression was marginally significantly associated with worse OS when analyzed 
using median or tertile cut points after adjustment for age at diagnosis (HR for upper median 
compared to lower median=1.55, 95% CI: 0.97, 2.45; HR for tertile 3 compared to tertile 1=1.73, 
95% CI: 0.93, 3.02). After further adjustment for tumor grade, basal-like subtype, and DUSP4 
expression, the association was completely attenuated. 
MTHFR expression above the median was significantly associated with better DFS, 
compared to the lower median, after adjustment for age at diagnosis and tumor grade (DFS 
HR=0.54, 95% CI: 0.32, 0.92). Further adjustment for markers of the basal-like subtype and 
DUSP4 expression attenuated the association (DFS HR=0.65, 95% CI: 0.37, 1.13). A similar 
pattern was observed when MTHFR expression was analyzed by tertiles. 
No association between TYMP expression and DFS or OS was observed. 
UMPS expression above the median, compared with below the median, was significantly 
associated with DFS after adjustment for age at diagnosis and tumor grade (HR=1.81, 95% CI: 
1.10, 2.98) and this association was strengthened slightly by adjustment for markers of the basal-
 105 
 
like subtype and DUSP4 expression (HR=1.92, 95% CI: 1.16, 3.19). No association with OS was 
observed. A similar pattern was observed when UMPS expression was analyzed by tertiles. 
Next, the results were stratified by whether the drug of interest, 5-fluorouracil, was taken 
(Table 43). The protective association between MTHFR expression and survival was only 
observed among those who did not take 5-fluorouracil and the interaction was significant for OS 
(p=0.04). No significant differences in the associations between gene expression and survival 
outcomes were observed for DPYD, TYMS, TYMP, or UMPS by whether 5-fluorouracil was 
taken. 
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Table 42: Disease-Free and Overall Survival by Expression of Genes Involved in 5-Fluorouracil Metabolism Among TNBC Participants in the 
SBCSS Cohort 
 
  5-yr Rate, %
1
 HR (95% CI)
2
 P HR (95% CI)
3
 P HR (95% CI)
4
 P HR (95% CI)
5
 P 
Disease-Free Survival 
DPYD 
         
 
Continuous 83.0 0.93 (0.82, 1.05) 0.23 0.93 (0.83, 1.05) 0.25 0.93 (0.82, 1.05) 0.24 1.00 (0.86, 1.16) 0.98 
           
 
<median 78.4 Reference Reference Reference Reference 
 
≥median 87.5 0.56 (0.34, 0.92) 0.02 0.59 (0.36, 0.97) 0.04 0.59 (0.36, 0.98) 0.04 0.64 (0.38, 1.06) 0.08 
           
 
Tertile 1 76.4 Reference Reference Reference Reference 
 
Tertile 2 86.5 0.51 (0.28, 0.91) 0.02 0.51 (0.28, 0.91) 0.02 0.52 (0.29, 0.93) 0.03 0.58 (0.32, 1.05) 0.07 
 
Tertile 3 85.7 0.57 (0.32, 1.02) 0.06 0.61 (0.34, 1.09) 0.10 0.63 (0.35, 1.13) 0.12 0.70 (0.38, 1.27) 0.24 
           TYMS 
         
 
Continuous 83.0 1.06 (0.93, 1.22) 0.37 1.02 (0.88, 1.17) 0.83 0.96 (0.83, 1.11) 0.58 0.98 (0.86, 1.12) 0.79 
           
 
<median 85.5 Reference Reference Reference Reference 
 
≥median 80.5 1.60 (0.98, 2.62) 0.06 1.44 (0.84, 2.47) 0.18 1.14 (0.61, 2.16) 0.68 1.15 (0.63, 2.12) 0.65 
           
 
Tertile 1 84.3 Reference Reference Reference Reference 
 
Tertile 2 84.8 1.04 (0.56, 1.95) 0.90 0.94 (0.49, 1.82) 0.86 0.78 (0.38, 1.59) 0.49 0.77 (0.38, 1.55) 0.46 
 
Tertile 3 79.8 1.61 (0.89, 2.90) 0.11 1.36 (0.69, 2.67) 0.37 0.93 (0.41, 2.13) 0.87 0.91 (0.41, 2.00) 0.81 
           MTHFR 
         
 
Continuous 83.0 0.95 (0.84, 1.08) 0.43 0.96 (0.84, 1.09) 0.53 0.97 (0.85, 1.12) 0.69 1.05 (0.90, 1.23) 0.51 
           
 
<median 77.7 Reference Reference Reference Reference 
 
≥median 88.4 0.51 (0.31, 0.84) 0.009 0.54 (0.32, 0.92) 0.02 0.59 (0.34, 1.02) 0.06 0.65 (0.37, 1.13) 0.13 
           
 
Tertile 1 77.4 Reference Reference Reference Reference 
 
Tertile 2 83.4 0.67 (0.38, 1.17) 0.15 0.68 (0.39, 1.19) 0.17 0.72 (0.41, 1.27) 0.25 0.81 (0.45, 1.45) 0.47 
 
Tertile 3 88.2 0.48 (0.26, 0.89) 0.02 0.53 (0.28, 1.01) 0.05 0.60 (0.31, 1.17) 0.13 0.68 (0.34, 1.36) 0.28 
           TYMP 
         
 
Continuous 83.0 0.98 (0.76, 1.26) 0.85 0.93 (0.72, 1.21) 0.59 0.91 (0.70, 1.18) 0.46 0.93 (0.73, 1.18) 0.55 
           
 
<median 83.0 Reference Reference Reference Reference 
 
≥median 82.8 1.16 (0.72, 1.87) 0.55 1.08 (0.67, 1.76) 0.75 1.03 (0.63, 1.68) 0.92 1.05 (0.64, 1.72) 0.84 
           
 
Tertile 1 81.9 Reference Reference Reference Reference 
 
Tertile 2 83.2 1.04 (0.58, 1.85) 0.90 1.00 (0.56, 1.79) 1.00 0.95 (0.53, 1.70) 0.86 1.00 (0.55, 1.79) 0.99 
 
Tertile 3 83.7 0.94 (0.52, 1.72) 0.85 0.86 (0.47, 1.58) 0.63 0.82 (0.44, 1.50) 0.51 0.83 (0.45, 1.54) 0.56 
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UMPS 
         
 
Continuous 83.0 1.04 (0.91, 1.18) 0.58 1.02 (0.90, 1.16) 0.78 1.01 (0.89, 1.15) 0.84 1.06 (0.92, 1.22) 0.40 
  
     
    
 
<median 86.8 Reference Reference Reference Reference 
 
≥median 79.2 1.84 (1.12, 3.03) 0.02 1.81 (1.10, 2.98) 0.02 1.79 (1.09, 2.94) 0.02 1.92 (1.16, 3.19) 0.01 
           
 
Tertile 1 85.1 Reference Reference Reference Reference 
 
Tertile 2 86.2 0.96 (0.51, 1.84) 0.91 0.91 (0.47, 1.74) 0.77 0.87 (0.46, 1.67) 0.68 1.00 (0.51, 1.94) 0.99 
 
Tertile 3 77.5 1.79 (1.00, 3.19) 0.048 1.70 (0.95, 3.04) 0.07 1.67 (0.93, 2.98) 0.08 1.96 (1.07, 3.58) 0.03 
            
 
Overall Survival 
DPYD 
         
 
Continuous 85.0 0.92 (0.82, 1.04) 0.18 0.93 (0.83, 1.04) 0.22 0.93 (0.82, 1.04) 0.21 1.00 (0.87, 1.15) 1.00 
           
 
<median 81.2 Reference Reference Reference Reference 
 
≥median 88.8 0.70 (0.44, 1.10) 0.12 0.74 (0.47, 1.17) 0.20 0.75 (0.47, 1.18) 0.21 0.82 (0.51, 1.32) 0.42 
           
 
Tertile 1 78.7 Reference Reference Reference Reference 
 
Tertile 2 89.4 0.62 (0.36, 1.07) 0.09 0.60 (0.35, 1.04) 0.07 0.61 (0.35, 1.06) 0.08 0.69 (0.39, 1.22) 0.21 
 
Tertile 3 86.8 0.70 (0.41, 1.21) 0.20 0.74 (0.43, 1.27) 0.28 0.76 (0.44, 1.31) 0.33 0.88 (0.50, 1.56) 0.67 
           TYMS 
         
 
Continuous 85.0 1.09 (0.95, 1.24) 0.24 1.01 (0.88, 1.16) 0.89 0.96 (0.83, 1.11) 0.57 0.98 (0.86, 1.12) 0.79 
           
 
<median 88.0 Reference Reference Reference Reference 
 
≥median 82.1 1.55 (0.97, 2.45) 0.06 1.29 (0.79, 2.11) 0.32 1.05 (0.58, 1.91) 0.86 1.04 (0.59, 1.83) 0.90 
           
 
Tertile 1 88.4 Reference Reference Reference Reference 
 
Tertile 2 85.1 1.17 (0.65, 2.11) 0.60 1.03 (0.56, 1.87) 0.94 0.90 (0.47, 1.72) 0.75 0.88 (0.46, 1.68) 0.70 
 
Tertile 3 81.5 1.73 (0.99, 3.02) 0.06 1.37 (0.74, 2.53) 0.32 1.06 (0.49, 2.26) 0.89 1.00 (0.48, 2.07) 0.99 
           MTHFR 
         
 
Continuous 85.0 0.91 (0.81, 1.03) 0.13 0.92 (0.82, 1.04) 0.20 0.93 (0.82, 1.06) 0.27 1.00 (0.87, 1.16) 0.95 
           
 
<median 81.0 Reference Reference Reference Reference 
 
≥median 89.2 0.62 (0.39, 0.98) 0.04 0.71 (0.44, 1.14) 0.16 0.77 (0.47, 1.27) 0.31 0.87 (0.52, 1.45) 0.60 
           
 
Tertile 1 79.1 Reference Reference Reference Reference 
 
Tertile 2 83.6 0.76 (0.46, 1.27) 0.30 0.78 (0.47, 1.31) 0.35 0.82 (0.49, 1.38) 0.46 0.93 (0.55, 1.59) 0.79 
 
Tertile 3 92.6 0.42 (0.23, 0.76) 0.004 0.49 (0.26, 0.92) 0.03 0.53 (0.28, 1.02) 0.06 0.62 (0.32, 1.21) 0.16 
            
 
 
 
 
 
         
 108 
 
TYMP 
 
Continuous 85.0 1.02 (0.81, 1.30) 0.85 0.95 (0.75, 1.21) 0.70 0.93 (0.73, 1.19) 0.58 0.96 (0.77, 1.21) 0.75 
           
 
<median 85.5 Reference Reference Reference Reference 
 
≥median 84.5 1.18 (0.75, 1.85) 0.48 1.05 (0.67, 1.66) 0.82 1.01 (0.64, 1.60) 0.95 1.04 (0.66, 1.65) 0.85 
           
 
Tertile 1 86.2 Reference Reference Reference Reference 
 
Tertile 2 83.1 1.14 (0.67, 1.95) 0.63 1.11 (0.65, 1.90) 0.70 1.06 (0.62, 1.81) 0.84 1.13 (0.66, 1.95) 0.66 
 
Tertile 3 85.8 0.96 (0.54, 1.71) 0.90 0.84 (0.47, 1.50) 0.56 0.81 (0.45, 1.45) 0.47 0.84 (0.47, 1.50) 0.55 
           UMPS 
         
 
Continuous 85.0 0.99 (0.89, 1.11) 0.92 0.97 (0.86, 1.09) 0.59 0.96 (0.86, 1.08) 0.55 1.00 (0.88, 1.13) 0.99 
     
  
    
 
<median 86.5 Reference Reference Reference Reference 
 
≥median 83.5 1.39 (0.88, 2.20) 0.16 1.38 (0.88, 2.18) 0.16 1.37 (0.87, 2.17) 0.17 1.44 (0.91, 2.28) 0.12 
     
      
 
Tertile 1 86.7 Reference Reference Reference Reference 
 
Tertile 2 84.7 0.94 (0.53, 1.66) 0.83 0.85 (0.48, 1.52) 0.59 0.83 (0.47, 1.48) 0.53 0.93 (0.51, 1.67) 0.80 
 Tertile 3 83.6 1.31 (0.76, 2.28) 0.33 1.24 (0.71, 2.15) 0.45 1.22 (0.70, 2.11) 0.49 1.38 (0.78, 2.44) 0.26 
1
Unadjusted, mean(se), DFS or OS, as appropriate 
2
Adjusted for age at diagnosis 
3
Adjusted for age at diagnosis and tumor grade 
4
Adjusted for age at diagnosis, tumor grade, and basal-like subtype 
5
Adjusted for age at diagnosis, tumor grade, basal-like subtype, and DUSP4 expression 
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Table 43: Disease-Free and Overall Survival by Expression of Genes Involved in 5-Fluorouracil Metabolism Among TNBC Participants in the 
SBCSS Cohort Stratified By Whether 5-Fluorouracil was Taken 
 
  
Disease-Free Survival 
 
Overall Survival 
  
5-FU Taken (N=316) 
 
5-FU Not Taken (N=102) 
  
5-FU Taken (N=316) 
 
5-FU Not Taken (N=102) 
 
 
HR (95% CI)
1
 P 
 
HR (95% CI)
1
 P Pint  
HR (95% CI)
1
 P 
 
HR (95% CI)
1
 P Pint 
DPYD 
             
 
Continuous 1.13 (0.94, 1.37) 0.19 
 
0.86 (0.70, 1.06) 0.15 0.39 
 
1.12 (0.93, 1.35) 0.22 
 
0.87 (0.71, 1.08) 0.20 0.78 
               
 
<median Reference 
 
Reference 
  
Reference 
 
Reference 
 
 
≥median 0.76 (0.40, 1.43) 0.39 
 
0.49 (0.20, 1.18) 0.11 0.64 
 
1.19 (0.66, 2.14) 0.56 
 
0.42 (0.18, 1.00) 0.05 0.19 
               
 
Tertile 1 Reference 
 
Reference 
0.69 
 
Reference 
 
Reference 
0.34 
 
Tertile 2 0.61 (0.28, 1.33) 0.21 
 
0.74 (0.27, 1.99) 0.55 
 
0.79 (0.38, 1.66) 0.54 
 
0.75 (0.29, 1.92) 0.55 
 
Tertile 3 0.86 (0.41, 1.82) 0.70 
 
0.52 (0.18, 1.49) 0.22 
 
1.33 (0.65, 2.71) 0.43 
 
0.46 (0.16, 1.31) 0.15 
               
TYMS 
             
 
Continuous 1.03 (0.87, 1.24) 0.71 
 
0.96 (0.78, 1.18) 0.71 0.58 
 
1.02 (0.86, 1.22) 0.80 
 
0.98 (0.80, 1.20) 0.85 0.74 
               
 
<median Reference 
 
Reference 
  
Reference 
 
Reference 
 
 
≥median 1.55 (0.75, 3.19) 0.24 
 
0.45 (0.12, 1.65) 0.23 0.13 
 
1.13 (0.58, 2.22) 0.72 
 
0.69 (0.20, 2.39) 0.56 0.48 
               
 
Tertile 1 Reference 
 
Reference 
0.16 
 
Reference 
 
Reference 
0.60 
 
Tertile 2 1.35 (0.57, 3.18) 0.49 
 
0.25 (0.05, 1.28) 0.10 
 
1.24 (0.58, 2.68) 0.58 
 
0.53 (0.14, 1.98) 0.34 
 
Tertile 3 1.40 (0.54, 3.64) 0.49 
 
0.31 (0.05, 1.85) 0.20 
 
1.10 (0.46, 2.66) 0.83 
 
0.87 (0.20, 3.75) 0.85 
               
MTHFR 
             
 
Continuous 1.18 (0.96, 1.45) 0.11 
 
0.95 (0.77, 1.19) 0.68 0.92 
 
1.10 (0.90, 1.33) 0.35 
 
0.93 (0.76, 1.14) 0.49 0.80 
               
 
<median Reference 
 
Reference 
  
Reference 
 
Reference 
 
 
≥median 1.10 (0.56, 2.15) 0.79 
 
0.23 (0.08, 0.71) 0.01 0.08 
 
1.42 (0.76, 2.64) 0.27 
 
0.35 (0.13, 0.91) 0.03 0.12 
               
 
Tertile 1 Reference 
 
Reference 
0.13 
 
Reference 
 
Reference 
0.04 
 
Tertile 2 1.31 (0.62, 2.77) 0.48 
 
0.54 (0.19, 1.56) 0.26 
 
1.30 (0.65, 2.59) 0.46 
 
0.77 (0.31, 1.87) 0.56 
 
Tertile 3 1.40 (0.58, 3.39) 0.45 
 
0.26 (0.07, 0.94) 0.04 
 
1.48 (0.66, 3.35) 0.34 
 
0.07 (0.01, 0.56) 0.01 
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TYMP 
 
Continuous 0.90 (0.70, 1.18) 0.45 
 
0.86 (0.54, 1.36) 0.51 0.90 
 
0.97 (0.75, 1.24) 0.80 
 
0.79 (0.51, 1.23) 0.30 0.75 
               
 
<median Reference 
 
Reference 
  
Reference 
 
Reference 
 
 
≥median 0.91 (0.49, 1.68) 0.76 
 
1.14 (0.48, 2.68) 0.77 0.61 
 
0.99 (0.56, 1.76) 0.98 
 
0.91 (0.40, 2.05) 0.82 0.93 
               
 
Tertile 1 Reference 
 
Reference 
0.90 
 
Reference 
 
Reference 
0.99 
 
Tertile 2 0.73 (0.35, 1.54) 0.41 
 
1.57 (0.57, 4.34) 0.39 
 
0.91 (0.46, 1.79) 0.78 
 
1.52 (0.58, 4.01) 0.39 
 
Tertile 3 0.74 (0.35, 1.55) 0.43 
 
0.78 (0.24, 2.51) 0.68 
 
0.76 (0.38, 1.54) 0.45 
 
0.70 (0.23, 2.15) 0.53 
               
UMPS 
             
 
Continuous 1.12 (0.94, 1.34) 0.21 
 
1.09 (0.85, 1.41) 0.49 0.81 
 
0.98 (0.85, 1.14) 0.84 
 
1.18 (0.90, 1.55) 0.23 0.17 
               
 
<median Reference 
 
Reference 
  
Reference 
 
Reference 
 
 
≥median 2.24 (1.18, 4.28) 0.01 
 
1.92 (0.80, 4.61) 0.15 0.73 
 
1.42 (0.81, 2.50) 0.22 
 
1.75 (0.76, 4.03) 0.19 0.76 
               
 
Tertile 1 Reference 
 
Reference 
0.71 
 
Reference 
 
Reference 
0.50 
 
Tertile 2 0.96 (0.41, 2.24) 0.92 
 
1.43 (0.47, 4.35) 0.53 
 
0.90 (0.44, 1.88) 0.79 
 
1.24 (0.44, 3.51) 0.68 
 
Tertile 3 2.04 (0.96, 4.33) 0.06 
 
2.32 (0.81, 6.58) 0.12 
 
1.31 (0.65, 2.63) 0.44 
 
1.70 (0.63, 4.58) 0.29 
1
Adjusted for age at diagnosis, tumor grade, basal-like subtype, and DUSP4 expression 
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The association between individual gene expression levels and the number of cycles of 5-
fluorouracil completed was evaluated as a surrogate for toxicity (Table 44). Participants with 
TYMP expression levels above the median were significantly less likely to complete 6 or more 
cycles as compared with those with TYMP expression level below the median (OR=0.40, 95% 
CI: 0.22, 0.72, p=0.002). No other significant associations were observed. 
 
Table 44: Association Between 5-Fluorouracil Gene Expression Levels and Cycles of 5-
Fluorouracil Completed 
 
  OR (95% CI)
1
 P 
DPYD 0.82 (0.47, 1.42) 0.47 
TYMS 1.57 (0.79, 3.14) 0.20 
MTHFR 0.63 (0.35, 1.16) 0.14 
TYMP 0.40 (0.22, 0.72) 0.002 
UMPS 1.12 (0.65, 1.94) 0.69 
1
Adjusted for age at diagnosis, tumor grade, 
basal-like subtype, and DUSP4 expression 
 
 
The association between 5-fluorouracil gene expression levels and breast cancer survival 
among those who took 5-fluorouracil was further evaluated through additional adjustment for the 
number of cycles of cyclophosphamide taken (Table 45). The observed associations between 5-
fluorouracil gene expression levels and survival outcomes were not materially changed after 
adjustment for cycles completed. 
  
 112 
 
Table 45: Disease-Free and Overall Survival by Expression of 5-Fluorouracil Metabolizing 
Genes Further Adjusted for Number of Cycles of 5-Fluorouracil Completed 
 
  
Disease-Free Survival 
 
Overall Survival 
  HR (95% CI)
1
 P HR (95% CI)
1
 P 
DPYD           
 Continuous 1.13 (0.94, 1.35) 0.21  1.12 (0.93, 1.34) 0.23 
       
 <median Reference  Reference 
 ≥median 0.74 (0.39, 1.40) 0.36  1.18 (0.66, 2.12) 0.58 
       
 Tertile 1 Reference  Reference 
 Tertile 2 0.62 (0.28, 1.37) 0.24  0.80 (0.38, 1.68) 0.56 
 Tertile 3 0.86 (0.41, 1.80) 0.68  1.32 (0.65, 2.69) 0.44 
       
TYMS      
 Continuous 1.03 (0.86, 1.23) 0.75  1.02 (0.85, 1.21) 0.84 
       
 <median Reference  Reference 
 ≥median 1.52 (0.74, 3.14) 0.26  1.11 (0.57, 2.18) 0.76 
       
 Tertile 1 Reference  Reference 
 Tertile 2 1.37 (0.58, 3.23) 0.47  1.25 (0.58, 2.69) 0.57 
 Tertile 3 1.38 (0.53, 3.57) 0.51  1.09 (0.45, 2.61) 0.85 
       
MTHFR      
 Continuous 1.20 (0.97, 1.48) 0.09  1.10 (0.91, 1.34) 0.33 
       
 <median Reference  Reference 
 ≥median 1.11 (0.56, 2.18) 0.76  1.43 (0.76, 2.67) 0.27 
       
 Tertile 1 Reference  Reference 
 Tertile 2 1.30 (0.61, 2.75) 0.49  1.30 (0.65, 2.59) 0.46 
 Tertile 3 1.52 (0.62, 3.77) 0.36  1.55 (0.68, 3.56) 0.30 
       
TYMP      
 Continuous 0.90 (0.69, 1.17) 0.43  0.97 (0.75, 1.24) 0.79 
       
 <median Reference  Reference 
 ≥median 0.93 (0.50, 1.72) 0.81  1.02 (0.57, 1.81) 0.95 
       
 Tertile 1 Reference  Reference 
 Tertile 2 0.74 (0.35, 1.56) 0.43  0.92 (0.47, 1.83) 0.82 
 Tertile 3 0.73 (0.35, 1.54) 0.41  0.76 (0.38, 1.55) 0.46 
       
UMPS      
 Continuous 1.11 (0.93, 1.33) 0.24  0.98 (0.85, 1.14) 0.80 
       
 <median Reference  Reference 
 ≥median 2.25 (1.18, 4.32) 0.01  1.42 (0.81, 2.49) 0.23 
       
 Tertile 1 Reference  Reference 
 Tertile 2 0.99 (0.42, 2.33) 0.97  0.92 (0.44, 1.92) 0.82 
 Tertile 3 2.08 (0.97, 4.45) 0.06  1.32 (0.66, 2.66) 0.43 
1
Adjusted for age at diagnosis, tumor grade, basal-like subtype, DUSP4 expression, and number of 
cycles of 5-fluorouracil 
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We stratified our results by timing of survival events, those that occurred in the first three 
years of follow-up and those that occurred after 3 years, among all women (Table 46) and 
restricted to those who took 5-fluorouracil (Table 47). The effect estimates for TYMS expression 
and MTHFR expression were greater in magnitude for events that occurred more than 3 years 
after diagnosis, particularly in those who took 5-fluorouracil, although neither association was 
significant; no association was observed among those with earlier events. UMPS expression was 
associated with significantly worse DFS among those who experienced a survival event in the 
first three years following breast cancer diagnosis (HR=2.01, 95% CI: 1.10, 3.70, p=0.02), 
particularly among those who were treated with 5-fluorouracil (HR=2.33, 95% CI: 1.05, 5.17, 
p=0.04); however, while not significant, the point estimate for those who had a later event was 
not significantly different from the HR associated with early events. No other differences 
between those who had events in the first 3 years and those after 3 years were apparent.
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Table 46: Association Between 5-fluorouracil Gene Expression Levels Stratified by Early vs. Late Events Among All Participants 
 
  
Events <3 years 
 
Events ≥3 years 
  
Disease-Free Survival  
(47 events) 
 
Overall Survival  
(34 events) 
 
Disease-Free Survival  
(20 events) 
 
Overall Survival  
(42 events) 
  HR (95% CI)
1
 P  HR (95% CI)
1
 P  HR (95% CI)
1
 P  HR (95% CI)
1
 P 
DPYD 
           
 Continuous 1.01 (0.85, 1.20) 0.94  1.10 (0.89, 1.36) 0.39 
 
0.98 (0.75, 1.29) 0.88  0.92 (0.77, 1.10) 0.37 
             
 <median Reference  Reference 
 
Reference  Reference 
 ≥median 1.01 (0.85, 1.20) 0.23  0.66 (0.32, 1.38) 0.27 
 
0.52 (0.20, 1.33) 0.17  0.97 (0.52, 1.81) 0.92 
             
 Tertile 1 Reference  Reference 
 
Reference  Reference 
 Tertile 2 0.49 (0.24, 1.04) 0.06  0.97 (0.20, 4.78) 0.97 
 
0.77 (0.27, 2.23) 0.63  0.88 (0.41, 1.90) 0.74 
 Tertile 3 0.73 (0.36, 1.46) 0.37  1.40 (0.29, 6.69) 0.67 
 
0.61 (0.19, 1.98) 0.41  1.12 (0.51, 2.44) 0.78 
             
TYMS      
 
     
 Continuous 0.95 (0.81, 1.11) 0.50  0.98 (0.81, 1.18) 0.80 
 
1.07 (0.81, 1.43) 0.62  0.99 (0.81, 1.20) 0.90 
             
 <median Reference  Reference 
 
Reference  Reference 
 ≥median 1.00 (0.48, 2.07) 0.99  1.03 (0.44, 2.41) 0.95 
 
1.57 (0.53, 4.64) 0.41  1.06 (0.50, 2.27) 0.88 
             
 Tertile 1 Reference  Reference 
 
Reference  Reference 
 Tertile 2 0.94 (0.41, 2.18) 0.89  1.78 (0.64, 4.95) 0.27 
 
0.38 (0.09, 1.60) 0.19  0.48 (0.19, 1.19) 0.11 
 Tertile 3 0.78 (0.29, 2.05) 0.61  1.20 (0.37, 3.86) 0.76 
 
1.32 (0.34, 5.11) 0.14  0.98 (0.37, 2.60) 0.97 
             
MTHFR      
 
     
 Continuous 1.02 (0.85, 1.23) 0.82  1.10 (0.88, 1.37) 0.42 
 
1.15 (0.83, 1.59) 0.41  0.95 (0.78, 1.14) 0.56 
             
 <median Reference  Reference 
 
Reference  Reference 
 ≥median 0.78 (0.40, 1.52) 0.47  0.88 (0.40, 1.92) 0.74 
 
0.42 (0.15, 1.17) 0.10  0.83 (0.42, 1.64) 0.60 
             
 Tertile 1 Reference  Reference 
 
Reference  Reference 
 Tertile 2 0.79 (0.40, 1.57) 0.51  1.02 (0.21, 5.01) 0.98 
 
0.85 (0.28, 2.58) 0.78  0.90 (0.43, 1.87) 0.77 
 Tertile 3 0.63 (0.27, 1.48) 0.29  1.46 (0.31, 6.98) 0.63 
 
0.79 (0.24, 2.59) 0.70  0.57 (0.24, 1.35) 0.20 
             
TYMP      
 
     
 Continuous 1.01 (0.75, 1.34) 0.96  0.92 (0.67, 1.26) 0.60 
 
0.77 (0.49, 1.19) 0.24  0.98 (0.71, 1.35) 0.90 
             
 <median Reference  Reference 
 
Reference  Reference 
 ≥median 1.37 (0.75, 2.49) 0.30  1.10 (0.55, 2.21) 0.78 
 
0.57 (0.23, 1.43) 0.23  0.98 (0.53, 1.80) 0.94 
             
 Tertile 1 Reference  Reference 
 
Reference  Reference 
 Tertile 2 0.84 (0.26, 2.66) 0.76  1.16 (0.51, 2.62) 0.72 
 
0.85 (0.30, 2.39) 0.76  1.13 (0.54, 2.35) 0.75 
 Tertile 3 0.86 (0.27, 2.74) 0.19  1.00 (0.97, 1.04) 0.50 
 
0.53 (0.17, 1.66) 0.28  0.88 (0.40, 1.93) 0.75 
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UMPS      
 
     
 Continuous 1.05 (0.89, 1.23) 0.55  1.11 (0.91, 1.36) 0.31  1.09 (0.84, 1.41) 0.52  0.94 (0.81, 1.09) 0.42 
             
 <median Reference  Reference 
 
Reference  Reference 
 ≥median 2.01 (1.10, 3.70) 0.02  2.14 (1.03, 4.43) 0.04 
 
1.72 (0.69, 4.28) 0.24  1.10 (0.60, 2.02) 0.77 
             
 Tertile 1 Reference  Reference 
 
Reference  Reference 
 Tertile 2 1.06 (0.48, 2.34) 0.89  1.18 (0.46, 3.07) 0.73 
 
0.87 (0.26, 2.95) 0.82  6.27 (0.83, 47.62) 0.08 
 Tertile 3 1.98 (0.96, 4.10) 0.07  2.07 (0.86, 4.99) 0.10 
 
1.93 (0.65, 5.75) 0.24  4.47 (0.57, 34.79) 0.15 
1
Adjusted for age at diagnosis, tumor grade, basal-like subtype, and DUSP4 expression 
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Table 47: Association Between 5-fluorouracil Gene Expression Levels Stratified by Early vs. Late Events Among Those who Took 5-Fluorouracil 
 
  
Events <3 years 
 
Events ≥3 years 
  
Disease-Free Survival  
(30 events) 
 
Overall Survival  
(22 events) 
 
Disease-Free Survival  
(14 events) 
 
Overall Survival (29 
events) 
  HR (95% CI)
1
 P  HR (95% CI)
1
 P  HR (95% CI)
1
 P  HR (95% CI)
1
 P 
DPYD 
           
 Continuous 1.21 (0.97, 1.51) 0.10  1.26 (0.98, 1.61) 0.07 
 
0.97 (0.71, 1.32) 0.85  0.98 (0.77, 1.24) 0.86 
             
 <median Reference  Reference 
 
Reference  Reference 
 ≥median 0.89 (0.41, 1.92) 0.76  1.33 (0.53, 3.32) 0.55 
 
0.55 (0.18, 1.69) 0.30  1.10 (0.51, 2.35) 0.81 
             
 Tertile 1 Reference  Reference 
 
Reference  Reference 
 Tertile 2 0.61 (0.23, 1.61) 0.32  0.72 (0.22, 2.35) 0.59 
 
0.60 (0.16, 2.25) 0.45  0.83 (0.32, 2.15) 0.70 
 Tertile 3 0.95 (0.38, 2.36) 0.91  1.25 (0.43, 3.64) 0.69 
 
0.71 (0.19, 2.65) 0.61  1.41 (0.54, 3.67) 0.48 
             
TYMS      
 
     
 Continuous 1.03 (0.84, 1.28) 0.76  0.99 (0.80, 1.23) 0.92 
 
1.05 (0.75, 1.45) 0.79  1.09 (0.82, 1.47) 0.55 
             
 <median Reference  Reference 
 
Reference  Reference 
 ≥median 1.27 (0.53, 3.04) 0.60  0.92 (0.34, 2.47) 0.86 
 
2.42 (0.68, 8.65) 0.17  1.37 (0.56, 3.30) 0.49 
             
 Tertile 1 Reference  Reference 
 
Reference  Reference 
 Tertile 2 1.53 (0.53, 4.42) 0.43  3.12 (0.82, 11.86) 0.10 
 
0.88 (0.18, 4.18) 0.87  0.57 (0.19, 1.69) 0.31 
 Tertile 3 1.10 (0.33, 3.66) 0.88  1.12 (0.24, 5.22) 0.88 
 
2.57 (0.53, 12.42) 0.24  1.34 (0.43, 4.16) 0.61 
             
MTHFR      
 
     
 Continuous 1.13 (0.91, 1.42) 0.27  1.24 (0.97, 1.60) 0.09 
 
1.62 (0.81, 3.24) 0.17  0.98 (0.75, 1.29) 0.90 
             
 <median Reference  Reference 
 
Reference  Reference 
 ≥median 1.35 (0.60, 3.06) 0.47  1.08 (0.40, 2.87) 0.88 
 
0.74 (0.23, 2.36) 0.61  1.68 (0.73, 3.84) 0.22 
             
 Tertile 1 Reference  Reference 
 
Reference  Reference 
 Tertile 2 1.19 (0.49, 2.86) 0.70  1.31 (0.46, 3.72) 0.61 
 
1.79 (0.41, 7.90) 0.44  1.34 (0.52, 3.45) 0.55 
 Tertile 3 1.12 (0.37, 3.43) 0.84  1.51 (0.41, 5.62) 0.53 
 
2.24 (0.46, 10.87) 0.32  1.45 (0.50, 4.19) 0.50 
             
TYMP      
 
     
 Continuous 0.93 (0.68, 1.27) 0.64  0.86 (0.60, 1.22) 0.39 
 
0.80 (0.47, 1.36) 0.41  1.02 (0.71, 1.47) 0.91 
             
 <median Reference  Reference 
 
Reference  Reference 
 ≥median 1.08 (0.51, 2.31) 0.84  0.92 (0.37, 2.27) 0.86 
 
0.60 (0.20, 1.80) 0.36  1.00 (0.48, 2.10) 1.00 
             
 Tertile 1 Reference  Reference 
 
Reference  Reference 
 Tertile 2 0.83 (0.33, 2.08) 0.70  0.91 (0.32, 2.54) 0.85 
 
0.59 (0.16, 2.16) 0.42  0.91 (0.37, 2.27) 0.85 
 Tertile 3 0.84 (0.34, 2.07) 0.70  0.55 (0.18, 1.66) 0.29 
 
0.55 (0.15, 2.06) 0.37  0.88 (0.35, 2.20) 0.78 
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UMPS      
 
     
 Continuous 1.17 (0.94, 1.46) 0.16  1.18 (0.91, 1.53) 0.20 
 
1.06 (0.80, 1.42) 0.68  0.91 (0.77, 1.09) 0.31 
             
 <median Reference  Reference 
 
Reference  Reference 
 ≥median 2.33 (1.05, 5.17) 0.04  2.58 (0.99, 6.70) 0.05 
 
2.19 (0.72, 6.70) 0.17  1.02 (0.49, 2.11) 0.97 
             
 Tertile 1 Reference  Reference 
 
Reference  Reference 
 Tertile 2 1.08 (0.38, 3.07) 0.88  1.71 (0.48, 6.15) 0.41 
 
0.77 (0.17, 3.57) 0.74  0.68 (0.27, 1.71) 0.41 
 Tertile 3 2.03 (0.80, 5.20) 0.14  2.46 (0.75, 8.07) 0.14 
 
2.28 (0.63, 8.30) 0.21  0.96 (0.39, 2.36) 0.94 
1
Adjusted for age at diagnosis, tumor grade, basal-like subtype, and DUSP4 expression 
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As previously described, a gene expression score based on the median cut point of 
expression was created and the association with clinical and treatment factors was evaluated 
(Table 48); higher scores are associated with higher drug exposure. The 5-fluorouracil gene 
expression score was significantly associated with higher grade (p=0.0007). No other significant 
associations were observed.  
 
Table 48: Clinical and Treatment Factors by 5-Fluorouracil Gene Expression Score Among 
TNBC Participants in the SBCSS Cohort 
 
   
Median Score 
  N mean (SD) P 
Age 
  
0.55  
<40 29 2.5 (0.9) 
 
40-49 154 2.5 (0.9) 
 
50-59 108 2.6 (1.0) 
 
≥60 127 2.4 (1.0) 
TNM Stage 
  
0.74  
0-I 137 2.5 (1.0) 
 
IIA 145 2.5 (1.0) 
 
IIB 85 2.6 (0.9) 
 
III-IV 38 2.5 (1.0) 
 
Missing 13 2.6 (1.0) 
 
Grade 
  
0.0007 
 
1 50 2.3 (0.9) 
 
2 132 2.3 (0.9) 
 
3 236 2.7 (1.0) 
Chemotherapy 
  0.58 
 
Yes 390 2.5 (1.0) 
 
No 28 2.6 (0.8) 
5-Fluorouracil 
  0.81 
 
Yes 316 2.5 (1.0) 
 
No 102 2.5 (0.9) 
Radiotherapy 
  0.86 
 
Yes 103 2.5 (0.9) 
 
No 315 2.5 (1.0) 
Mastectomy 
  0.37 
 
Yes 399 2.5 (1.0) 
 
No 19 2.3 (0.9) 
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No association was observed between the additive 5-fluorouracil gene expression score 
and DFS or OS (Table 49). The 5-fluorouracil gene expression score was associated with better 
DFS after adjustment for age at diagnosis, tumor grade, basal-like subtype, and DUSP4 
expression; although the association was not significant (highest score compared to lowest score 
HR=0.51, 95% CI: 0.20, 1.29, Ptrend=0.16). Although higher grade is associated with a higher 5-
fluorouracil gene expression score, there is no difference in the observed results when grade is 
not adjusted for. 
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Table 49: Disease-Free Survival and Overall Survival by Additive 5-Fluorouracil Gene Score Among TNBC Participants in the 
SBCSS Cohort 
 
    N HR (95% CI)
1
 P HR (95% CI)
2
 P HR (95% CI)
3
 P HR (95% CI)
4
 P 
  Disease-Free Survival 
Score
5
          
 Group 1 67 Reference Reference Reference Reference 
 Group 2 142 1.02 (0.50, 2.08) 0.96 1.01 (0.49, 2.07) 0.99 0.89 (0.43, 1.85) 0.75 0.84 (0.40, 1.75) 0.64 
 Group 3 138 1.05 (0.52, 2.15) 0.89 0.98 (0.48, 2.02) 0.97 0.82 (0.39, 1.72) 0.59 0.79 (0.37, 1.66) 0.53 
 Group 4 71 0.79 (0.33, 1.90) 0.60 0.72 (0.29, 1.75) 0.47 0.55 (0.22, 1.40) 0.21 0.51 (0.20, 1.29) 0.15 
 Ptrend  0.68 0.50 0.21 0.16 
             Overall Survival 
Score
5
          
 Group 1 67 Reference Reference Reference Reference 
 Group 2 142 1.11 (0.56, 2.21) 0.76 1.12 (0.56, 2.23) 0.75 1.01 (0.51, 2.04) 0.97 0.97 (0.48, 1.96) 0.93 
 Group 3 138 1.12 (0.57, 2.22) 0.74 1.02 (0.51, 2.04) 0.95 0.87 (0.43, 1.79) 0.71 0.85 (0.41, 1.74) 0.65 
 Group 4 71 1.02 (0.46, 2.27) 0.96 0.91 (0.40, 2.04) 0.81 0.73 (0.31, 1.70) 0.46 0.67 (0.29, 1.57) 0.36 
 Ptrend  0.96 0.72 0.37 0.29 
1
Adjusted for age at diagnosis 
2
Adjusted for age at diagnosis and grade 
3
Adjusted for age at diagnosis, grade, and basal-like-subtype 
4
Adjusted for age at diagnosis, grade, basal-like subtype, and DUSP4 
5
Score based on median cut point (higher score indicates faster metabolizer, slower activator, and poorer response) 
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When the association between the 5-fluorouracil gene score and survival was stratified by 
whether 5-fluorouracil was taken, no significant associations were observed for either stratum 
(Table 50). 
 
Table 50: Disease-Free Survival and Overall Survival by Additive 5-Fluorouracil Gene Score 
Among TNBC Participants in the SBCSS Cohort Stratified by Whether 5-Fluorouracil was 
Taken 
 
  
5-Fluorouracil Taken 5-Fluorouracil Not Taken 
  HR (95% CI)
1
 P HR (95% CI)
1
 P 
  Disease-Free Survival 
Score
2
     
 Group 1 Reference Reference 
 Group 2  0.87 (0.35, 2.18) 0.77 0.78 (0.22, 2.84) 0.71 
 Group 3 0.87 (0.34, 2.22) 0.78 0.46 (0.12, 1.78) 0.26 
 Group 4 0.49 (0.15, 1.59) 0.23 0.51 (0.10, 2.52) 0.40 
 Ptrend 0.28 0.28 
        Overall Survival 
Score
2
     
 Group 1 Reference Reference 
 Group 2  0.99 (0.42, 2.33) 0.97 1.02 (0.29, 3.54) 0.97 
 Group 3 0.89 (0.37, 2.15) 0.79 0.61 (0.16, 2.31) 0.46 
 Group 4 0.72 (0.25, 2.02) 0.53 0.61 (0.12, 3.02) 0.55 
 Ptrend 0.47 0.38 
1
Adjusted for age at diagnosis, tumor grade, basal-like subtype, and DUSP4 expression 
2
Score based on median cut point (higher score indicates faster metabolizer, slower activator, 
and poorer response) 
 
 
The association between the 5-fluorouracil gene expression score and the number of 
cycles of 5-fluorouracil completed was evaluated as a surrogate for toxicity. For every one unit 
increase in the gene expression score, there was a significantly increased likelihood of 
completing 6 or more cycles of 5-fluorouracail (OR=1.40, 95% CI: 1.03, 1.90, p=0.03), which is 
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expected as those with higher scores degrade 5-fluorouracil more quickly and activate it more 
slowly, resulting in a longer exposure to the active metabolite. 
The association between the 5-fluorouracil gene expression score and breast cancer 
survival among those who took 5-fluorouracil was further evaluated through additional 
adjustment for the number of cycles of 5-fluorouracil completed (Table 51). The results were not 
materially changed after adjustment for cycles completed. 
 
Table 51: Disease-Free and Overall Survival by Additive 5-Fluorouracil Gene Score Further 
Adjusted for Number of Cycles of 5-Fluorouracil Completed 
 
  
Disease-Free Survival 
 
Overall Survival 
  HR (95% CI)
1
 P HR (95% CI)
1
 P 
Score
2
      
 Group 1 Reference  Reference 
 Group 2  0.84 (0.34, 2.09) 0.70  0.96 (0.40, 2.26) 0.92 
 Group 3 0.82 (0.32, 2.09) 0.68  0.85 (0.35, 2.07) 0.72 
 Group 4 0.46 (0.14, 1.51) 0.20  0.69 (0.24, 1.95) 0.48 
 Ptrend 0.23   0.42  
1
Adjusted for age at diagnosis, tumor grade, basal-like subtype, DUSP4 expression, and 
number of cycles of 5-fluorouracil 
2
Score based on median cut point (higher score indicates faster metabolizer, slower activator, 
and poorer response) 
 
 
We stratified our results by timing of survival events, those that occurred in the first three 
years of follow-up and those that occurred after 3 years, among all women and restricted to those 
who took 5-fluorouracil (Table 52). During the first 3 years of follow-up, the 5-fluorouracil gene 
expression score was associated with significantly better DFS among all participants 
(Ptrend=0.04); a similar pattern was observed when the analyses were restricted to only those who 
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took 5-fluorouracil, although the Ptrend was not significant, possibly due to reduced sample size. 
These results indicate that those with a shorter exposure to the 5-fluorouracil drug had better 
survival. Further adjustment for the number of cycles of 5-fluorouracil completed slightly 
attenuated the observed association.
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Table 52: Association Between Disease-Free and Overall Survival and Additive 5-Fluorouracil Gene Score Stratified by Early vs. Late Events 
Among All Participants and Those Who Took 5-Fluorouracil 
 
 
  
Events <3 years 
 
Events ≥3 years 
  
Disease-Free Survival  
(47 events) 
 
Overall Survival  
(34 events) 
 
Disease-Free Survival  
(20 events) 
 
Overall Survival  
(42 events) 
  HR (95% CI)
1
 P  HR (95% CI)
1
 P  HR (95% CI)
1
 P  HR (95% CI)
1
 P 
Among All Participants           
Score
2
      
 
     
 Group 1 Reference  Reference 
 
Reference  Reference 
 Group 2  0.88 (0.37, 2.05) 0.76  2.45 (0.71, 8.50) 0.16 
 
0.62 (0.14, 2.82) 0.54  0.38 (0.14, 1.04) 0.06 
 Group 3 0.56 (0.22, 1.39) 0.21  0.75 (0.19, 3.03) 0.69 
 
1.49 (0.39, 5.65) 0.56  0.94 (0.40, 2.20) 0.89 
 Group 4 0.40 (0.13, 1.22) 0.11  0.91 (0.21, 4.03) 0.91 
 
0.88 (0.17, 4.69) 0.88  0.65 (0.22, 1.89) 0.43 
 Ptrend 0.04   0.11   0.61   0.93  
             
Among Those Who Took 5-Fluorouracil        
Score
2
      
 
     
 Group 1 Reference  Reference 
 
Reference  Reference 
 Group 2  1.18 (0.37, 3.70) 0.78  1.91 (0.41, 8.98) 0.41 
 
0.31 (0.05, 1.92) 0.21  0.49 (0.15, 1.56) 0.23 
 Group 3 0.66 (0.19, 2.30) 0.51  0.62 (0.11, 3.58) 0.59 
 
1.37 (0.34, 5.55) 0.66  1.07 (0.38, 3.05) 0.89 
 Group 4 0.56 (0.13, 2.33) 0.42  1.09 (0.19, 6.29) 0.92 
 
0.34 (0.03, 3.53) 0.37  0.56 (0.14, 2.22) 0.41 
 Ptrend 0.17   0.35   0.93   0.91  
1
Adjusted for age at diagnosis, tumor grade, basal-like subtype, and DUSP4 expression 
2
Score based on median cut point (higher score indicates faster metabolizer, slower activator, and poorer response) 
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Conclusions/Discussion 
Very few studies have investigated the effect of expression of drug metabolizing enzymes 
on prognosis in breast cancer, in particular among TNBC patients. In this study, we evaluated the 
association between enzymes which metabolize the two most commonly used chemotherapy 
drugs in our population, cyclophosphamide and 5-fluorouracil. We further evaluated the 
association between these genes and breast cancer survival by creating gene expression scores. 
We found an inverse association between ALDH1A1 expression and DFS, although this 
association was observed in both those who underwent treatment with chemotherapy and those 
that did not, and these results have been published.
121
 GSTP1 gene expression was associated 
with significantly better DFS for events occurring in the first three years following breast cancer 
diagnosis, particularly among those who took cyclophosphamide. GSTT1 gene expression was 
associated with significantly worse OS for events occurring in the first three years following 
diagnosis, particularly among those who took cyclophosphamide. The cyclophosphamide gene 
expression score was associated with worse OS among all TNBC patients for events occurring in 
the first three years after cancer diagnosis. We also found a significant association between 
UMPS and DFS among all TNBC patients. The association between UMPS and DFS was similar 
in those who took 5-fluorouracil and those who did not. The 5-fluorouracil gene expression score 
was significantly associated with better DFS in the first three years of follow-up. 
Cyclophosphamide requires activation by CYP genes in the liver before the active 
metabolites can passively enter the tumor cells. Therefore, tumor tissue gene expression of these 
CYP genes should not play a major role in cyclophosphamide activation. In our study, we have 
measured the tumor tissue expression of these genes but four of these genes were expressed in 
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~≤10% of breast cases (CYP2B6, CYP3A5, CYP2A6, CYP2C8) and two genes were only 
expressed in one tumor sample each (CYP3A4 and CYP2C19). This supports the idea that these 
genes are not responsible for cyclophosphamide activation within the tumor cell, or that these 
genes do not play a key role in tumor biology in TNBC.  
ALDH1A1 is involved in deactivation of the cyclophosphamide active metabolite and 
ALDH1A1 gene expression has been shown to be associated with ER and PR negativity and 
poorer breast cancer outcomes.
170-172
 In our study, ALDH1A1 gene expression was positively 
associated with ER and PR expression (r=0.22 and r=0.30, respectively). We also found that 
ALDH1A1 expression was associated with better breast cancer survival in our study which we 
previously reported.
121
  
Glutathione S-transferases are also involved in the deactivation of the cyclophosphamide 
active metabolite. In line with our hypothesis, GSTT1 gene expression was associated with 
worse OS for events occurring in the first three years following breast cancer diagnosis; a similar 
trend was observed for GSTM1, although the association with OS was not statistically 
significant. Conversely, we found an association between higher GSTP1 gene expression and 
better DFS. This may be a chance finding or this gene may be involved in other mechanisms 
which influence survival. 
Due to the potentially large impact of ALDH1A1 expression on the cyclophosphamide 
gene expression score, we further evaluated this association by creating a score which only 
included the GST genes. Among all participants, we found that high GST expression (all four 
GST genes) was associated with significantly better DFS (highest score compared to lowest 
score HR=0.25, 95% CI: 0.07, 0.97, p=0.046); however, a dose-response relationship was not 
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observed. This score was not associated with ALDH1A1 expression and the consistence suggests 
that the observed association may potentially be true. When stratified by whether 
cyclophosphamide was taken, no significant difference was observed between the two groups. 
These findings suggest that GSTs may play other roles in survival among TNBC patients, 
although the small sample size may have limited our ability to detect an interaction. 
The cyclophosphamide gene expression score was associated with an increased risk of 
death in the first 3 years (Ptrend=0.03); a similar association was observed when restricted to only 
those who took cyclophosphamide, although the Ptrend was no longer significant. We 
hypothesized that this score would be associated with worse survival since the genes included in 
it were associated with increased degradation of the active metabolite of cyclophosphamide and 
would result in a shorter exposure period. We would expect the score to be stronger in those who 
took the drug and survival directly following diagnosis because this is the time frame when the 
effects of chemotherapy are most likely to be observed, although our potential to detect a 
significant association may have been limited by our sample size. Among those who survived 
three years post-diagnosis, the association between survival and the cyclophosphamide gene 
expression score was in the opposite direction (better survival), although the trend was not 
statistically significant. The cyclophosphamide gene expression score was not associated with 
the number of cycles of cyclophosphamide completed and further adjustment for cycles of 
cyclophosphamide did not alter the observed associations.  
In line with our hypotheses for genes involved in metabolism of 5-fluorouracil, TYMP 
expression was associated with better DFS and TYMS was associated with worse DFS among 
those who received 5-fluorouracil treatment, though neither reached statistical significance. 
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TYMS activity is essential for DNA synthesis and cell proliferation.
173
 The major mechanism of 
action of 5-fluorouracil is to inhibit TYMS enzyme activity.
51
 The TYMP enzyme catalyzes one 
step in the conversion of 5-fluorouracil to fluorodeoxyuridine monophosphate (FdUMP), the 
latter of which is crucial for inhibiting the TYMS enzyme.
51
 These findings support previous 
studies which have shown similar associations between TYMP
130-132
 and TYMS
129,133
 expression 
and breast cancer outcomes. 
We found no association between tumor-level DPYD gene expression and breast cancer 
survival among those who were treated with 5-fluorouracil. Although some studies have shown 
an association between DPYD expression and worse survival in breast cancer
128
 and other 
cancers
174-176
, other studies have found no association.
129,177,178
 Most of these studies looked at 
protein expression, rather than gene expression; several studies have shown that DPYD protein 
activity and mRNA levels may not be strongly correlated, which may explain why we did not 
find an associaition. Alternatively, although degradation of 5-fluorouracil by DPYD occurs in all 
tissues, including tumor, it primarily occurs in the liver.
49,62
 It may be that tumor-level 
expression and degradation have little effect on survival outcomes.  
Our study found an association between higher UMPS expression amd worse survival. 
UMPS, also known as OPRT, is the main enzyme involved in the conversion of 5-fluorouracil to 
5-fluorouridine monophosphate, which is essential for inhibiting TYMS, and previous studies 
have shown that high levels of UMPS/OPRT are associated with better survival.
179-181
 However, 
another study found that the ratio of OPRT to DPYD, in addition to OPRT expression, may be of 
importance in survival in patients with metastatic CRC treated with 5-fluorouracil.
182
 Among 
those who took 5-fluorouracil, we found no association between the ratio of UMPS/DPYD and 
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DFS (p=0.92); however, we did see a non-significant decrease in OS after adjustment for age at 
diagnosis, tumor grade, basal-like subtype, DUSP4 expression, and number of cycles of 5-
fluorouracil (HR=0.47, 95% CI: 0.17, 1.33, p=0.16).  
MTHFR expression was associated with significantly better DFS and OS among all 
participants; however, after fully adjusting the model, the association lost significance. The 
observed association was limited to those that did not take 5-fluorouracil as compared with those 
that did and the interaction was significant for OS (p=0.04). MTHFR metabolizes folate which 
acts as a cofactor in the inhibition of TYMS by the active metabolite of 5-fluorouracil; however, 
one study showed that higher gene expression levels of MTHFR were significantly associated 
with methylenetetrahydrofolate concentration, the form of folate which acts as a cofactor in the 
TS inhibition mechanism.
183
 The role of MTHFR extends far beyond that of 5-fluorouracil 
action.
49
 Folate plays a critical role in DNA synthesis and methylation.
184
 Among those treated 
with 5-fluorouracil, there was no difference in expression of MTHFR; however, among those 
who were not treated with 5-fluorouracil, those who had a survival event had significantly lower 
levels of MTHFR. This suggests that other aspects of MTHFR activity may be the driving factor 
between expression and survival.  
The 5-fluorouracil gene expression score was associated with significantly better DFS for 
the first three years following cancer diagnosis. This indicates that those with shorter exposure 
periods to the active metabolite of 5-fluorouracil were less likely to have a recurrence or die from 
breast cancer. This may be due to toxicity. When number of cycles of 5-fluorouracil completed 
was controlled for, the observed association was slightly attenuated and lost statistical 
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significance. There is a trade-off between toxicity and long-term outcome; toxicity may increase 
short-term mortality but may improve long-term outcome through lower rates of recurrence.  
We used the PAM50 subtype predictor to classify our TNBC patients by molecular 
subtype based on gene expression profiling, which enabled adjustment for basal-like subtype in 
our analyses. However, the proportion of basal-like TNBC patients in our populations was lower 
than expected. It should be noted that the PAM50 score was designed to be used in samples with 
a global population of breast cancer patients where all 5 subtypes are present.
137
 Our subtype 
prediction was done in our sample of Chinese TNBC patients only which may lead to 
misclassification of subtype or underestimation due to the inability to measure basal-like breast 
cancers that are not TNBC. 
As previously mentioned, metabolism of chemotherapy drugs occurs outside of the breast 
tissue, primarily in the liver. Gene expression level in the breast tumor tissue of metabolizing 
genes may not be directly related to the drug exposure in target tissue. Using log2-tranformed 
gene expression data from from GTEx, we examined the correlation between gene expression in 
the breast and expression in the liver and whole blood for the genes included in this study. 
GSTM1 and GSTT1 expression in the breast tissue were highly significantly correlated with 
expression in the liver (Spearman correlation=0.82, p<.0001; Spearman correlation=0.65, 
p<.0001, respectively) and whole blood (Spearman correlation=0.84, p<.0001; Spearman 
correlation=0.79, p<.0001, respectively). This suggests that the expression level of these two 
genes in the breast tissue can serve as as surrogate measurements for their level in liver where 
most of the chemotherapy drugs are metabolized. Thus, the association we observed between 
these gene expressions in breast cancer tissue and worse OS for events occurring in the first three 
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years following breast cancer diagnosis may have more biological relevance. TYMP expression 
in breast tissue was also highly correlated with expression in liver tissue (Spearman 
correlation=0.57, p<.0001) and whole blood (Spearman correlation=0.18, p=0.02). UMPS, 
DPYD, TYMS, and ALDH1A1 expression in breast tissue, on the other hand, were moderately 
correlated with expression in the liver (Spearman correlation=0.28, p=0.02; Spearman 
correlation=0.24, p=0.05; Spearman correlation=0.24, p=0.05; Spearman correlation=0.32, 
p=0.01, respectively ), but not in the blood. These findings lend some supporting evidence on the 
relevance of the findings of our study between tumor-level expression of these metabolizing 
genes and breast cancer survival outcomes. No statistically significant correlations between 
breast tissue gene expression of MTHFR, GSTP1, and GSTA1 and liver or blood expression 
were observed, which may partially explain the overall null results we found for these gene 
expressions in the current study. However, the level of folate, which is metabolized by MTHFR, 
available for the reaction inhibiting TYMS and preventing DNA replication would be on the 
cellular level. Therefore, the association between MTHFR and better survival among participants 
treated with 5-fluorouracil would not be diminished by the lack of correlation between breast and 
liver or blood expression of MTHFR. 
The gene expression in tumor tissue in this study was measured from tumor tissue taken 
prior to chemotherapy initiation. Because the majority of the women included in our study had a 
mastectomy (95%), the influence of gene expression level in breast cancer tissue may be of less 
relevance if they are not correlated to those of the metablizing organ (i.e., liver). Tumor-level 
gene expression may be more relevant in those who undergo neoadjuvant chemotherapy 
treatment. 
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The majority of previous studies which have been published and mentioned here used 
protein expression whereas we evaluated gene expression. Differences in our results compared to 
these studies may be due to low correlation between protein and gene expression levels, which 
may vary by gene. Few studies have looked at tumor level gene expression, particularly in breast 
cancer; therefore, more studies are needed to further assess the potential clinical utility of gene 
expression of chemotherapy metabolizing genes.  
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CHAPTER VI 
JOINT EFFECT BETWEEN GERMLINE VARIATION GENE SCORES AND TUMOR-
LEVEL GENE EXPRESSION SCORES AND TNBC SURVIVAL 
Aim 4-Specific Methods 
For this aim, we used all participants with both gene expression and genotyping data 
available, resulting in 312 total participants; although data for all 312 participants was not 
available for all SNPs. We calculated Pearson’s correlation coefficients and corresponding p-
values to evaluate the association between each SNP and its corresponding gene expression as 
well as its corresponding gene expression score. For comparability, the correlation between the 
SNP and the corresponding gene expression were also evaluated in the TCGA data. 
For the genes involved in cyclophosphamide metabolism, we used the SNP gene score 
created in Aim 2 and the gene expression score created in Aim 3. For the genes involved in 5-
fluorouracil, we used the SNP gene score created in Aim 2 which only included SNPs in the 
DPYD, TYMP, and UMPS for comparability to the cyclophosphamide score, which only 
included SNPs from genes involved in activation and deactivation. Therefore, we created a new 
gene expression score based on median cut points that only included these same three genes. For 
the joint effect analysis, there were only 95 participants that had data available for both the SNP 
score and the gene expression score. 
Participants were categorized as low or high metabolizers based on their SNP score and 
gene expression score, separately, and then categorized into groups: low-low, low-high, high-
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low, and high-high. Those in the higher categories have longer exposure time to the drug of 
interest while those in the low categories have shorter exposure times.  
Results 
The correlation between the minor allele for each SNP and expression of it’s 
corresponding gene as well as the total gene expression score associated with that gene among 
only those participants with data available for SNPs and gene expression was evaluated (Table 
53). The A allele in SNP rs3764435 was moderately correlated with ALDH1A1 gene expression 
(r=0.20, p=0.06). The G allele in SNP rs1695 was moderately inversely associated with GSTP1 
gene expression (r=-0.11, p=0.06). The C allele in the SNP rs1801159 was significantly 
inversely correlated with DPYD gene expression (r=-0.16, p=0.006). The G allele in the SNP 
rs1801265 was moderately associated with DPYD expression (r=0.11, p=0.06). The G allele in 
the SNP rs17376848 was significantly inversely correlated with the 5-fluorouracil gene 
expression score (r=-0.23, p=0.02). The G allele in the SNP rs3772809 was significantly 
correlated with the 5-fluorouracil gene expression score (r=0.12, p=0.03). None of the 
significant findings were also significant in the TCGA data; however, the direction of association 
was similar in all cases. SNPs in the promotor regions of the genes of interest were not included 
in this study. SNPs in the promotor region may play a larger role in the role of the expression 
levels of these genes in the tumor tissue. 
There was no correlation between the cyclophosphamide gene expression score and the 
cyclophosphamide SNP score (r=0.06, p=0.59) or between the 5-fluorouracil gene expression 
score and the 5-fluorouracil SNP score (r=-0.0002, p>0.99).  
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Among the 95 participants with genoptyping data and gene expression score data 
available, there were 13 recurrences/breast cancer-specific deaths and 16 total deaths over a 
median follow-up of 5.3 years (range: 0.7-8.9 years). Cyclophosphamide was taken by 76 
patients and 5-fluorouracil was taken by 78 patients; 75 patients took both drugs. 
We evaluated the joint effect of the SNP score (Aim 2) and gene expression score (Aim 
3) on DFS and OS among all participants and among only those who took the chemotherapy 
drug of interest for cyclophosphamide (Table 54) and 5-fluorouracil (Table 55).  
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Table 53: Correlations Between SNPs and Gene Expression and Gene Scores 
 
     
SBCSS Data 
 
TCGA Data (N=887) 
     
Correlation with Tumor-Level 
Gene Expression  
Correlation with Tumor-
Level Gene Expression 
       Gene rs ID N MAF r p
1
   r p
1
 
Cyclophosphamide 
       
Activation 
        
 
CYP2B6 rs3745274 97 T=0.19 -0.09 0.38 
 
-0.04 0.29 
 
CYP2C19 rs4244285 311 A=0.33 -0.05 0.36 
 
-0.07 0.05 
 
CYP2C19 rs4986893 311 A=0.06 -0.02 0.73 
 
0.01 0.77 
 
CYP2C8 rs2071426 311 C=0.07 0.01 0.84 
 
0.001 0.98 
Deactivation 
        
 
ALDH1A1 rs3764435 95 A=0.47 0.20 0.06 
 
0.02 0.63 
 
ALDH1A1 rs63319 95 G=0.44 -0.09 0.38 
 
Not available 
 
ALDH3A1 rs2228100 n/a C=0.42 Expression data not available 
 
Not evaluated 
 
ALDH3A1 rs887241 n/a A=0.06 Expression data not available 
 
Not evaluated 
 
ALDH3A1 rs3744692 n/a T=0.07 Expression data not available 
 
Not evaluated 
 
GSTA1 rs3957357 95 A=0.14 0.03 0.76 
 
-0.01 0.72 
 
GSTP1 rs1695 311 G=0.20 -0.11 0.06 
 
-0.03 0.33 
Overall SNP 
Score 
n/a 95 n/a n/a 
 
n/a 
5-Fluorouracil 
        
Activation 
        
 
TYMP rs11479 311 A=0.21 -0.03 0.66 
 
0.02 0.48 
 
UMPS rs1801019 311 C=0.18 0.05 0.39 
 
-0.004 0.90 
 
UMPS rs3772809 312 G=0.06 -0.04 0.45 
 
-0.003 0.93 
Deactivation 
        
 
DPYD rs17376848 95 G=0.10 -0.03 0.79 
 
0.06 0.07 
 
DPYD rs1801159 311 C=0.27 -0.16 0.006 
 
-0.03 0.46 
 
DPYD rs1801265 311 G=0.09 0.11 0.06 
 
-0.01 0.72 
 
DPYD rs72728438 95 C=0.23 -0.003 0.98 
 
-0.06 0.06 
Response 
  
      
 
MTHFR rs1801131 312 G=0.18 0.08 0.18 
 
0.09 0.007 
 
MTHFR rs1801133 95 A=0.44 -0.06 0.59 
 
0.01 0.66 
 
MTHFR rs2274976 311 T=0.09 -0.002 0.97 
 
0.006 0.86 
 
TYMS rs2847153 97 A=0.36 0.06 0.55 
 
0.06 0.07 
 
TYMS rs2853533 95 G=0.49 -0.04 0.70 
 
-0.11 0.001 
Overall SNP 
Score 
n/a 95 n/a n/a   n/a 
1
P-values not adjusted for multiple comparisons 
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Table 54: Joint Effect of Cyclophosphamide Gene Expression Score and SNP Score 
 
 
  
Disease-Free Survival 
 
Overall Survival 
  
Gene Expression Score  
HR
1
 (95%CI) 
 
Gene Expression Score  
HR
1
 (95%CI) 
SNP Gene Score Low Expression High expression   Low expression High expression 
Overall (n=95) 
   
 
Shorter exposure 1.00 (reference) 0.28 (0.03, 2.41) 
 
1.00 (reference) 2.27 (0.56, 9.28) 
 
Longer exposure 0.48 (0.14, 1.68) 0.55 (0.07, 4.59) 
 
1.19 (0.34, 4.25) 0.91 (0.10, 8.22) 
       Those who Took Cyclophosphamide (n=76) 
   
 
Shorter exposure 1.00 (reference) 0.22 (0.02, 2.10) 
 
1.00 (reference) 2.05 (0.36, 11.66) 
 
Longer exposure 0.62 (0.16, 2.37) 0.71 (0.08, 6.17) 
 
1.56 (0.39, 6.30) 1.31 (0.13, 12.87) 
1
Adjusted for age at diagnosis and tumor grade 
 
 
Table 55: Joint Effect of 5-Fluorouracil Gene Expression Score and SNP Score 
 
 
  
Disease-Free Survival 
 
Overall Survival 
  
Gene Expression Score  
HR
1
 (95%CI) 
 
Gene Expression Score  
HR
1
 (95%CI) 
SNP Gene Score Shorter exposure Longer exposure   Shorter exposure Longer exposure 
Overall (n=95) 
   
 
Shorter exposure 1.00 (reference) 0.50 (0.09, 2.71) 
 
1.00 (reference) 0.34 (0.07, 1.67) 
 
Longer exposure 0.98 (0.28, 3.40) 0.24 (0.03, 2.09) 
 
0.52 (0.16, 1.73) 0.36 (0.08, 1.70) 
       Those who Took 5-Fluorouracil (n=78) 
   
 
Shorter exposure 1.00 (reference) 0.63 (0.11, 3.68) 
 
1.00 (reference) 0.40 (0.08, 1.97) 
 
Longer exposure 1.46 (0.38, 5.58) 0.24 (0.03, 2.15) 
 
0.51 (0.13, 2.02) 0.32 (0.07, 1.55) 
1
Adjusted for age at diagnosis and tumor grade 
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CHAPTER VII 
SUMMARY/FUTURE DIRECTIONS 
Response to chemotherapy varies widely among TNBC patients and those who respond 
well to treatment have 5-year survival rates similar to those diagnosed with other breast cancer 
subtypes. Little is known about why some patients respond well while others do not; individual 
inherited differences in chemotherapy drug metabolism likely play a role in differences in 
response. A better understanding of the underlying molecular biological mechanisms is critical to 
address the unmet clinical need to improve the outcomes for this group of aggressive breast 
cancers. Ultimately, identification of determinants of chemotherapy response will guide clinical 
decision-making and allow for a personalized approach to chemotherapy selection for TNBC 
patients. 
Drug metabolizing genes play an important role in the success or failure of cancer 
therapies.
19,185
 Identification of responsive tumors may guide clinical therapeutic decisions 
leading to more personalized approaches for breast cancer chemotherapy.
186,187
 Understanding 
the pharmacogenetic variables which influence prognosis could lead to more effective treatment 
selection and improved outcomes in breast cancer patients.
186
 TNBC patients who respond well 
to chemotherapy and achieve a pCR have survival and recurrence rates which are similar to other 
breast cancer subtypes; therefore, identifying determinants of chemotherapy response has the 
potential to influence clinical practice and improve outcomes and TNBC patients stand to gain 
the most from better chemotherapy selection.  
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The majority of previous studies evaluating the association between genetics and 
chemotherapy response have evaluated one or a few polymorphisms in a given gene. It has been 
suggested that multigene- and pathway-oriented analysis may be a better approach,
188
 although 
few studies have been able to evaluate these associations. We used a gene score approach to 
account for multiple genetic polymorphisms which influence the metabolism of a certain 
chemotherapy drug. This gene score approach allowed us to maximize the power of our study, 
particularly for less common variants, as well as to assess whether more polymorphisms in 
particular genes in the biological pathways of interest led to differences in survival (a dose-
response relationship).  
Both heritable genetic factors and tumor genomic factors may affect individual response 
to drug treatment.
64,189
 In this study, we analyzed data on both the germline DNA as well as the 
gene expression profiles of the tumor tissue. This unique combination allows for a more 
comprehensive evaluation, both separately and jointly, of their relationship with disease-free and 
overall survival. This is particularly important for our study of genes involved in chemotherapy 
metabolism since activation and deactivation of the chemotherapy metabolites occurs both in 
normal tissue (typically the liver) as well as in the tumor tissue. By incorporating genetic 
variation in both sources, we may be able to better understand chemotherapy metabolism and 
cancer outcomes. 
Most studies assessing the pharmacogenetics of chemotherapy drug response and cancer 
survival have treated breast cancer as a single disease; however, this is not the strongest approach 
because breast cancer is a heterogeneous disease. Discrepancies in the results of previous 
biomarkers studies in breast cancer may be due to differences across subtypes of breast cancer.
190
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In our study, we were able to run our gene expression analyses in TNBC patients only; however, 
we were unable to do so for the germline genetic variation analysis due to a limited number of 
TNBC patients with data available on the SNPs of interest. We plan to rerun the analyses among 
TNBC patients only when data is available.  
Our study has several additional noteworthy strengths. The cohort that this data was 
collected from is a large, population-based study with comprehensive collection of information 
related to covariates and chemotherapy use. The validity of the data was increased through 
review of medical charts for disease and clinical information. Additionally, our study was done 
in an Asian population while the majority of previous studies have been conducted in Causasian 
populations. This allowed for the study of some SNPs which are extremely rare in Caucasian 
populations but more common among Asians (e.g. rs4986893, rs3744692, and rs3772809). 
The sample size of our study limited our ability to draw conclusions for some of our 
findings, particularly for analyses stratified by whether the chemotherapy drug of interest was 
taken, and our ability to assess interactions by chemotherapy regimen. Additionally, our joint 
analysis of germline variation and tumor-level gene expression among TNBC patients was 
limited by small sample size.  
In our study, we did not have information on toxicity for our patients. Patients who have 
longer exposure periods to the active metabolite of a chemotherapy drug may be more likely to 
experience an adverse reaction or toxicity event. This may occur through faster activation of the 
drug or slower deactivation. If the reaction is severe enough, then the chemotherapy regimen that 
the patient is receiving may be changed. We used number of cycles of chemotherapy as a 
surrogate to try to account for this in our analyses. Information on adverse reactions and toxicity 
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events may allow for a better understanding of individual response to chemotherapy which 
would affect survival outcomes. Future studies should better incorporate toxicity events into data 
analyses for a more comprehensive evaluation of the effect of SNPs on chemotherapy response 
and survival outcomes. Further, it would be interesting to incorporate data on circulating drug 
levels into future studies to better understand the effects of genetic and tumor variation on drug 
metabolism. 
Extensive information on chemotherapy was available for the participants in our study. 
However, many of the participants in our study were taking multiple chemotherapy drugs. We 
looked at genes involved in the metabolism of cyclophosphamide and 5-fluorouracil but not 
other chemotherapy drugs. This is particularly important for those who took an anthracycline as 
some studies have shown anthracycline-based chemotherapy regimens to be associated with 
better outcomes in breast cancer patients.
15
 A little over 50% of the participants in the SBCSS 
cohort took an anthracycline; however, further controlling for anthracycline use did not 
materially change our results.  
A suitable validation data set for this study was not available. We attempted to validate 
our findings using TCGA data (see Appendix C for full write-up of TCGA findings); however, 
most of the findings from our study did not replicate in this population. There are several 
important limitations in using TCGA data as a validation set for this study. The biggest issue is 
that treatment information is not known for the patients included in the TCGA data set. We do 
not know whether the patients received chemotherapy nor do we have information on what types 
of chemotherapy were given. Our study focused on genes involved in chemotherapy metabolism 
which should only be relevant among those who took certain types of chemotherapy drugs 
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metabolized by the genes studied. Furthermore, the TCGA data was not a systematic collection 
of cases and the breast cancer cases were more likely to be diagnosed at a later stage than the 
women in the SBCSS cohort. Additionally, follow-up time for these patients is relatively short 
and the number of TNBC patients is extremely limited (n=93). The next important step for this 
study would be to validate our findings in a more suitable dataset in order to strengthen our 
results. 
More studies are needed to further elucidate the genes involved in the pathways by which 
chemotherapy drugs are metabolized. While many of the genes involved in metabolism have 
been identified, these genes often play other roles in normal cell function as well as tumor 
progression and cancer survival. Additionally, the effect of both germline and tumor-level 
genetic variation may be better evaluated in a randomized trial where chemotherapy treatment is 
more controlled, i.e. types and dosages, combination therapy, etc. It would also be interesting to 
look at both tumor response and survival as outcomes to get a better understanding of the role of 
chemotherapy metabolizing genes on breast cancer outcomes. These types of studies may allow 
for genetic variation in genes involved in chemotherapy metabolism to be incorporated in 
clinical use to guide chemotherapy selection, but at this time our understanding is too limited. 
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APPENDIX 
A. Methods for Systematic Review 
Based on the PRISMA guidelines, a systematic review was conducted to identify studies 
investigating associations between expression of chemotherapy metabolizing genes and breast 
cancer outcomes. The following databases were searched: PubMed and EMBASE. The main 
PubMed search was: ("breast neoplasms"[MeSH Major Topic] OR "breast cancer"[All Fields]) 
AND "drug therapy"[Subheading] AND expression[tiab] AND (survival[tiab] OR mortality[tiab] 
OR disease-free[tiab] OR recurrence[tiab] OR relapse[tiab] OR prognosis[tiab] OR death[tiab]). 
Limitations included human, female, and English language. Additionally, ISI Web of Science 
was used to do a cited reference search and the reference lists of relevant studies were searched 
to identify additional studies. 
Observational studies or randomized trials with follow-up were included in the present 
review. Inclusion criteria included tumor-level protein or gene expression measurement of at 
least one chemotherapy metabolizing gene (cytochrome P450s (CYP), glutathione-S-transferases 
(GSTs), aldehyde dehydrogenases (ALDHs) which play a role in the metabolism of the majority 
of chemotherapy drugs or DPYD, MTHFR, or TYMP which metabolize fluoropyrimidines). 
Studies which assessed overall survival, disease-free or progression-free survival, or time to 
recurrence were included. Additionally, we also included studies which looked at pathologic 
complete response, response rate, or clinical response as outcomes. 
Using Endnote software, duplicate studies selected from more than one database were 
removed. The study titles were screened and abstracts were reviewed for inclusion in the present 
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review. Full manuscripts of all identified studies were reviewed for inclusion. The data was 
extracted from the selected studies into Excel spreadsheets. Data extracted for this review 
included: author, title of article, citation, publication type, country of origin, study design, study 
inclusion/exclusion criteria, number of participants, breast cancer characteristics (stage, subtype 
information), expression measurement method, outcome measurement, definition of outcome 
measurement, length of follow-up, loss to follow-up, type of analysis, and results of analysis.  
The PRISMA flow diagram is shown in Figure A1. A total of 2,466 citations were 
identified through PubMed, Web of Science, and reference list searches. 2,423 citations were 
excluded by title due to chemotherapy genes of interest not included in the study, study done in 
non-breast cancer population, or outcomes of interest were not measured. Of the 45 abstracts 
reviewed, 22 were excluded due to drug of interest was not chemotherapy agent (n=8), gene or 
protein expression was not measured (n=10), or outcomes of interest were not measured (n=4) 
and the remaining 23 full-text articles were obtained. After full text review, 17 studies (16 
observational studies and 1 randomized trial) met inclusion criteria and were included in the 
systematic review.  
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Figure A1: PRISMA Flow Diagram of Study Selection Process 
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B. Quality Control Checks of Allele Frequencies by Study 
 
 
Legend for Table B1 
 
Data not Available     
Overlapping Data: Imputed data only used when genotype data missing 
Overlapping Data: Imputed data not needed 
Imputed data had poor imputation quality (R2<0.3) 
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Table B1: Allele Frequencies by Study 
Gene rs ID 
Reference 
Allele
1
 
Alternate 
Allele
1
 
Alternate 
Allele 
Frequency in 
Asians
1,2
 
Alternate 
Allele 
Frequency 
from 
ExomeChip 
(genotyped) 
Alternate 
Allele 
Frequency 
from 
ExomeSeq 
(genotyped) 
Alternate 
Allele 
Frequency 
from GWAS 
(genotyped) 
Alternate 
Allele 
Frequency 
from 
ExomeChip 
(imputed) 
Alternate 
Allele 
Frequency 
from GWAS 
(imputed) 
Cyclophosphamide 
        
  Activation 
        
CYP2B6 rs3745274 G T T=0.18   0.22 0.19   0.19 
CYP2C19 rs4244285 G A A=0.33   0.36   0.33 0.33 
CYP2C19 rs4986893 G A A=0.05 0.05 0.06     0.06 
CYP2C8 rs2071426 T C C=0.07 0.07       0.06 
  Deactivation 
        
ALDH1A1 rs3764435 A C C=0.54         0.54 
ALDH1A1 rs63319 G T T=0.58         0.56 
ALDH3A1 rs2228100 G C C=0.43 0.42 0.42 0.42 0.42   
ALDH3A1 rs3744692 C T T=0.06 0.07 0.07   0.07 0.07 
ALDH3A1 rs887241 A C C=0.94 0.94 0.93 0.94     
GSTA1 rs3957357 A G G=0.88         0.86 
GSTP1 rs1695 A G G=0.17 0.19 0.20     0.20 
5-Fluorouracil 
     
    
 
  Activation 
        
TYMP rs11479 G A A=0.25 0.22     0.22 0.20 
UMPS rs1801019 G C C=0.19 0.18 0.23     0.18 
UMPS rs3772809 A G G=0.06 0.06 0.05 0.06 0.06 0.06 
  Deactivation 
        
DPYD rs17376848 A G G=0.12   0.19     0.10 
DPYD rs1801159 T C C=0.26 0.27 0.26     0.26 
DPYD rs1801265 G A A=0.94 0.92 0.92     0.90 
DPYD rs72728438 T C C=0.20         0.23 
  Other 
   
        
 
MTHFR rs1801131 T G G=0.19   0.23 0.18 0.18 0.18 
MTHFR rs1801133 G A A=0.37   0.38     0.44 
MTHFR rs2274976 C T T=0.10 0.09 0.11     0.09 
TYMS rs2847153 G A A=0.40     0.36     
TYMS rs2853533 G C C=0.54   0.52     0.51 
1
Source: HaploReg v3, forward strand alleles 
     
2
Source: 1000 Genomes 
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C. Results from Validation in Breast Cancer Cases from The Cancer Genome Atlas (TCGA) 
There were 887 TCGA breast cancer cases available with gene expression data available 
and 87 deaths. There were 887 available with genotyping data for the SNPs investigated in this 
study and 93 deaths. Note that the populations for these differ by 39 individuals. The average 
follow-up time for the TCGA breast cancer cases was 1.2 years (range: 0.0-18.6 years). 
Available demographic and clinical predictors for breast cancer survival in TCGA breast cancer 
cases were tabulated for those included in the genotyping analyses and gene expression analyses 
(Table C1). 
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Table C1:Demographic and Clinical Predictors for Breast Cancer Survival in Breast Cancer 
Cases from The Cancer Genome Atlas (TCGA) 
 
 
Gene Expression Data  Genotyping Data  
 
N=887 N=887 
 mean(SD) or N(%) 
Age at Diagnosis 58.3 (13.1) 58.0 (13.1) 
   Survival Time (years) 2.4 (2.9) 2.4 (2.9) 
   Deaths 87 93 
   Stage 
  I 153 (17.3) 151 (17.0) 
II 507 (57.2) 506 (57.1) 
III 198 (22.3) 200 (22.6) 
IV 15 (1.7) 15 (1.7) 
Unknown 14 (1.6) 15 (1.7) 
   ER Status 
  Positive 646 (72.8) 648 (73.1) 
Negative 197 (22.2) 197 (22.2) 
Unknown 44 (5.0) 42 (4.7) 
   PR Status 
  Positive 561 (63.3) 563 (63.5) 
Negative 279 (31.5) 279 (31.5) 
Unknown 47 (5.3) 45 (5.1) 
   HER2 Status 
  Positive 133 (15.0) 135 (15.2) 
Borderline 134 (15.1) 136 (15.3) 
Negative 461 (52.0) 470 (53.0) 
Unknown 159 (17.9) 146 (16.5) 
 
 
The allele frequencies for the SBCSS and TCGA breast cancer cases for the SNPs 
included in this study were compared to the established allele frequencies from the 1000 
Genomes project (Table C2). All SNPs were similar in frequency to the relevant populations.
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Table C2: Frequency of Alleles in SBCSS and TCGA Breast Cancer Cases 
  Gene rs ID Alleles
1,2
 
Allele 
Frequency in 
Asians
1
 
Allele Frequency 
in SBCSS Study 
Population 
Allele Frequency 
in European
1
 
Frequency in 
TCGA Study 
Population 
Cyclophosphamide 
    
Activation 
      
 
CYP2B6 rs3745274 G, T G=0.82 G=0.81 G=0.77 G=0.74 
 
CYP2C19 rs4244285 G, A A=0.33 A=0.33 A=0.15 A=0.16 
 
CYP2C19 rs4986893 G, A G=0.95 G=0.94 G=1.00 G=0.993 
 
CYP2C8 rs2071426 T, C T=0.93 T=0.93 T=0.72 T=0.71 
Deactivation 
      
 
ALDH1A1 rs3764435 A, C C=0.54 C=0.53 C=0.47 C=0.45 
 
ALDH1A1 rs63319 G, T G=0.42 G=0.44 G=0.49 Not Available 
 
ALDH3A1 rs2228100 G, C G=0.57 G=0.58 G=0.77 G=0.70 
 
ALDH3A1 rs887241 A, C C=0.94 C=0.94 C=0.64 C=0.68 
 
ALDH3A1 rs3744692 C, T T=0.06 T=0.07 T=0.00 T=0.002 
 
GSTA1 rs3957357 A, G G=0.88 G=0.86 G=0.60 G=0.62 
 
GSTP1 rs1695 A, G A=0.83 A=0.80 A=0.68 A=0.66 
5-Fluorouracil 
    
Activation 
      
 
TYMP rs11479 G, A A=0.25 A=0.21 A=0.08 A=0.11 
 
UMPS rs1801019 G, C C=0.19 C=0.18 C=0.14 C=0.17 
 
UMPS rs3772809 A, G A=0.94 A=0.94 A=0.99 A=0.99 
Deactivation 
      
 
DPYD rs17376848 A, G G=0.12 G=0.10 G=0.04 G=0.05 
 
DPYD rs1801159 T, C T=0.74 T=0.73 T=0.83 T=0.81 
 
DPYD rs1801265 G, A A=0.94 A=0.91 A=0.78 A=0.75 
 
DPYD rs72728438 T, C T=0.80 T=0.77 T=0.81 T=0.81 
Other 
 
     
 
MTHFR rs1801131 T, G G=0.19 G=0.18 G=0.32 G=0.28 
 
MTHFR rs1801133 G, A G=0.63 G=0.56 G=0.65 G=0.69 
 
MTHFR rs2274976 C, T C=0.90 C=0.91 C=0.96 C=0.95 
 
TYMS rs2847153 G, A A=0.40 A=0.36 A=0.20 A=0.22 
 
TYMS rs2853533 G, C G=0.46 G=0.49 G=0.86 G=0.80 
1
Source: 1000 Genomes 
2
Forward strand alleles 
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Cyclophosphamide 
The association between each SNP in genes involved in metabolism of 
cyclophosphamide and OS among all breast cancer cases in the TCGA were evaluated (Table 
C3). The alleles were coded in the same way as for the SBCSS data (even when the minor allele 
differed) for ease of comparison of the results. After adjustment for age at diagnosis, TNM stage, 
ER, PR, and HER2 status, the C allele in the SNP rs887241 in the ALDH3A1 gene was 
marginally associated with poorer overall survival (HR=1.33, 95% CI: 0.99, 1.79, p=0.06) and 
the C allele in the SNP rs3764435 in the ALDH1A1 gene was marginally associated with poorer 
overall survival (HR=0.77, 95% CI: 0.56, 1.05, p=0.10). The minor allele frequency for the 
rs4986893 and rs3744692 SNPs were too low to be evaluated (MAF = 0.007 and 0.002, 
respectively). Data was not available for the SNP rs63319 in the ALDH1A1 gene. No other 
associations between SNPs involved in cyclophosphamide metabolism and overall survival 
among TCGA breast cancer cases were observed. Neither of the observed marginal associations 
was observed in the SBCSS data. 
Each of the three gene scores created for SNPs in genes involved in cyclophosphamide 
metabolism were evaluated for their association with DFS and OS (Table C4). None of the gene 
scores were associated with overall survival among TCGA breast cancer cases.  
When the results were stratified by the timing of survival events, those that occurred in 
the first three years of follow-up and those that occurred after three years, the activation score 
and total score were in the expected direction (HR<1) for among those who had events in the 
first three years but not in those who had later events, although the interaction was not significant 
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(Table C5). The results for those who had earlier events in the TCGA study population were very 
similar to those who had earlier events in the SBCSS study population.  
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Table C3: Associations Between Individual SNPs in Cyclophosphamide Metabolizing Genes and Overall Survival in TCGA Breast Cancer Cases 
  
TCGA 
 
SBCSS 
Gene rs ID 
Allele 
Frequency 
N HR (95% CI)
1
 P   
Allele 
Frequency 
N HR (95% CI)
2
 P 
Activation 
        
    
CYP2B6 rs3745274 G=0.74 885 1.19 (0.84, 1.68) 0.33  G=0.81 1144 1.10 (0.79, 1.55) 0.57 
CYP2C19 rs4244285 A=0.16 885 0.79 (0.51, 1.23) 0.29  A=0.33 3736 0.94 (0.82, 1.08) 0.39 
CYP2C19 rs4986893 G=0.993 885 MAF too low  G=0.94 3736 0.75 (0.58, 0.96) 0.02 
CYP2C8 rs2071426 T=0.71 885 1.16 (0.84, 1.61) 0.37  T=0.93 3736 0.79 (0.62, 1.01) 0.06 
Deactivation 
   
   
  
  
ALDH1A1 rs3764435 C=0.45 885 0.77 (0.56, 1.05) 0.10  C=0.53 1124 1.18 (0.89, 1.57) 0.25 
ALDH1A1 rs63319 Not Available 
 
G=0.44 1124 1.05 (0.78, 1.40) 0.74 
ALDH3A1 rs2228100 G=0.70 885 0.84 (0.61, 1.16) 0.30  G=0.48 3739 1.04 (0.91, 1.19) 0.57 
ALDH3A1 rs887241 C=0.68 885 1.33 (0.99, 1.79) 0.06  C=0.94 3739 1.09 (0.82, 1.46) 0.54 
ALDH3A1 rs3744692 T=0.002 885 MAF too low  T=0.07 3736 1.20 (0.95, 1.51) 0.13 
GSTA1 rs3957357 G=0.62 885 1.11 (0.82, 1.50) 0.51  G=0.86 1124 1.02 (0.70, 1.49) 0.92 
GSTP1 rs1695 A=0.66 885 1.15 (0.80, 1.64) 0.45   A=0.80 3736 1.07 (0.90, 1.26) 0.44 
1
Adjusted for age at diagnosis, tumor grade, ER, PR, and HER2 status 
   
  2Adjusted for age at diagnosis, tumor grade, ER, PR, and HER2 status 
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Table C4: Association Between Cyclophosphamide Gene Scores and Overall Survival in TCGA Breast Cancer Cases 
 
   
TCGA 
 
SBCSS 
Role in 
Metabolism 
# of 
SNPs 
N HR (95% CI)
3
 P 
  
N HR (95% CI)
4
 P 
 
Activation
1
 4 885 1.06 (0.88, 1.29) 0.54 
 
1141 0.94 (0.78, 1.12) 0.47 
 
Deactivation
2
 6 885 1.03 (0.89, 1.18) 0.70 
 
1124 1.03 (0.92, 1.15) 0.10 
  Total Score
1,2
 10 885 1.00 (0.89, 1.12) 0.96   1124 0.96 (0.88, 1.06) 0.44 
1
Includes SNPs from CYP genes 
2
Includes SNPs from ALDH and GST genes 
3
Adjusted for age at diagnosis, TNM stage, and ER, PR, and HER2 status 
4
Adjusted for age at diagnosis, tumor grade, and ER, PR, and HER2 status 
 
 
 
Table C5: Association Between Cyclophosphamide Gene Scores and Overall Survival Stratified by Early vs Late Events in TCGA Breast Cancer 
Cases 
   
TCGA 
 
SBCSS 
   
Event <3 years 
 
Event ≥3 years 
 
Event <3 years 
 
Event ≥3 years 
Role in 
Metabolism 
# of 
SNPs 
Events/ 
Total N 
HR (95% CI)
3
 
 
Events/ 
Total N 
HR (95% CI)
3
 
 
HR (95% CI)
3
 
 
HR (95% CI)
3
 
 
Activation
1
 4 34/885 0.82 (0.60, 1.11)   59/277 1.19 (0.92, 1.54)   1.03 (0.76, 1.40)   0.88 (0.71, 1.10) 
 
Deactivation
2
 6 34/885 1.04 (0.84, 1.28)   59/277 1.05 (0.87, 1.26) 
 
1.06 (0.89, 1.28) 
 
1.01 (0.88, 1.16) 
  Total Score
1,2
 10 34/885 0.91 (0.76, 1.09)   59/277 1.04 (0.89, 1.21)   0.94 (0.84, 1.05)   0.96 (0.86, 1.08) 
1
Includes SNPs from CYP genes 
        2Includes SNPs from ALDH and GST genes 
3
Adjusted for age at diagnosis, TNM stage, ER, PR, and HER2 status 
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The gene expression levels of each of the genes involved in cyclophosphamide 
metabolism among TCGA breast cancer cases are shown in Table C6. CYP3A4, CYP2C9, and 
CYP2C19 were expressed in a very low percentage of TCGA tumor tissue samples, similar to 
what was observed in the SBCSS data. However, unlike the SBCSS tumor tissue, CYP2B6, 
CYP3A5, CYP2A6, and CYP2C8 were expressed in more than half of the tumor samples. This 
may be due to differences in breast cancer subtype of the populations or timing of chemotherapy 
treatment, the latter of which is unknown for the TCGA population. 
ALDH1A1 and GSTP1were expressed in all tumor tissue samples from TCGA breast 
cancer cases. GSTA1, GSTT1, and GSTM1 were expressed in a smaller percentage of tumors, 
though these percentages were higher than observed in the SBCSS population (SBCSS: GSTA1 
10.0%, GSTT1 44.0%, and GSTM1 37.6%). GST deletions are more common in Asian 
populations than European populations so this was expected. 
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Table C6: Log-Transformed Expression Levels of Cyclophosphamide Metabolizing Genes in 
TCGA Breast Cancer Cases 
 
Gene % Expressed Mean SD Median Minimum Maximum 
CYP2B6 52.5% 2.14 1.88 1.84 0 9.88 
CYP3A4 11.0% 0.26 0.59 0 0 7.52 
CYP2C9 11.1% 0.42 0.93 0 0 7.22 
CYP3A5 92.9% 2.39 1.35 2.32 0 8.88 
CYP2A6 62.0% 3.33 3.75 2.15 0 18.24 
CYP2C8 74.7% 2.48 1.98 2.30 0 10.93 
CYP2C19 1.9% 0.25 0.65 0 0 3.29 
ALDH1A1 100.0% 8.32 1.38 8.37 2.99 12.88 
GSTP1 100.0% 10.96 1.56 10.82 6.35 15.59 
GSTA1 61.2% 2.31 2.88 1.07 0 13.80 
GSTT1 83.0% 7.31 3.76 9.03 0 11.92 
GSTM1 81.7% 5.38 4.59 5.65 0 15.39 
 
 
The gene expression levels for genes involved in metabolism of cyclophosphamide and 
overall survival among all TCGA breast cancer cases and TCGA TNBC cases only were 
evaluated (Table C7). No significant associations were observed between any of the genes and 
survival in the TCGA, either among all breast cancer cases or TNBC only. 
No association was observed between the additive cyclophosphamide gene score and OS, 
either among all breast cancer cases or TNBC only (Table C8).  
When stratified by events in the first three years and events occurring after three years, no 
clear differences were observed among all breast cancer cases and individual gene expression 
levels or the combined gene expression score (Table C9). 
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Table C7: Overall Survival by Expression of Genes Involved in Cyclophosphamide Metabolism in TCGA Breast Cancer Cases 
  
TCGA 
 
SBCSS 
  
All Participants 
 
TNBC (n=93) 
 
TNBC 
  5-yr OS Rate, %
1
 HR (95% CI)
2
 P 
 
HR (95% CI)
3
 P   HR (95% CI)
4
 P 
ALDH1A1 
 
          
   
 
Continuous 81.0 0.88 (0.75, 1.03) 0.11 
 
1.12 (0.68, 1.84) 0.65 
 
0.89 (0.81, 0.98) 0.02 
           
 
<median 77.5 Reference 
 
Reference 
 
Reference 
 
≥median 84.6 0.84 (0.53, 1.34) 0.47 3.35 (0.70, 16.14) 0.13 0.65 (0.41, 1.04) 0.07 
   
        
 
Tertile1 75.5 Reference 
 
Reference 
 
Reference 
 
Tertile 2 82.0 0.70 (0.42, 1.17) 0.17 
 
1.68 (0.29, 9.71) 0.56 
 
0.70 (0.41, 1.17) 0.17 
 
Tertile 3 85.7 0.62 (0.34, 1.12) 0.11 
 
1.87 (0.25, 14.15) 0.54 
 
0.45 (0.25, 0.80) 0.007 
           GSTP1 
         
 
Continuous 81.0 0.93 (0.79, 1.10) 0.38 
 
0.80 (0.43, 1.48) 0.47 
 
1.07 (0.85, 1.33) 0.57 
           
 
<median 82.4 Reference 
 
Reference 
 
Reference 
 
≥median 79.8 0.93 (0.56, 1.52) 0.76 
 
1.12 (0.28, 4.44) 0.87 
 
1.30 (0.83, 2.04) 0.26 
           
 
Tertile1 77.9 Reference 
 
Reference 
 
Reference 
 
Tertile 2 84.3 0.87 (0.49, 1.54) 0.62 
 
0.67 (0.10, 4.70) 0.69 
 
1.16 (0.66, 2.04) 0.60 
 
Tertile 3 80.4 0.87 (0.46, 1.66) 0.67 
 
1.31 (0.19, 9.14) 0.79 
 
1.20 (0.68, 2.09) 0.53 
           GSTA1 
         
 
Not Expressed 80.6 Reference 
 
Reference 
 
Reference 
 
Expressed 81.3 0.87 (0.54, 1.39) 0.56 
 
0.46 (0.10, 2.13) 0.32 
 
1.20 (0.57, 2.50) 0.63 
           GSTM1 
         
 
Not Expressed 85.5 Reference 
 
Reference 
 
Reference 
 
Expressed 80.3 1.29 (0.69, 2.41) 0.43 
 
3.68E6 (0.00, .) 0.99 
 
1.16 (0.73, 1.84) 0.52 
           GSTT1 
         
 
Not Expressed 78.1 Reference 
 
Reference 
 
Reference 
 
Expressed 81.7 0.77 (0.42, 1.44) 0.42   1.04 (0.15, 7.10) 0.97 
 
1.13 (0.72, 1.78) 0.58 
1
Unadjusted, mean(se)  
   
      
2
Adjusted for age at diagnosis, TNM Stage, ER, PR, and HER2 status 
    
3
Adjusted for age at diagnosis and TNM stage 
       
4
Adjusted for age at diagnosis and tumor grade 
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Table C8: Overall Survival by Additive Cyclophosphamide Gene Scores in TCGA Breast Cancer Cases 
 
  
TCGA 
 
SBCSS 
  
All Subtypes 
 
TNBC 
 
TNBC 
  
N HR (95% CI)
2
 P 
 
HR (95% CI)
2
 P 
 
HR (95% CI)
2
 P 
Score
4
       
 
  
 Group 1 243 Reference  Reference 
 
Reference 
 Group 2  247 0.69 (0.37, 1.26) 0.23  0.11 (0.01, 2.22) 0.15 
 
1.39 (0.81, 2.39) 0.24 
 Group 3 397 0.88 (0.49, 1.58) 0.67  0.36 (0.03, 3.92) 0.40 
 
1.26 (0.69, 2.28) 0.45 
 Ptrend  0.82  0.94 
 
0.41 
1
Adjusted for age at diagnosis, TNM stage, ER, PR, and HER2 status 
2
Adjusted for age at diagnosis and TNM stage 
      3Adjusted for age at diagnosis and tumor grade 
      6Score based on median cut point (higher score indicates faster metabolizer) 
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Table C9: Association Between Cyclophosphamide Gene Expression Levels and Scores Stratified by Early vs. Late Events in TCGA Breast Cancer 
Cases 
  
TCGA 
 
SBCSS 
  
Events <3 years (33 events) Events ≥3 years (54 events) 
 
Events <3 years (34 events) Events ≥3 years (42 events) 
  HR (95% CI)1 P HR (95% CI)1 P  HR (95% CI)1 P HR (95% CI)1 P 
ALDH1A1 
 
 
 
 
      Continuous 0.81 (0.63, 1.04) 0.10 0.96 (0.77, 1.19) 0.71 
 
1.10 (0.93, 1.32) 0.27 0.86 (0.75, 0.98) 0.03 
      
 
    
 <median Reference Reference 
 
Reference Reference 
 ≥median 0.55 (0.26, 1.15) 0.11 1.19 (0.64, 2.20) 0.58 
 
1.22 (0.57, 2.61) 0.61 0.65 (0.34, 1.27) 0.21 
      
 
    
 Tertile 1 Reference Reference 
 
Reference Reference 
 Tertile 2 0.53 (0.23, 1.24) 0.15 0.86 (0.44, 1.68) 0.66 
 
1.16 (0.53, 2.58) 0.71 0.63 (0.29, 1.33) 0.22 
 Tertile 3 0.27 (0.10, 0.76) 0.01 1.14 (0.53, 2.43) 0.73 
 
0.82 (0.30, 2.24) 0.70 0.50 (0.22, 1.11) 0.09 
      
 
    
GSTP1     
 
    
 Continuous 1.05 (0.80, 1.38) 0.71 0.80 (0.64, 1.01) 0.06 
 
0.86 (0.59, 1.25) 0.43 1.01 (0.73, 1.41) 0.93 
      
 
    
 <median Reference Reference 
 
Reference Reference 
 ≥median 1.54 (0.65, 3.60) 0.32 0.58 (0.30, 1.14) 0.11 
 
1.04 (0.50, 2.17) 0.91 1.07 (0.57, 2.03) 0.83 
      
 
    
 Tertile 1 Reference Reference 
 
Reference Reference 
 Tertile 2 0.43 (0.14, 1.32) 0.14 1.19 (0.57, 2.51) 0.64 
 
0.86 (0.32, 2.34) 0.77 0.96 (0.41, 2.23) 0.92 
 Tertile 3 1.59 (0.56, 4.51) 0.38 0.48 (0.20, 1.15) 0.10 
 
0.86 (0.32, 2.31) 0.77 0.82 (0.36, 1.90) 0.65 
      
 
    
GSTA1     
 
    
 <median Reference Reference 
 
Reference Reference 
 ≥median 0.57 (0.27, 1.24) 0.16 1.16 (0.63, 2.16) 0.63 
 
0.87 (0.30, 2.53) 0.80 0.96 (0.33, 2.77) 0.94 
      
 
    
GSTM1     
 
    
 <median Reference Reference 
 
Reference Reference 
 ≥median 0.85 (0.36, 1.97) 0.70 1.67 (0.68, 4.08) 0.26 
 
1.67 (0.84, 3.30) 0.14 0.94 (0.49, 1.80) 0.86 
      
 
    
GSTT1     
 
    
 <median Reference Reference 
 
Reference Reference 
 ≥median 0.71 (0.26, 1.91) 0.49 0.72 (0.32, 1.62) 0.43 
 
2.18 (1.08, 4.42) 0.03 0.79 (0.42, 1.51) 0.48 
      
 
    
Score2     
 
    
 Group 1 Reference Reference 
 
Reference Reference 
 Group 2  0.83 (0.32, 2.14) 0.70 0.63 (0.28, 1.42) 0.26 
 
2.03 (0.81, 5.10) 0.13 1.14 (0.57, 2.25) 0.71 
 Group 3 0.50 (0.18, 1.36) 0.18 1.05 (0.49, 2.25) 0.90 
 
2.68 (1.08, 6.65) 0.03 0.64 (0.26, 1.54) 0.32 
1Adjusted for age at diagnosis, TNM stage, ER, PR, and HER2 status 
     2Adjusted for age at diagnosis and TNM stage 
     3Adjusted for age at diagnosis, TNM stage, ER, PR, and HER2 status 
     2Score based on median cut point (higher score indicates faster metabolizer) 
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5-Fluorouracil 
The association between each SNP in genes involved in metabolism of 5-fluorouracil and 
OS among all breast cancer cases in the TCGA were evaluated (Table C10). The alleles were 
coded in the same way as for the SBCSS data for ease of comparison of the results. After 
adjustment for age at diagnosis, TNM stage, ER, PR, and HER2 status, the T allele in the SNP 
rs1801159 in the DPYD gene was significantly associated with better overall survival (HR=0.68, 
95% CI: 0.48, 0.96, p=0.03) and the G allele in the SNP rs1801131 in the MTHFR gene was 
marginally associated with poorer overall survival (HR=1.36, 95% CI: 0.99, 1.86, p=0.06). No 
other associations between SNPs involved in cyclophosphamide metabolism and overall survival 
among TCGA breast cancer cases were observed. Neither of the observed associations was 
observed in the SBCSS data. 
Each of the five gene scores created for SNPs in genes involved in cyclophosphamide 
metabolism were evaluated for their association with DFS and OS (Table C11). The deactivation 
gene score was associated with significantly better overall survival (HR=0.79, 95% CI: 0.65, 
0.97, p=0.02. Both of the total scores were associated with significantly worse overall survival 
(p=0.02 for both). These results are opposite of what was hypothesized and observed in the 
SBCSS data. 
When the results were stratified by the timing of survival events, those that occurred in 
the first three years of follow-up and those that occurred after three years, no clear differences 
were observed between any of the scores among those who had events in the first three years 
compared to those who had later events (Table C12).   
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Table C10: Associations Between Individual SNPs in 5-Fluorouracil Metabolizing Genes and Overall Survival in TCGA Breast 
Cancer Cases 
  TCGA 
 
SBCSS 
Gene rs ID 
Allele 
Frequency 
N HR (95% CI)
1
 P   
Allele 
Frequency 
N HR (95% CI)
2
 P 
Activation 
        
    
TYMP rs11479 A=0.11 885 0.99 (0.56, 1.75) 0.97  A=0.21 3736 0.98 (0.83, 1.16) 0.84 
UMPS rs1801019 C=0.17 885 1.21 (0.82, 1.80) 0.34  C=0.18 3736 0.97 (0.82, 1.15) 0.71 
UMPS rs3772809 A=0.99 885 1.68 (0.23, 12.35) 0.61  A=0.94 3739 1.20 (0.89, 1.62) 0.22 
Deactivation 
          
DPYD rs17376848 G=0.05 885 0.54 (0.17, 1.69) 0.29  G=0.10 1124 1.20 (0.75, 1.93) 0.45 
DPYD rs1801159 T=0.81 885 0.68 (0.48, 0.96) 0.03  T=0.73 3736 0.98 (0.85, 1.13) 0.81 
DPYD rs1801265 A=0.75 885 0.83 (0.61, 1.14) 0.25  A=0.91 3736 1.06 (0.84, 1.34) 0.63 
DPYD rs72728438 T=0.81 885 0.97 (0.68, 1.37) 0.84  T=0.77 1124 1.28 (0.92, 1.77) 0.15 
Other 
 
  
   
  
  
MTHFR rs1801131 G=0.28 885 1.36 (0.99, 1.86) 0.06  G=0.18 3739 0.89 (0.75, 1.07) 0.22 
MTHFR rs1801133 G=0.69 885 1.11 (0.80, 1.55) 0.54  G=0.56 1124 0.93 (0.69, 1.24) 0.60 
MTHFR rs2274976 C=0.95 885 0.82 (0.39, 1.71) 0.59  C=0.91 3736 0.98 (0.78, 1.22) 0.85 
TYMS rs2847153 A=0.22 885 1.00 (0.70, 1.44) 1.00  A=0.36 1145 0.90 (0.69, 1.18) 0.46 
TYMS rs2853533 G=0.80 885 0.78 (0.51, 1.18) 0.24  G=0.49 1124 0.99 (0.75, 1.32) 0.95 
1
Adjusted for age at diagnosis, tumor grade, ER, PR, and HER2 status           
2
Adjusted for age at diagnosis, tumor grade, ER, PR, and HER2 status 
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Table C11: Association Between 5-Fluorouracil Gene Scores and Overall Survival in TCGA Breast Cancer Cases 
 
  
TCGA 
 
SBCSS 
Role in Metabolism # of SNPs N HR (95% CI)
4
 P   N HR (95% CI)
5
 P 
 
Activation
1
 3 884 1.15 (0.83, 1.58) 0.40 
 
3736 1.00 (0.90, 1.11) 0.96 
 
Deactivation
2
 4 884 0.79 (0.65, 0.97) 0.02 
 
1124 1.01 (0.84, 1.21) 0.95 
 
Other
3
 5 884 1.08 (0.89, 1.31) 0.42 
 
1124 0.91 (0.76, 1.09) 0.29 
 
Total Score
1,2
 7 884 1.22 (1.03, 1.44) 0.02 
 
1124 0.91 (0.78, 1.05) 0.19 
  Total Score
1,2,3
 12 884 1.16 (1.02, 1.31) 0.02   1124 0.90 (0.80, 1.01) 0.08 
1
Includes SNPs from TYMP and UMPS genes 
     2Includes SNPs from DPYD gene 
      
3
Includes SNPs from TYMS and MTHFR genes 
     
4
Adjusted for age at diagnosis, TNM stage, and ER, PR, and HER2 status 
 
 
  
5
Adjusted for age at diagnosis, tumor grade, and ER, PR, and HER2 status 
    
Table C12: Association Between 5-Fluorouracil Gene Scores and Overall Survival Stratified by Early vs Late Events in TCGA Breast 
Cancer Cases 
 
  TCGA 
 
SBCSS 
   
Event <3 years 
 
Event ≥3 years 
 
Event <3 years 
 
Event ≥3 years 
Role in Metabolism 
# of 
SNPs 
Events/ 
Total N 
HR (95% CI)
4
 
 
Events/ 
Total N 
HR (95% CI)
4
 
 
HR (95% CI)
5
 
 
HR (95% CI)
5
 
 
Activation
1
 3 34/885 1.34 (0.80, 2.23)   59/277 0.98 (0.65, 1.49)   0.98 (0.84, 1.15)   1.02 (0.89, 1.18) 
 
Deactivation
2
 4 34/885 0.66 (0.47, 0.91) 
 
59/277 0.89 (0.69, 1.15) 
 
0.90 (0.66, 1.21) 
 
1.07 (0.85, 1.35) 
 
Response
3
 5 34/885 0.81 (0.59, 1.10) 
 
59/277 1.29 (1.00, 1.66) 
 
0.94 (0.70, 1.26) 
 
0.89 (0.71, 1.12) 
 
Total Score
1,2
 7 34/885 1.45 (1.10, 1.90) 
 
59/277 1.07 (0.88, 1.32) 
 
1.05 (0.83, 1.33) 
 
0.83 (0.69, 1.00) 
  Total Score
1,2,3
 12 34/885 1.13 (0.91, 1.40)   59/277 1.14 (0.98, 1.32)   1.00 (0.83, 1.22)   0.84 (0.73, 0.98) 
1
Includes SNPs from TYMP and UMPS genes 
  
 
  
2
Includes SNPs from DPYD gene 
        
3
Includes SNPs from TYMS and MTHFR genes 
    
4
Adjusted for age at diagnosis, TNM stage, ER, PR, and HER2 status 
    
5
Adjusted for age at diagnosis, tumor grade, and ER, PR, and HER2 status 
    
 190 
 
The gene expression levels of each of the genes involved in 5-fluorouracil metabolism 
among TCGA breast cancer cases are shown in Table C13. All genes of interest were expressed 
in all of the tumor tissues from TCGA breast cancer cases.  
 
 
Table C13: Expression Levels of 5-Fluorouracil Metabolizing Genes in TCGA Breast Cancer 
Cases 
 
Gene % Expressed Mean SD Median Minimum Maximum 
DPYD 100.0% 8.52 1.07 8.63 4.42 11.59 
TYMS 100.0% 9.12 1.08 9.09 5.85 12.76 
MTHFR 100.0% 9.29 0.83 9.30 6.49 11.63 
TYMP 100.0% 10.45 1.18 10.47 5.66 13.62 
UMPS 100.0% 9.55 0.42 9.52 8.18 10.99 
 
 
The gene expression levels for genes involved in metabolism of 5-fluorouracil and 
overall survival among all TCGA breast cancer cases and TCGA TNBC cases only were 
evaluated (Table C14). TYMP expression was associated with significantly improved survival 
among all breast cancer cases (continuous analysis HR=0.82, 95% CI: 0.70, 0.96, p=0.02). This 
is similar in magnitude and direction to the SBCSS results when the analysis was restricted to 
those who took 5-fluorouracil (HR=0.79, 95% CI: 0.51, 1.23), though the SBCSS finding was 
not significant. No association between TYMP and OS was observed among TCGA TNBC cases 
only. When analyzed by tertiles, UMPS expression was associated with significantly worse 
overall survival among TCGA TNBC cases (highest tertile compared to lowest HR=14.63, 95% 
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CI: 1.19, 179.43, p=0.04), but not among all breast cancer cases. No other significant associations 
were observed between any of the other gene expression levels and survival in the TCGA, either 
among all breast cancer cases or TNBC only. 
No association was observed between the additive 5-fluorouracil gene score and OS 
among all breast cancer cases (Table C15). There were too few events among TNBC cases to run 
this analysis. 
When stratified by events in the first three years and events occurring after three years, 
DPYD expression was associated with better survival in the first 3 years following diagnosis 
(HR based on median cut point=0.44, 95% CI: 0.20, 0.95, p=0.04) and worse survival after three 
years (HR based on median cut point=2.38, 95% CI: 1.31, 4.32, p=0.004) (Table C16). TYMP 
expression was associated with better survival only among those who had events after three years 
(continuous HR=0.73, 95% CI: 0.59, 0.89, p=0.002). UMPS was significantly associated with 
worse survival among those who had an event in the first three years (continuous HR=3.52, 95% 
CI: 1.48, 8.33, p=0.004) but not those who had an event after three years. This finding is similar 
in magnitude and direction as the SBCSS when analyzed by median cut point (TCGA: HR=2.39, 
95% CI: 1.10, 5.18, p=0.03; SBCSS: HR=2.14, 95% CI: 1.03, 4.43, p=0.04).  
The 5-fluorouracil gene score was associated with significantly better overall survival 
among those who had events in the first three years after diagnosis (highest score compared to 
lowest score HR=0.10, 95% CI: 0.01, 0.97, p=0.05) and significantly worse survival among 
those who had events after three years (highest score compared to lowest score HR=3.15, 95% 
CI: 1.08, 9.20, p=0.04). In the SBCSS, a similar difference in survival outcomes was observed, 
although the estimates were not significant and no significant difference was detectable.
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Table C14: Overall Survival by Expression of Genes Involved in 5-Fluorouracil Metabolism in TCGA Breast Cancer Cases 
 
 
 
TCGA 
 
SBCSS 
  
All Participants 
 
TNBC (n=93) 
 
TNBC 
  
5-yr OS 
Rate, %
1
 HR (95% CI)
2
 P 
 
HR (95% CI)
3
 P   HR (95% CI)
4
 P 
DPYD 
 
          
   
 
Continuous 81.0 1.00 (0.82, 1.23) 0.98 
 
1.40 (0.82, 2.38) 0.21 
 
0.92 (0.82, 1.04) 0.18 
           
 
<median 80.9 Reference 
 
Reference 
 
Reference 
 
≥median 80.5 1.32 (0.83, 2.09) 0.24 
 
6.26 (1.13, 34.75) 0.04 
 
0.70 (0.44, 1.10) 0.12 
           
 
Tertile 1 79.0 Reference 
 
Reference 
 
Reference 
 
Tertile 2 84.0 1.08 (0.65, 1.81) 0.76 
 
9.90 (0.82,119.99) 0.07 
 
0.62 (0.36, 1.07) 0.09 
 
Tertile 3 79.6 1.10 (0.61, 2.01) 0.75 
 
7.48 (0.67, 83.52) 0.10 
 
0.70 (0.41, 1.21) 0.20 
           TYMS 
         
 
Continuous 81.0 0.97 (0.78, 1.20) 0.78 
 
0.63 (0.31, 1.28) 0.20 
 
1.09 (0.95, 1.24) 0.24 
           
 
<median 79.1 Reference 
 
Reference 
 
Reference 
 
≥median 82.1 0.89 (0.56, 1.41) 0.61 
 
0.10 (0.01, 0.77) 0.03 
 
1.55 (0.97, 2.45) 0.06 
           
 
Tertile 1 75.7 Reference 
 
Reference 
 
Reference 
 
Tertile 2 86.3 0.59 (0.34, 1.03) 0.06 
 
0.81 (0.17, 3.91) 0.80 
 
1.17 (0.65, 2.11) 0.60 
 
Tertile 3 79.2 0.94 (0.52, 1.69) 0.83 
 
0.06 (0.00, 0.93) 0.04 
 
1.73 (0.99, 3.02) 0.06 
           MTHFR 
         
 
Continuous 81.0 0.82 (0.63, 1.08) 0.16 
 
1.43 (0.73, 2.77) 0.29 
 
0.91 (0.81, 1.03) 0.13 
           
 
<median 79.0 Reference 
 
Reference 
 
Reference 
 
≥median 83.1 0.98 (0.62, 1.54) 0.93 
 
1.46 (0.32, 6.65) 0.63 
 
0.62 (0.39, 0.98) 0.04 
           
 
Tertile 1 75.9 Reference 
 
Reference 
 
Reference 
 
Tertile 2 85.8 1.48 (0.85, 2.56) 0.16 
 
6.62 (0.91, 48.28) 0.06 
 
0.76 (0.46, 1.27) 0.30 
 
Tertile 3 82.4 0.87 (0.46, 1.62) 0.65 
 
1.10 (0.17, 7.27) 0.92 
 
0.42 (0.23, 0.76) 0.004 
TYMP 
         
 
Continuous 81.0 0.82 (0.70, 0.96) 0.02 
 
1.02 (0.57, 1.83) 0.94 
 
1.02 (0.81, 1.30) 0.85 
           
 
<median 78.5 Reference 
 
Reference 
 
Reference 
 
≥median 83.6 0.51 (0.32, 0.82) 0.005 
 
1.57 (0.36, 6.91) 0.55 
 
1.18 (0.75, 1.85) 0.48 
           
 
Tertile 1 78.7 Reference 
 
Reference 
 
Reference 
 
Tertile 2 79.4 1.04 (0.62, 1.72) 0.89 
 
2.24 (0.38, 13.34) 0.37 
 
1.14 (0.67, 1.95) 0.63 
 
Tertile 3 85.6 0.41 (0.23, 0.74) 0.003 
 
3.58 (0.48, 26.42) 0.21 
 
0.96 (0.54, 1.71) 0.90 
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           UMPS 
         
 
Continuous 81.0 1.52 (0.90, 2.57) 0.12 
 
2.55 (0.54, 12.07) 0.24 
 
0.99 (0.89, 1.11) 0.92 
           
 
<median 82.7 Reference 
 
Reference 
 
Reference 
 
≥median 79.3 1.40 (0.90, 2.18) 0.13 
 
1.99 (0.34, 11.54) 0.44 
 
1.39 (0.88, 2.20) 0.16 
           
 
Tertile 1 81.6 Reference 
 
Reference 
 
Reference 
 
Tertile 2 88.2 0.81 (0.44, 1.49) 0.49 
 
1.17 (0.13, 10.64) 0.89 
 
0.94 (0.53, 1.66) 0.83 
 
Tertile 3 73.7 1.23 (0.72, 2.10) 0.44  14.63 (1.19,179.43) 0.04  1.31 (0.76, 2.28) 0.33 
1
Unadjusted, mean(se) 
        
2
Adjusted for age at diagnosis, TNM Stage, ER, PR, and HER2 status 
3
Adjusted for age at diagnosis and TNM stage 
       
4
Adjusted for age at diagnosis and tumor grade 
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Table C15: Overall Survival by Additive 5-Fluorouracil Gene Scores in TCGA Breast Cancer Cases 
  
TCGA 
 
SBCSS 
  
All Subtypes 
 
TNBC 
  N HR (95% CI)
1
 P 
 
HR (95% CI)
1
 P 
Score
4
    
 
  
 Group 1 132 Reference 
 
Reference 
 Group 2 308 0.97 (0.47, 2.01) 0.94 
 
0.97 (0.48, 1.96) 0.93 
 Group 3 312 1.17 (0.56, 2.46) 0.67 
 
0.85 (0.41, 1.74) 0.65 
 Group 4 135 1.29 (0.57, 2.92) 0.54 
 
0.67 (0.29, 1.57) 0.36 
 Ptrend  0.38 
 
0.29 
1
Adjusted for age at diagnosis, TNM stage, ER, PR, and HER2 status 
   2Adjusted for age at diagnosis and TNM stage 
   3Adjusted for age at diagnosis and tumor grade 
   
4
Score based on median cut point (higher score indicates faster metabolizer, slower activator, and poorer 
response) 
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Table C16: Association Between 5-Fluorouracil Gene Expression Levels and Scores Stratified by Early vs. Late Events in TCGA 
Breast Cancer Cases 
  
TCGA 
 
SBCSS 
  
Events <3 years (33 events) Events ≥3 years (54 events) 
 
Events <3 years (34 events) Events ≥3 years (42 events) 
  HR (95% CI)
1
 P HR (95% CI)
1
 P  HR (95% CI)
2
 P HR (95% CI)
2
 P 
DPYD 
    
      Continuous 0.77 (0.58, 1.01) 0.06 1.28 (0.98, 1.68) 0.07 
 
1.10 (0.89, 1.36) 0.39 0.92 (0.77, 1.10) 0.37 
      
 
    
 <median Reference Reference 
 
Reference Reference 
 ≥median 0.44 (0.20, 0.95) 0.04 2.38 (1.31, 4.32) 0.004 
 
0.66 (0.32, 1.38) 0.27 0.97 (0.52, 1.81) 0.92 
      
 
    
 Tertile 1 Reference Reference 
 
Reference Reference 
 Tertile 2 0.63 (0.28, 1.43) 0.27 1.78 (0.91, 3.49) 0.09 
 
0.97 (0.20, 4.78) 0.97 0.88 (0.41, 1.90) 0.74 
 Tertile 3 0.28 (0.10, 0.79) 0.02 2.47 (1.15, 5.31) 0.02 
 
1.40 (0.29, 6.69) 0.67 1.12 (0.51, 2.44) 0.78 
      
 
    
TYMS     
 
    
 Continuous 0.89 (0.63, 1.26) 0.53 0.96 (0.73, 1.27) 0.77 
 
0.98 (0.81, 1.18) 0.80 0.99 (0.81, 1.20) 0.90 
      
 
    
 <median Reference Reference 
 
Reference Reference 
 ≥median 0.79 (0.38, 1.64) 0.52 0.97 (0.53, 1.78) 0.92 
 
1.03 (0.44, 2.41) 0.95 1.06 (0.50, 2.27) 0.88 
      
 
    
 Tertile 1 Reference Reference 
 
Reference Reference 
 Tertile 2 0.88 (0.35, 2.24) 0.79 0.42 (0.20, 0.87) 0.02 
 
1.78 (0.64, 4.95) 0.27 0.48 (0.19, 1.19) 0.11 
 Tertile 3 0.96 (0.38, 2.43) 0.93 0.86 (0.41, 1.81) 0.68 
 
1.20 (0.37, 3.86) 0.76 0.98 (0.37, 2.60) 0.97 
      
 
    
MTHFR     
 
    
 Continuous 0.93 (0.60, 1.42) 0.72 0.76 (0.53, 1.08) 0.12 
 
1.10 (0.88, 1.37) 0.42 0.95 (0.78, 1.14) 0.56 
      
 
    
 <median Reference Reference 
 
Reference Reference 
 ≥median 1.39 (0.67, 2.88) 0.38 0.75 (0.42, 1.34) 0.33 
 
0.88 (0.40, 1.92) 0.74 0.83 (0.42, 1.64) 0.60 
      
 
    
 Tertile 1 Reference Reference 
 
Reference Reference 
 Tertile 2 1.51 (0.67, 3.40) 0.32 1.46 (0.68, 3.12) 0.33 
 
1.02 (0.21, 5.01) 0.98 0.90 (0.43, 1.87) 0.77 
 Tertile 3 1.08 (0.40, 2.89) 0.88 0.70 (0.31, 1.62) 0.41 
 
1.46 (0.31, 6.98) 0.63 0.57 (0.24, 1.35) 0.20 
      
 
    
TYMP     
 
    
 Continuous 0.95 (0.72, 1.25) 0.70 0.73 (0.59, 0.89) 0.002 
 
0.92 (0.67, 1.26) 0.60 0.98 (0.71, 1.35) 0.90 
      
 
    
 <median Reference Reference 
 
Reference Reference 
 ≥median 0.77 (0.37, 1.61) 0.49 0.33 (0.17, 0.63) 0.0008 
 
1.10 (0.55, 2.21) 0.78 0.98 (0.53, 1.80) 0.94 
      
 
    
 Tertile 1 Reference Reference 
 
Reference Reference 
 Tertile 2 2.10 (0.88, 5.01) 0.10 0.62 (0.31, 1.21) 0.16 
 
1.16 (0.51, 2.62) 0.72 1.13 (0.54, 2.35) 0.75 
 Tertile 3 0.82 (0.30, 2.25) 0.70 0.27 (0.12, 0.60) 0.001 
 
1.00 (0.97, 1.04) 0.50 0.88 (0.40, 1.93) 0.75 
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UMPS     
 
    
 Continuous 3.52 (1.48, 8.33) 0.004 1.02 (0.49, 2.12) 0.95 
 
1.11 (0.91, 1.36) 0.31 0.94 (0.81, 1.09) 0.42 
      
 
    
 <median Reference Reference 
 
Reference Reference 
 ≥median 2.39 (1.10, 5.18) 0.03 1.11 (0.63, 1.98) 0.71 
 
2.14 (1.03, 4.43) 0.04 1.10 (0.60, 2.02) 0.77 
      
 
    
 Tertile 1 Reference Reference 
 
Reference Reference 
 Tertile 2 0.82 (0.24, 2.84) 0.76 0.85 (0.41, 1.76) 0.66 
 
1.18 (0.46, 3.07) 0.73 6.27 (0.83, 47.62) 0.08 
 Tertile 3 3.16 (1.17, 8.49) 0.02 0.74 (0.35, 1.56) 0.44 
 
2.07 (0.86, 4.99) 0.10 4.47 (0.57, 34.79) 0.15 
      
 
    
Score
3
     
 
    
 Group 1 Reference Reference 
 
Reference Reference 
 Group 2  1.38 (0.45, 4.21) 0.58 0.57 (0.20, 1.66) 0.30 
 
2.45 (0.71, 8.50) 0.16 0.38 (0.14, 1.04) 0.06 
 Group 3 0.68 (0.19, 2.40) 0.55 1.79 (0.66, 4.88) 0.25 
 
0.75 (0.19, 3.03) 0.69 0.94 (0.40, 2.20) 0.89 
 Group 4 0.10 (0.01, 0.97) 0.05 3.15 (1.08, 9.20) 0.04 
 
0.91 (0.21, 4.03) 0.91 0.65 (0.22, 1.89) 0.43 
1
Adjusted for age at diagnosis and TNM stage 
     
2
Adjusted for age at diagnosis, tumor grade, basal-like subtype, and DUSP4 expression 
3
Score based on median cut point (higher score indicates faster metabolizer, slower activator, and poorer response) 
   
 
